Pantetheine derivatives and uses thereof

Abstract

To provide a compound for treating CoA deficiency, acetyl CoA deficiency, and other acyl CoA deficiencies.SOLUTION: The present disclosure relates to compounds of Formula (I), (II), or (II'), and pharmaceutically acceptable salts or solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds and therapeutic and diagnostic uses of the compounds and pharmaceutical compositions.SELECTED DRAWING: None

Description

[Technical Field]

[0001] Related Applications This application is a continuation of U.S. Provisional Patent Application No. 62 / 941,64, filed November 27, 2019. No. 4, filed November 27, 2019; No. 62 / 941,643, filed January 2019; No. 62 / 795,490 filed on January 22, 2019, and No. 6 filed on January 18, 2019. No. 2 / 794,503, filed December 3, 2018, No. 62 / 774,759, filed December 3, 2018; and the benefit of and priority to Application No. 62 / 773,952 filed November 30, 2018. No. 6,399,499, filed on Dec. 1, 2003, and each of which is incorporated by reference in its entirety. [Background technology]

[0002] Coenzyme A (CoA) and acyl-CoA derivatives are essential for cellular metabolism, energy, and CoA is a vitamin B5 required for mammals. It is derived from pantothenate, which can be obtained from diet and intestinal bacteria. CoA synthesis from pantothenate occurs in five enzymatic steps, the first of which is pantothenate. catalyzed by pantothenate kinase (PANK), followed by 4'-phosphopantothenoyl Cysteine ​​synthetase (PPCS), 4'-phospho-N-pantothenoylcysteine ​​dehydrogenase carboxylase (PPCDC), 4'-phosphopantetheine adenylyltransferase The enzyme is catalyzed by dephosphorylation of CoA by PPAT and dephosphorylation of CoA by DPCK. The main function of CoA is to deliver different acyl groups to participate in various metabolic and regulatory processes. CoA has a high affinity between the acyl group and the free sulfhydryl substituent of CoA. It is acylated by forming an energetic thioester bond. Various acyl Co Among the A derivatives, acetyl coenzyme A (acetyl CoA) plays a particularly important role. CoA is acetylated during the processes of carbohydrate, fatty acid, and amino acid catabolism. One of the main functions of acetyl-CoA is to convert it into acetyl-CoA for energy production. The cetyl group is delivered to the citric acid cycle (also known as the Krebs cycle). Acetyl CoA is involved in the metabolism of fatty acids and amino acids, steroid synthesis, acetylcholine synthesis, Melatonin synthesis and acetylation pathways (lysine acetylation, post-translational acetylation, etc.) It is also an important intermediate in other biological pathways, including but not limited to: acetyl-CoA concentration acts in an allosteric manner or by altering the availability of substrates including, but not limited to, pyruvate dehydrogenase kinase and pyruvate carboxylase It also affects the activity or specificity of various enzymes that are not involved in the synthesis of histones. Affects the acetylation profile of several proteins, including but not limited to By providing ATP, key cellular processes such as energy metabolism, mitosis, and autophagy are stimulated. They regulate this process both directly and through epigenetic regulation of gene expression. Acetyl-CoA is converted into acetyl-CoA in several ways, including extra- and intra-mitochondrial ways. In the mitochondria, pyruvate is converted into acid when blood glucose levels are high. sugars by pyruvate dehydrogenase reaction, which undergoes oxidative decarboxylation to form acetyl CoA The final product of degradation is acetyl-CoA. The synthesis of pyruvate with acetyl-CoA, including the disproportionation of pyruvate to cetyl-CoA and formate. When glucose levels are low, acetyl CoA is used for the beta-oxidation of fatty acids. Fatty acids are first converted to acyl-CoA, which undergoes dehydrogenation, hydration, oxidation, and It is further decomposed in a four-step cycle of thiolysis and acetyl-CoA to form acetyl-CoA. The four steps are catalyzed by acyl-CoA dehydrogenase, enoyl-CoA hydratase, and , 3-hydroxyacyl-CoA dehydrogenase, and thiolase. In addition, leucine, isoleucine, lysine, tryptophan, phenylalanine, and tyrosine The breakdown of amino acids such as acetyl-CoA can also produce acetyl-CoA. The keto acids are converted to α-keto acids by transamination in the cytosol, and then It is then transported to the mitochondria via the ATP shuttle and finally to α-keto acid dehydrogenase It is processed within the mitochondrial matrix by enzyme complexes, where it undergoes multistep dehydrogenation, Acetyl CoA is produced by carboxylation and hydration of CoA. Acetyl-CoA synthase, an enzyme that uses acetate and ATP to acetylate It can also be synthesized in mitochondria by the enzyme acetylcholinesterase. There are organ-specific pathways for cetyl-CoA production. For example, neurons produce the ketone body D- β-hydroxybutyrate and acetoacetate are used to produce acetyl-CoA. (Cahill, 2006), and hepatocytes can convert acetaldehyde and acetate into This conversion allows the production of acetyl-CoA from ethanol as a carbon source. . Outside the mitochondria, acetyl-CoA is converted to acetyl-CoA by the tricarboxylic acid cycle. ATP citrate lyase, which converts tritrate to acetyl-CoA and oxaloacetate Second, acetyl-CoA can be produced by acyl-CoA synthetase. It can also be produced in the cytosol from acetate in an ATP-dependent reaction catalyzed by Cut.

[0003] The decrease in acetyl-CoA levels is due to the activation of various metabolic enzymes and pathways involved in acetyl-CoA biosynthesis. This can be caused by the inhibition, loss, or reduction of short-chain acyl-CoA dehydrogenase activity. SCADD, medium-chain acyl-CoA dehydrogenase deficiency (MCADD), long-chain acyl-CoA Acyl-CoA dehydrogenase deficiency (LCADD) and very long-chain acyl-CoA dehydrogenase deficiency (VL Diseases such as organic acidemias with deficient branched-chain amino acid catabolism (e.g., CADD) or impaired fatty acid oxidation This may lead to a decrease in acetyl-CoA levels and the accumulation of other CoA species, including acyl-CoA species. These conditions can include hypoglycemia, liver dysfunction, lethargy, seizures, coma, and even death. Therefore, in the art, CoA deficiency, acetylcholinesterase inhibitors (ACE inhibitors) are known. There is a need for compositions and methods for treating CoA deficiency, as well as other acyl-CoA deficiencies. It is being done. In addition to acetyl, CoA can be substituted with other carboxyl groups, including, but not limited to, propionyl, butyryl, 2-hydroxyisobutyryl, crotonyl, malonyl, succinyl, glutaryl, etc. Many acylated acyl-CoA species can be accepted, and such acylated acyl-CoA species can be converted to high-energy Carbon units in anabolic processes as carriers of energy via thioester bonds or as a donor of protein modifications such as, but not limited to, histone lysine modifications It is also important in cellular metabolism and regulation, such as as an acyl group donor in cellular regulation via It plays a vital role. Summary of the Invention

[0004] In some aspects, the present disclosure provides, inter alia, a compound of formula (I) or (II') [ka] or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is H, C1-C 20 a L Kill, C2~C 20 Alkenyl, C2-C 20 Alkynyl, -C(=O)-(C1-C2 0 alkyl), -C(=O)-(C2-C 20 alkenyl), -C(=O)-(C2-C 20 alkynyl), -C(=O)R 1b , -C(=O)R 1c , -C(=O)R 1z ,- C(=O)-(CH=CH) n -R 1a , -C(=O)CH2-[C(=O)CH2] p -[CH2] q -R 1a , -C(=O)CH2-[CH(OR 1c )-CH2] p -[C H2] q -R 1a , -C(=O)CH2-[c(=O)CH2] p -[CH(OR 1c ) -CH2]r-[CH2] q -R 1a , -C(=O)-CH(C(=O)R 1b )-[C (=O)CH2] p -[CH(OR 1c )-CH2] r -[CH2] q -R 1a , -C( =O)CH2-[CH(OR 1c )-CH2] r -[C(=O)CH2] p -[CH2] q -R 1a , -C(=O)OR 1c , -C(=O)N(R 1c )2, -C(=O)-CH =CH-C(=O)OR 1c , -C(=O)-[CH2] q -C(=O)OR 1c , -C (=O)-CH2CH2-C(=O)OR 1c , -C(=O)CH2-[C(=O)CH 2] p -[CH2] q -C(=O)OR 1c , -C(=O)-[CH2] q -C(=O) R 1a , -C(=O)-[CH2] q -C(=O)R 1z , -[C(=O)CH2] q - C(=O)R 1z , -C(=O)-CH2CH2-C(=O)R 1z , -C(=O)-C H=CH-[C(=O)] p R 1z , -C(=O)CH2-[C(=O)CH2] p -[ CH2] q -C(=O)R 1z , -SR 1d , [ka] wherein C1 to C 20 Alkyl, C2-C 20 Alkenyl or C2-C 20 Archi Nil is one or more R 1a are optionally substituted with C1 to C 20 Alkyl, C2-C20 a Alkenyl, or C2-C 20 One or more methylene moieties of alkynyl may be one or more optionally substituted with a carbonyl moiety, Each R 1a are independently H, halogen, C1-C 20 Alkyl, C2-C 20 Alkenyl , -OR 1c , -C(=O)OR 1c , -C(=O)N(R 1c )2, -N(R 1c )2 , -N(R 1c )C(=O)R 1b , -N(R 1c )C(=O)R 1z , -N(R 1c ) C(=O)OR 1c , -OC(=O)R 1b , -OC(=O)R 1z , -OC(=O)O R 1c , -OSi(R 1g )3, -SC(=O)R 1b , -SC(=O)R 1z , -SC (=O)OR 1c , -SC(=O)N(R 1c )2, -C(=O)R 1b , -C(=O) R 1z , -SR 1d , or R 1z wherein C1 to C 20 Alkyl, C2-C 20 a Alkenyl, or C2-C 20 Alkynyl can be one or more R 1e optionally replaced by Each R 1b are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C2 0Alkynyl, -(CH2) q -C(=O)OR 1c , -(CH2)q -C(=O)R1 c , -CH2-C(=O)-(CH2) q -C(=O)OR 1c , -CH2-[C(=O )CH2] p -[CH2] q -C(=O)OR 1c , -CH=CH-C(=O)OR 1c , -C(R 1e )=C(R 1e )-C(R 1e )-C(=O)OR 1c , -C(=O)N (R 1c )2, or R 1z wherein C1 to C 20 Alkyl, C2-C 20 Arkeny or C2~C 20 Alkynyl is a group consisting of one or more R 1e optionally replaced by Each R 1c are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2~ C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 heterocycloalkyl, C3~C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 alkyl)-( C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterogeneity Chloroalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), or -(C 1~C 20 Alkyl)-(C3~C 12 heteroaryl), wherein C1-C 20 Alkyl , C2~C20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C 3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl , -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 a Rukill)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl)-(C 3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroary R) is one or more R 1e or two R 1c But they ended up C3 to C, together with one or more intervening atoms 12 Cycloalkyl or C3-C1 2 heterocycloalkyl, wherein C3-C 12 Cycloalkyl or C3-C 12 Heterocycloalkyl can be one or more R 1e optionally replaced by Each R 1d are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C2 0Alkynyl, C3-C 10 Cycloalkyl, C3-C 12 Cycloalkyl, C3-C1 2Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C 1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 alkyl) -(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C1 2aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl In the formula, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Ally Lu, C3~C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 Cyclo alkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), - (C1~C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 Alkyl )-(C3~C 12 heteroaryl) can be one or more R 1e optionally replaced by Each R 1e are independently H, halogen, oxo, C1-C 20 Alkyl, C2-C 20 Al Kenyl, C2-C 20 Alkynyl, -OR 1g , -C(=O)OR 1g , -C(=O)N (R 1g )2, -N(R 1f )2, -N(R 1g )2, -N(R 1g )C(=O)R 1f , -N(R 1g )C(=NH)R 1f , -N(R 1g )C(=O)R 1z, -N(R 1g )C(=O)OR 1g , -OC(=O)R 1f , -OC(=O)R 1z , -OC(=O) OR 1g , -OSi(R 1g )3, -SR 1g , -N + (R 1g )3, -SC(=O)R 1f , -SC(=O)R 1z , -SC(=O)OR 1g , -SC(=O)N(R 1g )2 , -C(=O)R 1f , -C(=O)R 1z , C3~C 12 Cycloalkyl, C3-C1 2Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, or R 1z wherein C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Al Quinyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C1 2 aryl or C3-C 12 Heteroaryl is one or more R 1f or R 1z At the discretion of replaced by will, Each R 1f are independently H, oxo, C1-C 20 Alkyl, C2-C 20 Alkenyl, C 2~C 20 Alkynyl, -OSi(R 1g )3, -OR 1g , -CH2C(=O)OR1 g , -CH=CH-C(=O)OR 1g , -C(=O)OR 1g, -C(=O)N(R1 g )2, -N(R 1g )2, or R 1z wherein C1 to C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 Alkynyl is a group consisting of one or more R 1z optionally replaced by R, Each R 1g are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2~ C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 heterocycloalkyl, C3~C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 alkyl)-( C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterogeneity Chloroalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), or -(C 1~C 20 Alkyl)-(C3~C 12 heteroaryl, wherein C1-C 20 Al Kill, C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 cycloalkyl , C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Hetero ant Rule, -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C2 0 alkyl)-(C3~C 12heterocycloalkyl), -(C1-C 20 alkyl)- (C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroa Reel) is one or more R 1z optionally replaced by Each R 1z is independent [ka] and each n is independently an integer ranging from 0 to 20; each p is independently an integer ranging from 0 to 20; each q is independently an integer ranging from 0 to 20; each r is independently an integer ranging from 0 to 20; R2 and R3 are independently H, -C(=O)R 1b , -C(=O)OR 1c , -C(= O)N(R 1c )2, -C(=O)R 1z , -C(=O)-CH=CH-C(=O)OR 1c , -C(=O)-CH2-CH2-C(=O)OR 1c , [ka] -C(=O)-CH=CH-C(=O)-R 1z , -C(=O)-CH2-CH2-C( =O)-R 1z , -Si(R 1g )3. [ka] and Each X is independently -OR 1c , -SR 1c , -N(R 1c )2, [ka] or R 1z Or or two Xs, together with one or more intervening atoms to which they are attached, form a C5-C 12 Heterocycloalkyl or C5-C 12 Forming a heteroaryl, wherein C5-C 12 F Heterocycloalkyl or C5-C 12 Heteroaryl may optionally be one or more R 1a in is replaced, T is a bond or one or more R 1e Optionally substituted C1 to C 20 Alkyl is. In some aspects, the present disclosure provides, inter alia, a compound of formula (I) or (II'): [ka] or a pharmaceutically acceptable salt or solvate thereof, In the formula, R1 is H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Al Quinyl, -C(=O)R 1b , -C(=O)R 1c , -C(=O)R 1z , -C(=O) -(CH=CH) n -R 1a , -C(=O)CH2-[C(=O)CH2] p -[CH2 ] q -R 1a , -C(=O)CH2-[CH(OR 1c )-CH2] p -[CH2] q - R 1a , -C(=O)CH2-[C(=O)CH2] p-[CH(OR 1c )-CH2] r -[CH2] q -R 1a 、-C(=O)-CH(C(=O)R 1b )-[C(=O)C H2] p -[CH(OR 1c )-CH2] r -[CH2] q -R 1a 、-C(=O)CH 2-[CH(OR 1c )-CH2] r -[C(=O)CH2] p -[CH2] q -R 1a 、-C(=O)OR 1c 、-C(=O)N(R 1c )2、-C(=O)-CH=CH-C (=O)OR 1c 、-C(=O)-[CH2] q -C(=O)OR 1c 、-C(=O)- CH2CH2-C(=O)OR 1c 、-C(=O)CH2-[C(=O)CH2] p - CH2] q -C(=O)OR 1c 、-C(=O)-[CH2] q -C(=O)R 1z 、- C(=O)-CH2CH2-C(=O)R 1z 、-C(=O)CH2-[C(=O)CH 2] p -[CH2] q -C(=O)R 1z 、-SR 1d 、

Chemical formula

[0005] In some embodiments, the present disclosure provides a method for treating a rheumatoid arthritis, comprising administering a therapeutically effective amount of at least one compound of the present disclosure to a patient. The present invention provides a method for treating or preventing a disease in a subject, comprising administering to In some aspects, the present disclosure provides a method for treating or preventing a disease in a subject. At least one compound of the disclosure is provided, wherein the at least one compound of the disclosure comprises at least Also intended for administration to a subject in a single therapeutically effective amount. In some aspects, the present disclosure provides a method for the manufacture of a medicament for treating or preventing a disease in a subject. and the use of at least one compound of the present disclosure for the treatment of a cancer, is for administration to a subject in at least one therapeutically effective amount. Unless otherwise defined, all technical and scientific terms used herein are within the meaning of the present disclosure. has the same meaning as commonly understood by a person of ordinary skill in the art. In this specification, the singular forms "a," "an," and "the" include the plural forms unless the context clearly dictates otherwise. Use of methods and materials similar or equivalent to those described in the present disclosure in the practice or testing of the present disclosure. Suitable methods and materials are described below. All patent applications, patents and other references are incorporated by reference. The documents are not admitted to be prior art to the claimed invention. The present specification, including its definitions, takes precedence. Furthermore, the materials, methods, and examples are illustrative only and are not limiting. No distinction is intended between the chemical structures and names of the compounds disclosed herein. In case of a conflict, the chemical structure shall prevail. Other features and advantages of the present disclosure will become apparent from the following detailed description and claims. It would be. [Brief explanation of the drawings]

[0006] [Figure 1] FIG. 1 is a schematic diagram of fatty acid oxidation and acetyl-CoA synthesis. [Figure 2] FIG. 1 is a schematic diagram of a compound of the present disclosure that is converted to two or more equivalents of acetyl-CoA. [Figure 3] FIG. 1 shows endogenous and D-labeled CoA measured in the brain (cerebellum) after administration of compound 1216. [Figure 4] FIG. 1 shows endogenous and D-labeled CoA measured in the brain (cerebrum) after administration of compound 1216. [Figure 5] FIG. 1 shows endogenous and D-labeled CoA measured in the brain (remaining part of the brain including the globus pallidus) following administration of compound 1216. [Figure 6] FIG. 1 shows endogenous and D-labeled CoA measured in the liver after administration of compound 1216. [Figure 7] FIG. 1 depicts endogenous and D-labeled CoA measured in the heart after administration of compound 1216. [Figure 8] FIG. 1 depicts endogenous and D-labeled CoA measured in the kidney after administration of compound 1216. [Figure 9] FIG. 1 shows the time course of D-labeled CoA measured in the brain (cerebellum) after administration of compound 1216. [Figure 10] FIG. 1 shows the time course of D-labeled CoA measured in the brain (cerebrum) after administration of compound 1216. [Figure 11] FIG. 1 shows the time course of D-labeled CoA measured in the brain (rest of the brain including the globus pallidus) following administration of compound 1216. [Figure 12] FIG. 1 shows the time course of D-labeled CoA measured in the liver after administration of compound 1216. [Figure 13] FIG. 1 shows the time course of D-labeled CoA measured in the liver after administration of compound 1216. [Figure 14] FIG. 1 shows the time course of D-labeled CoA measured in the kidney after administration of compound 1216. [Figure 15A] FIG. 10 depicts grip strength in mice fed a cbl− / − diet compared to healthy mice fed a control diet. [Figure 15B] FIG. 1 shows grip strength in mice on a cbl− / − diet compared to healthy mice on a control diet and mice on a cbl− / − diet treated with Compound No. 500 and Compound No. 410. DETAILED DESCRIPTION OF THE INVENTION

[0007] Compounds of the Disclosure In some aspects, the present disclosure provides, inter alia, a compound of formula (I) or (II'): [ka] or a pharmaceutically acceptable salt or solvate thereof, wherein: R1 is H, C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl , -C(=O)-(C1~C 20 alkyl), -C(=O)-(C2-C 20 Alkenyl ), -C(=O)-(C2~C 20 alkynyl), -C(=O)R 1b , -C(=O)R 1c , -C(=O)R 1z , -C(=O)-(CH=CH) n -R 1a , -C(=O)C H2-[C(=O)CH2] p -[CH2] q -R 1a , -C(=O)CH2-[CH( OR 1c )-CH2] p -[CH2] q -R 1a , -C(=O)CH2-[C(=O)C H2] p -[CH(OR 1c )-CH2] r -[CH2] q -R 1a , -C(=O)-C H(C(=O)R 1b )-[C(=O)CH2] p -[CH(OR 1c )-CH2] r - [CH2]q -R 1a , -C(=O)CH2-[CH(OR 1c )-CH2] r -[C( =O)CH2] p -[CH2] q -R 1a , -C(=O)OR 1c , -C(=O)N(R 1c )2, -C(=O)-CH=CH-C(=O)OR 1c , -C(=O)-[CH2] q -C(=O)OR 1c , -C(=O)-CH2CH2-C(=O)OR 1c , -C(= O)CH2-[C(=O)CH2] p -[CH2] q -C(=O)OR 1c , -C(=O )-[CH2] q -C(=O)R 1a , -C(=O)-[CH2] q -C(=O)R 1z , -[C(=O)CH2] q C(=O)R 1z , -C(=O)-CH2CH2-C(=O )R 1z , -C(=O)-CH=CH-[C(=O)] p R 1z , -C(=O)CH2- [C(=O)CH2] p -[CH2] q -C(=O)R 1z , -SR 1d , [ka] wherein C1 to C 20 Alkyl, C2-C 20 Alkenyl or C2-C 20 Archi Nyl may optionally be one or more R 1a It is substituted with C1 to C20 Alkyl, C2~ C 20 Alkenyl, or C2-C 20 One or more methylene moieties in an alkynyl group are optional. is substituted with one or more carbonyl moieties, Each R 1a are independently H, halogen, C1-C 20 Alkyl, C2-C 20 alkenyl, -OR 1c , -C(=O)OR 1c , -C(=O)N(R 1c )2, -N(R 1c )2, -N(R 1c )C(=O)R 1b , -N(R 1c )C(=O)R 1z , -N(R 1c )C (=O)OR 1c , -OC(=O)R 1b , -OC(=O)R 1z , -OC(=O)OR 1c , -OSi(R 1g )3, -SC(=O)R 1b , -SC(=O)R 1z , -SC( =O)OR 1c , -SC(=O)N(R 1c )2, -C(=O)R 1b , -C(=O)R 1z , -SR 1d , or R 1z wherein C1 to C 20 Alkyl, C2-C 20 Al Kenyl, or C2-C 20 The alkynyl may optionally be one or more R 1e is replaced by Each R 1b are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C2 0Alkynyl, -(CH2) q -C(=O)OR1c , -(CH2) q -C(=O)R1 c , -CH2-C(=O)-(CH2) q -C(=O)OR 1c , -CH2-[C(=O )CH2] p -[CH2] q -C(=O)OR 1c , -CH=CH-C(=O)OR 1c , -C(R 1e )=C(R 1e )-C(=O)OR 1c , -C(=O)OR 1c , -C( =O)N(R 1c )2, or R 1z , in the formula C1~C 20 Alkyl, C2-C 20 Arkeny or C2~C 20 The alkynyl may optionally be one or more R 1e is replaced by Each R 1c are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2~ C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 heterocycloalkyl, C3~C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 alkyl)-( C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterogeneity Chloroalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), or -(C 1~C 20 Alkyl)-(C3~C 12 Heteroaryl in the formula C1-C 20 Alkyl, C 2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3~ C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, - (C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Archi C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~ C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl) is optionally one or more R 1e or two R 1c But they are connected C3-C with one or more intervening atoms 12 Cycloalkyl or C3-C 12 Forming a heterocycloalkyl, wherein C3-C 12 Cycloalkyl or C3-C 12 F A tetracycloalkyl may optionally be one or more R 1e Each R is replaced by 1d is independently H , C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 10 Cycloalkyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl , C3~C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 alkyl)- (C3~C 12Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Hetero Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), or -( C1~C 20 Alkyl)-(C3~C 12 heteroaryl), wherein C1-C 20 Archi Lu, C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 cycloalkyl, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroary Le, -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl)-( C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Hetero ant The group (R) may optionally be one or more R 1e is replaced by Each R 1e are independently H, halogen, oxo, C1-C 20 Alkyl, C2-C 20 a Alkenyl, C2-C 20 Alkynyl, -OR 1g , -C(=O)OR 1g , -C(=O) N(R 1g )2, -N, (R 1f )2, -N(R 1g )2, -N(R 1g )C(= O)R 1f , -N(R 1g)C(=NH)R 1f , -N(R 1g )C(=O)R 1z ,- N(R 1g )C(=O)OR 1g , -OC(=O)R 1f , -OC(=O)R 1z , -O C(=O)OR 1g , -OSi(R 1g )3, -SR 1g , -N + (R 1g )3, -SC (=O)R 1f , -SC(=O)R 1z , -SC(=O)OR 1g , -SC(=O)N( R 1g )2, -C(=O)R 1f , -C(=O)R 1z , C3~C 12 cycloalkyl, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroary Ru or R 1z , where C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3~ C 12 Aryl or C3-C 12 The heteroaryl may optionally include one or more R 1f also is R 1z is replaced by Each R 1f are independently H, oxo, C1-C 20 Alkyl, C2-C 20 Alkenyl, C 2~C 20 Alkynyl, -OSi(R 1g )3, -OR 1g , -CH2C(=O)OR1 g , -CH=CH-C(=O)OR 1g , -C(=O)OR 1g , -C(=O)N(R1 g )2, -N(R 1g )2, or R 1z , C1~C in the formula 20 Alkyl, C2-C 20 Al Kenyl, or C2-C 20 Alkynyl option, one or more OR 1g or R 1z is replaced by Each R 1g are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2~ C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 heterocycloalkyl, C3~C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 alkyl)-( C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterogeneity Chloroalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), or -(C 1~C 20 Alkyl)-(C3~C 12 Heteroaryl in the formula C1-C 20 Alkyl, C 2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3~ C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, - (C1~C20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Archi C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~ C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl) is optionally one or more R 1z is replaced by Each R 1z independently [ka] and each n is independently an integer ranging from 0 to 20; each p is independently an integer ranging from 0 to 20; each q is independently an integer ranging from 0 to 20; each r is independently an integer ranging from 0 to 20; R2 and R3 are independently H, -C(=O)R 1b , -C(=O)OR 1c , -C(=O) N(R 1c )2, -C(=O)R 1z , -C(=O)-CH=CH-C(=O)OR 1c , -C(=O)-CH2-CH2-C(=O)OR 1c , [ka] -C(=O)-CH=CH-C(=O)-R 1z , -C(=O)-CH2-CH2-C( =O)-R 1z , -Si(R 1g )3. [ka] and Each X is independently -OR 1c , -SR 1c , -N(R 1c )2, [ka] or R 1z and or two Xs, together with one or more intervening atoms to which they are connected, form a C5-C1 2 heterocycloalkyl or C5-C 12 Forming a heteroaryl, wherein C5-C 12 Heterocycloalkyl or C5-C 12 Heteroaryl may optionally be one or more R 1a is replaced by, and T is one or more R 1e or C1-C 20 is alkyl . In some aspects, the present disclosure provides, inter alia, compounds of formula (I) or (II'): R: [ka] or a pharmaceutically acceptable salt or solvate thereof, wherein: R1 is H, C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl , -C(=O)R 1b , -C(=O)R 1c , -C(=O)R 1z , -C(=O)-(C H=CH) n -R 1a , -C(=O)CH2-[C(=O)CH2] p -[CH2] q - R 1a , -C(=O)CH2-[CH(OR1c )-CH2] p -[CH2] q -R 1a 、-C(=O)CH2-[C(=O)CH2] p -[CH(OR 1c )-CH2] r -[ CH2] q -R 1a 、-C(=O)-CH(C(=O)R 1b )-[C(=O)CH2] p -[CH(OR 1c )-CH2] r -[CH2] q -R 1a 、-C(=O)CH2-[ CH(OR 1c )-CH2] r -[C(=O)CH2] p -[CH2] q -R 1a 、-C (=O)OR 1c 、-C(=O)N(R 1c )2、-C(=O)-CH=CH-C(=O )OR 1c 、-C(=O)-[CH2] q -C(=O)OR 1c 、-C(=O)-CH2 CH2-C(=O)OR 1c 、-C(=O)CH2-[C(=O)CH2] p -[CH2 ] q -C(=O)OR 1c 、-C(=O)-[CH2] q -C(=O)R 1a 、-C(= O)-[CH2] q -C(=O)R 1z 、-[C(=O)CH2] q C(=O)R 1z 、 -C(=O)-CH2CH2-C(=O)R 1z 、-C(=O)-CH=CH-[C(= O)] p R1z , -C(=O)CH2-[C(=O)CH2] p -[CH2] q -C(= O)R 1z , -SR 1d , [ka] wherein C1 to C 20 Alkyl, C2-C 20 Alkenyl or C2-C 20 Archi Nyl may optionally be one or more R 1a wherein C1 to C 20 One of the alkyl Or multiple methylene moieties are C2 to C 20 Alkenyl, or C2-C 20 Alkynyl is optionally substituted by one or more carbonyl moieties; Each R 1a are independently H, halogen, C1-C 20 Alkyl, C2-C 20 alkenyl, -OR 1c , -C(=O)OR 1c , -C(=O)N(R 1c )2, -N(R 1c )2, -N(R 1c )C(=O)R 1b , -N(R 1c )C(=O)R 1z , -N(R 1c )C (=O)OR 1c , -OC(=O)R 1b , -OC(=O)R 1z , -OC(=O)OR 1c , -SC(=O)R 1b , -SC(=O)R 1z , -SC(=O)OR 1c , -SC (=O)N(R 1c )2, -C(=O)R 1b , -C(=O)R1z , -SR 1d , or R 1z wherein C1 to C 20 Alkyl, C2-C 20 Alkenyl, or C2-C2 Alkynyl is optionally substituted with one or more R 1e is replaced by Each R 1b are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C2 0Alkynyl, -(CH2) q -C(=O)OR 1c , -(CH2) q -C(=O)R1 c , -CH2-C(=O)-(CH2) q -C(=O)OR 1c , -CH2-[C(=O )CH2] p -[CH2] q -C(=O)OR 1c , -CH=CH-C(=O)OR 1c , -C(R 1e )=C(R 1e )-C(=O)OR 1c , -C(=O)OR 1c , -C( =O)N(R 1c )2, or R 1z , C1~C in the formula 20 Alkyl, C2-C 20 Arkeny or C2~C 20 The alkynyl may optionally be one or more R 1e is replaced by Each R 1c are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2~ C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 heterocycloalkyl, C3~C 12 Aryl, C3-C12 Heteroaryl, -(C1-C 20 alkyl)-( C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterogeneity Chloroalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), or -(C 1~C 20 Alkyl)-(C3~C 12 Heteroaryl in the formula C1-C 20 Alkyl, C 2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3~ C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, - (C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Archi C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~ C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl) is optionally one or more R 1e or two R 1c But they are connected C3-C with one or more intervening atoms 12 Cycloalkyl or C3-C 12 Forming a heterocycloalkyl, wherein C3-C 12 Cycloalkyl or C3-C 12 F A tetracycloalkyl may optionally be one or more R 1e is replaced by Each R 1d are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C2 0 alkynyl, C3-C10 cycloalkyl, C3-C 12 Cycloalkyl, C3-C1 2Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C 1-C20 alkyl)-(C3-C 12 Cycloalkyl), -(C1-C 20 alkyl) -(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C1 2aryl), or -(C1-C 20 Alkyl)-(C3~C 12 heteroaryl), the formula Medium, C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3~ C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C 3~C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 Cycloalkane -(C1~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1 ~C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 alkyl)-( C3~C 12 heteroaryl) optionally includes one or more R 1e is replaced by Each R 1e are independently H, halogen, C1-C 20 Alkyl, C2-C20 alkenyl, C2~C 20 Alkynyl, -OR 1g , -C(=O)OR 1g , -C(=O)N(R 1g )2, -N(R 1g )2, -N(R 1g )C(=O)R 1f , -N(R 1g )C(=NH )R 1f , -N(R 1g )C(=O)R 1z , -N(R 1g )C(=O)OR 1g , -O C(=O)R 1f , -OC(=O)R 1z , -OC(=O)OR 1g , -SR 1g , -N + (R 1g )3, -SC(=O)R 1f , -SC(=O)R 1z , -SC(=O)OR1 g , -SC(=O)N(R 1g )2, -C(=O)R 1f , -C(=O)R 1z , C3~ C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C 3~C 12 Heteroaryl, or R 1z , where C1~C 20 Alkyl, C2-C 20 a Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Hetero Cycloalkyl, C3-C 12 Aryl or C3-C 12 Optionally one heteroaryl or multiple R 1f or R1z is replaced by Each R 1f are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, -OR 1g , -CH2C(=O)OR 1g , -CH=CH-C(=O) OR 1g , -C(=O), OR 1g , -C(=O)N(R 1g )2, -N(R 1g )2, or R 1z wherein C1 to C 20 Alkyl, C2-C 20 alkenyl, or C2~C 20 The alkynyl may optionally be one or more -OR 1g or R 1z is replaced by Each R 1g are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2~ C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 heterocycloalkyl, C3~C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 alkyl)-( C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterogeneity Chloroalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), or -(C 1~C 20 Alkyl)-(C3~C 12 Heteroaryl in the formula C1-C 20 Alkyl, C 2~C 20 Alkenyl, C2-C20 Alkynyl, C3-C 12 Cycloalkyl, C3~ C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, - (C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Archi C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~ C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl) is optionally one or more R 1z Each R 1z is independent [ka] and each n is independently an integer ranging from 0 to 20; each p is independently an integer ranging from 0 to 20; each q is independently an integer ranging from 0 to 20; each r is independently an integer ranging from 0 to 20; R2 and R3 are independently H, -C(=O)R 1b , -C(=O)OR 1c , -C(=O )N(R 1c )2, -C(=O)R 1z , -C(=O)-CH=CH-C(=O)OR1 c , -C(=O)-CH2-CH2-C(=O)OR 1c , [ka] -C(=O)-CH=CH-C(=O)-R 1z, -C(=O)-CH2-CH2-C( =O)-R 1z , [ka] and Each X is independently -OR 1c , -SR 1c , -N(R 1c )2, [ka] or R 1z Or or two Xs, together with one or more intervening atoms to which they are attached, form a C5-C 12 Heterocycloalkyl or C5-C 12 Forming a heteroaryl, wherein C5-C 12 F Heterocycloalkyl or C5-C 12 Heteroaryl may optionally be one or more R 1a in is replaced, T is a bond or one or more R 1e Optionally substituted C1 to C 20 Alkyl is. In some aspects, the present disclosure provides a compound of formula (I) or (II): [ka] or a pharmaceutically acceptable salt or solvate thereof, In the formula, R1 is H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Al Quinyl, -C(=O)R 1b , -C(=O)R 1z , -C(=O)-(CH=CH) n - R 1a , -C(=O)CH(R1a )-[C(=O)CH(R 1a )] p -[CH2] q -R 1a 、-C(=O)CH2-[CH(OR 1c )-CH2] p ​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​wherein C1 to C 20 Alkyl, C2-C 20 Alkenyl or C2-C 20 Archi Nil is one or more R 1a are optionally substituted with C1 to C 20 Alkyl, C2-C 20 a Alkenyl, or C2-C 20 One or more methylene moieties of alkynyl may be one or more optionally substituted with a carbonyl moiety, Each R 1a are independently H, halogen, C1-C 20 Alkyl, C2-C 20 Alkenyl , -OR 1c , -C(=O)OR 1c , -C(=O)N(R 1c )2, -N(R 1c )2 , -N(R 1c )C(=O)R 1b , -N(R 1c )C(=O)R 1z , -N(R 1c ) C(=O)OR 1c , -OC(=O)R 1b , -OC(=O)R 1z , -OC(=O)O R 1c , -OSi(R 1g )3, -SC(=O)R 1b , -SC(=O)R 1z , -SC (=O)OR 1c , -SC(=O)N(R 1c )2, -C(=O)R 1b , -C(=O) R 1z , -SR 1d , or R 1z wherein C1 to C 20 Alkyl, C2-C 20 a Alkenyl, or C2-C 20 Alkynyl can be one or more R 1e optionally replaced by Each R 1b are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C2 0Alkynyl, -(CH2) q -C(=O)OR 1c , -CH2-C(=O)-(CH2 ) q -C(=O)OR 1c , -CH2-[C(=O)CH2] p -[CH2] q -C(= O)OR 1c , -CH=CH-C(=O)OR 1c , -C(=O)OR 1c , -C(=O )N(R 1c )2, or R 1z wherein C1 to C 20 Alkyl, C2-C 20 Al Kenyl, or C2-C 20 Alkynyl is a group consisting of one or more R 1e optionally replaced by Each R 1c are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2~ C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 heterocycloalkyl, C3~C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 alkyl)-( C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterogeneity Chloroalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), or -(C 1~C 20 Alkyl)-(C3~C 12heteroaryl), wherein C1-C 20 Alkyl , C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C 3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl , -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 a Rukill)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl)-(C 3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroary R) is one or more R 1e or two R 1c But they ended up C3 to C, together with one or more intervening atoms 12 Cycloalkyl or C3-C1 2 heterocycloalkyl, wherein C3-C 12 Cycloalkyl or C3-C 12 Heterocycloalkyl can be one or more R 1e optionally replaced by Each R 1d are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C2 0Alkynyl, C3-C 10 Cycloalkyl, C3-C 12 Cycloalkyl, C3-C1 2Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C 1~C 20 Alkyl)-(C3~C12 Cycloalkyl), -(C1-C 20 alkyl) -(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C1 2aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl In the formula, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Ally Lu, C3~C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 Cyclo alkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), - (C1~C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 Alkyl )-(C3~C 12 heteroaryl) can be one or more R 1e optionally replaced by Each R 1e are independently H, halogen, C1-C 20 Alkyl, C2-C 20 alkenyl, C2~C 20 Alkynyl, -OR 1g , -C(=O)OR 1g , -C(=O)N(R 1g )2, -N(R 1g )2, -N(R 1g )C(=O)R 1f , -N(R 1g )C(=O) R 1z , -N(R1g )C(=O)OR 1g , -OC(=O)R 1f , -OC(=O)R 1z , -OC(=O)OR 1g , -OSi(R 1g )3, -SR 1g , -N + (R 1g ) 3. -SC(=O)R 1f , -SC(=O)R 1z , -SC(=O)OR 1g , -SC( =O)N(R 1g )2, -C(=O)R 1f , -C(=O)R 1z , or R 1z and In the formula, C1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 Alkynyl is , one or more R 1z optionally replaced by Each R 1f are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C2 0 alkynyl, -OSi(R 1g )3, -CH2C(=O)OR 1g , -CH=CH-C (=O)OR 1g , -C(=O)OR 1g , -C(=O)N(R 1g )2, or R 1z , Here, C1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 Alkynyl is one or more R 1z optionally replaced by Each R 1g are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2~ C 20Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 heterocycloalkyl, C3~C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 alkyl)-( C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterogeneity Chloroalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), or -(C 1~C 20 Alkyl)-(C3~C 12 heteroaryl, wherein C1-C 20 Al Kill, C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 cycloalkyl , C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Hetero ant Rule, -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C2 0 alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl)- (C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroa Reel) is one or more R 1z optionally replaced by Each R 1z is independently [ka] and each n is independently an integer ranging from 0 to 20; each p is independently an integer ranging from 0 to 20; each q is independently an integer ranging from 0 to 20; each r is independently an integer ranging from 0 to 20; R2 and R3 are independently H, -C(=O)R 1b , -C(=O)OR 1c , -C(= O)N(R 1c )2, -C(=O)R 1z , -C(=O)-CH=CH-C(=O)OR 1c , -C(=O)-CH2-CH2-C(=O)OR 1c , [ka] -C(=O)-CH=CH-C(=O)-R 1z、 -C(=O)-CH2-CH2-C( =O)-R 1z , [ka] and Each X is independently -OR 1c , -SR 1c , -N(R 1c )2, [ka] or R 1z is.

[0008] In some embodiments, the compound is of formula (I): [ka] or a pharmaceutically acceptable salt or solvate thereof, wherein: R1 is H, C1~C 20 Alkyl, C2-C 20アルケニル、C2~C 20 アルキニル 、-C(=O)R 1b 、-C(=O)R 1c 、-C(=O)R 1z 、-C(=O)-(C H=CH) n -R 1a 、-C(=O)CH2-[C(=O)CH2] p -[CH2] q - R 1a 、-C(=O)CH2-[CH(OR 1c )-CH2] p -[CH2] q -R 1a 、-C(=O)CH2-[C(=O)CH2] p -[CH(OR 1c )-CH2] r -[ CH2] q -R 1a 、-C(=O)-CH(C(=O)R 1b )-[C(=O)CH2] p -[CH(OR 1c )-CH2] r -[CH2] q -R 1a 、-C(=O)CH2-[ CH(OR 1c )-CH2] r -[C(=O)CH2] p -[CH2] q -R 1a 、-C (=O)OR 1c 、-C(=O)N(R 1c )2、-C(=O)-CH=CH-C(=O )OR 1c 、-C(=O)-[CH2] q -C(=O)OR 1c 、-C(=O)-CH2 CH2-C(=O)OR 1c 、-C(=O)CH2-[C(=O)CH2] p -[CH2 ] q -C(=O)OR1c , -C(=O)-[CH2] q -C(=O)R 1a , -C(= O)-[CH2] q -C(=O)R 1z , -[C(=O)CH2] q C(=O)R 1z , -C(=O)-CH2CH2-C(=O)R 1z , -C(=O)-CH=CH-[C(= O)] p R 1z , -C(=O)CH2-[C(=O)CH2] p -[CH2] q -C(= O)R 1z , [ka] wherein C1 to C 20 Alkyl, C2-C 20 Alkenyl or C2-C 20 Archi Nyl may optionally be one or more R 1a It is substituted with C1 to C 20 Alkyl, C2~ C 20 Alkenyl, or C2-C 20 One or more methylene moieties in an alkynyl may optionally be optionally substituted with one or more carbonyl moieties, Each R 1a are independently H, halogen, C1-C 20 Alkyl, C2-C 20 alkenyl, -OR 1c , -C(=O)OR 1c , -C(=O)N(R 1c )2, -N(R 1c )2, -N(R 1c )C(=O)R 1b , -N(R 1c )C(=O)R 1z , -N(R 1c )C (=O)OR 1c , -OC(=O)R 1b , -OC(=O)R 1z , -OC(=O)OR 1c , -SC(=O)R 1b , -SC(=O)R 1z , -SC(=O)OR 1c , -SC (=O)N(R 1c )2, -C(=O)R 1b , -C(=O)R 1z , -SR 1d , or R 1z wherein C1 to C 20 Alkyl, C2-C 20 Alkenyl, or C2-C2 Alkynyl is optionally substituted with one or more R 1e is replaced by Each R 1b are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C2 0Alkynyl, -(CH2) q -C(=O)OR 1c , -(CH2) q -C(=O)R1 c , -CH2-C(=O)-(CH2) q -C(=O)OR 1c , -CH2-[C(=O )CH2] p -[CH2] q -C(=O)OR 1c , -CH=CH-C(=O)OR 1c , -C(R 1e )=C(R 1e )-C(=O)OR 1c , -C(=O)OR 1c , -C( =O)N(R 1c )2, or R 1z , C1~C in the formula 20 Alkyl, C2-C 20 Arkeny or C2~C 20The alkynyl may optionally be one or more R 1e is replaced by Each R 1c are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2~ C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 heterocycloalkyl, C3~C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 alkyl)-( C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterogeneity Chloroalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), or -(C 1~C 20 Alkyl)-(C3~C 12 Heteroaryl in the formula C1-C 20 Alkyl, C 2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3~ C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, - (C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Archi C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~ C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl) is optionally one or more R 1eor two R 1c But they are connected C3-C with one or more intervening atoms 12 Cycloalkyl or C3-C 12 Forming a heterocycloalkyl, wherein C3-C 12 Cycloalkyl or C3-C 12 F A tetracycloalkyl may optionally be one or more R 1e is replaced by Each R 1d are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C2 0Alkynyl, C3-C 10 Cycloalkyl, C3-C 12 Cycloalkyl, C3-C1 2Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C 1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 alkyl) -(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C1 2aryl), or -(C1-C 20 Alkyl)-(C3~C 12 heteroaryl), the formula Medium, C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3~ C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C 3~C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 Cycloalkane -(C1~C 20Alkyl)-(C3~C 12 heterocycloalkyl), -(C1 ~C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 alkyl)-( C3~C 12 heteroaryl) optionally includes one or more R 1e is replaced by Each R 1e are independently H, halogen, C1-C 20 Alkyl, C2-C 20 alkenyl, C2~C 20 Alkynyl, -OR 1g , -C(=O)OR 1g , -C(=O)N(R 1g )2, -N(R 1g )2, -N(R 1g )C(=O)R 1f , -N(R 1g )C(=NH )R 1f , -N(R 1g )C(=O)R 1z , -N(R 1g )C(=O)OR 1g , -O C(=O)R 1f , -OC(=O)R 1z , -OC(=O)OR 1g , -SR 1g , -N + (R 1g )3, -SC(=O)R 1f , -SC(=O)R 1z , -SC(=O)OR1 g , -SC(=O)N(R 1g )2, -C(=O)R 1f , -C(=O)R 1z , C3~ C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C 3~C 12Heteroaryl, or R 1z , where C1~C 20 Alkyl, C2-C 20 a Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Hetero Cycloalkyl, C3-C 12 Aryl or C3-C 12 Optionally one heteroaryl or multiple R 1f or R 1z is replaced by Each R 1f are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, -OR 1g , -CH2C(=O)OR 1g , -CH=CH-C(=O) OR 1g , -C(=O), OR 1g , -C(=O)N(R 1g )2, -N(R 1g )2, or R 1z wherein C1 to C 20 Alkyl, C2-C 20 alkenyl, or C2~C 20 The alkynyl may optionally be one or more -OR 1g or R 1z is replaced by Each R 1g are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2~ C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 heterocycloalkyl, C3~C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 alkyl)-( C3~C12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterogeneity Chloroalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), or -(C 1~C 20 Alkyl)-(C3~C 12 Heteroaryl in the formula C1-C 20 Alkyl, C 2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3~ C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, - (C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Archi C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~ C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl) is optionally one or more R 1z is replaced by Each R 1z is independent [ka] and each n is independently an integer ranging from 0 to 20; each p is independently an integer ranging from 0 to 20; each q is independently an integer ranging from 0 to 20; each r is independently an integer ranging from 0 to 20; R2 and R3 are independently H, -C(=O)R 1b, -C(=O)OR 1c , -C(=O) N(R 1c )2, -C(=O)R 1z , -C(=O)-CH=CH-C(=O)OR 1c 、-C( =O)-CH2-CH2-C(=O)OR 1c , [ka] and Each X is independently -OR 1c , -SR 1c , -N(R 1c )2, [ka] or R 1z and or two Xs, together with one or more intervening atoms to which they are attached, form a C5-C 12 Heterocycloalkyl or C5-C 12 Forming a heteroaryl, wherein C5-C 12 F Heterocycloalkyl or C5-C 12 Heteroaryl may optionally be one or more R 1a in is replaced, T is a bond or one or more R 1e Optionally substituted C1 to C 20 Alkyl and R1, R2, and R3 are not all H.

[0009] In some embodiments, the compound is of formula (II'): [ka] or a pharmaceutically acceptable salt or solvate thereof, wherein: Each R 1aare independently H, halogen, C1-C 20 Alkyl, C2-C 20 alkenyl, -OR 1c , -C(=O)OR 1c , -C(=O)N(R 1c )2, -N(R 1c )2, -N(R 1c )C(=O)R 1b , -N(R 1c )C(=O)R 1z , -N(R 1c )C (=O)OR 1c , -OC(=O)R 1b , -OC(=O)R 1z , -OC(=O)OR 1c , -SC(=O)R 1b , -SC(=O)R 1z , -SC(=O)OR 1c , -SC (=O)N(R 1c )2, -C(=O)R 1b , -C(=O)R 1z , -SR 1d , or R 1z wherein C1 to C 20 Alkyl, C2-C 20 Alkenyl, or C2-C2 Alkynyl is optionally substituted with one or more R 1e is replaced by Each R 1b are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C2 0Alkynyl, -(CH2) q -C(=O)OR 1c , -(CH2) q -C(=O)R1 c , -CH2-C(=O)-(CH2) q -C(=O)OR 1c , -CH2-[C(=O )CH2] p -[CH2] q -C(=O)OR1c , -CH=CH-C(=O)OR 1c , -C(R 1e )=C(R 1e )-C(=O)OR 1c , -C(=O)OR 1c , -C( =O)N(R 1c )2, or R 1z , C1~C in the formula 20 Alkyl, C2-C 20 Arkeny or C2~C 20 The alkynyl may optionally be one or more R 1e is replaced by Each R 1c are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2~ C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 heterocycloalkyl, C3~C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 alkyl)-( C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterogeneity Chloroalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), or -(C 1~C 20 Alkyl)-(C3~C 12 Heteroaryl in the formula C1-C 20 Alkyl, C 2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3~ C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, - (C1~C20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Archi C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~ C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl) is optionally one or more R 1e or two R 1c But they are connected C3-C with one or more intervening atoms 12 Cycloalkyl or C3-C 12 Forming a heterocycloalkyl, wherein C3-C 12 Cycloalkyl or C3-C 12 F A tetracycloalkyl may optionally be one or more R 1e is replaced by Each R 1d are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C2 0 alkynyl, C3-C10 cycloalkyl, C3-C 12 Cycloalkyl, C3-C1 2Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C 1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 alkyl) -(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C1 2aryl), or -(C1-C 20 Alkyl)-(C3~C 12 heteroaryl), the formula Medium, C1~C 20Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3~ C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C 3~C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 Cycloalkane -(C1~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1 ~C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 alkyl)-( C3~C 12 heteroaryl) optionally includes one or more R 1e is replaced by

[0010] Each R 1e are independently H, halogen, C1-C 20 Alkyl, C2-C 20 alkenyl, C2~C 20 Alkynyl, -OR 1g , -C(=O)OR 1g , -C(=O)N(R 1g )2, -N(R 1g )2, -N(R 1g )C(=O)R 1f , -N(R 1g )C(=NH )R 1f , -N(R 1g )C(=O)R 1z , -N(R 1g )C(=O)OR 1g , -O C(=O)R 1f , -OC(=O)R 1z , -OC(=O)OR 1g , -SR 1g , -N + (R1g )3, -SC(=O)R 1f , -SC(=O)R 1z , -SC(=O)OR1 g , -SC(=O)N(R 1g )2, -C(=O)R 1f , -C(=O)R 1z , C3~ C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C 3~C 12 Heteroaryl, or R 1z , where C1~C 20 Alkyl, C2-C 20 a Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Hetero Cycloalkyl, C3-C 12 Aryl or C3-C 12 Optionally one heteroaryl or multiple R 1f or R 1z is replaced by Each R 1f are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, -OR 1g , -CH2C(=O)OR 1g , -CH=CH-C(=O) OR 1g , -C(=O), OR 1g , -C(=O)N(R 1g )2, -N(R 1g )2, or R 1z wherein C1 to C 20 Alkyl, C2-C 20 alkenyl, or C2~C 20 The alkynyl may optionally be one or more -OR 1g or R 1zis replaced by Each R 1g are independently H, C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2~ C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 heterocycloalkyl, C3~C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 alkyl)-( C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterogeneity Chloroalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), or -(C 1~C 20 Alkyl)-(C3~C 12 Heteroaryl in the formula C1-C 20 Alkyl, C 2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3~ C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, - (C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Archi C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~ C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl) is optionally one or more R 1z is replaced by Each R1z is independent [ka] and each n is independently an integer ranging from 0 to 20; each p is independently an integer ranging from 0 to 20; each q is independently an integer ranging from 0 to 20; each r is independently an integer ranging from 0 to 20; R2 and R3 are independently H, -C(=O)R 1b , -C(=O)OR 1c , -C(=O) N(R 1c )2, -C(=O)R 1z , -C(=O)-CH=CH-C(=O)OR 1c , -C(=O)-CH2-CH2-C(=O)OR 1c , [ka] -C(=O)-CH=CH-C(=O)-R 1z , -C(=O)-CH2-CH2-C( =O)-R 1z , or [ka] and Each X is independently -OR 1c , -SR 1c , -N(R 1c )2, [ka] or R 1z and or two Xs, together with one or more intervening atoms to which they are connected, form a C5-C1 2 heterocycloalkyl or C5-C 12 Forming a heteroaryl, wherein C5-C12 Heterocycloalkyl or C5-C 12 Heteroaryl may optionally be one or more R 1a is replaced by, and T is one or more R 1e or C1-C 20 It is an alkyl , wherein R2 and R3 are not both H. For compounds of formula (I), (II), or (II'), R, R 1a , R 1b , R1 c , R 1d , R 1e , R 1f , R 1g , R 1z , R2, R3, X, T, n, p, q, and r is selected from groups described herein, where applicable, and R, R 1a , R 1b , R 1c , R 1d , R 1e , R 1f , R 1g , R 1z ,R2,R3,X,T,n,p,q, Any group described herein for any of R, R and r, if applicable, 1a , R 1b , R 1c , R 1d , R 1e , R 1f , R 1g , R 1z ,R2,R3,X,T,n It is understood that the residues p, q, and r may be combined with one or more of the residues p, q, and r. do.

[0011] Variable R1 In some embodiments, R1 is H. In some embodiments, R1 is C1-C 20アルキル、C2~C 20 アルケニル、 C2~C 20 アルキニル、-C(=O)R 1b 、-C(=O)R 1c 、-C(=O)R1 z 、-C(=O)-(CH=CH) n -R 1a 、-C(=O)CH2-[C(=O)CH 2] p -[CH2] q -R 1a 、-C(=O)CH2-[CH(OR 1c )-CH2] p -[CH2] q -R 1a 、-C(=O)CH2-[C(=O)CH2] p -[CH(OR 1c )-CH2] r -[CH2] q -R 1a 、-C(=O)-CH(C(=O)R 1b ) -[C(=O)CH2] p -[CH(OR 1c )-CH2] r -[CH2] q -R 1a 、 -C(=O)CH2-[CH(OR 1c )-CH2] r -[C(=O)CH2] p -[C H2] q -R 1a 、-C(=O)OR 1c 、-C(=O)N(R 1c )2、-C(=O) -CH=CH-C(=O)OR 1c 、-C(=O)-[CH2] q -C(=O)OR 1c 、-C(=O)-CH2CH2-C(=O)OR 1c 、-C(=O)CH2-[C(=O )CH2] p -[CH2]q -C(=O)OR 1c , -C(=O)-[CH2] q -C( =O)R 1a , -C(=O)-[CH2] q -C(=O)R 1z , -[C(=O)CH2 ] q -C(=O)R 1z , -C(=O)-CH2CH2-C(=O)R 1z , -C(=O )-CH=CH-[C(=O)] p R 1z , -C(=O)CH2-[C(=O)CH2] p -[CH2] q -C(=O)R 1z , -SR 1d , [ka] wherein C1 to C 20 Alkyl, C2-C 20 Alkenyl or C2-C 20 Archi Nyl is one or more R 1a are optionally substituted with C1 to C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 The methylene moiety or moieties of an alkynyl may be one or more Optionally substituted with a number of carbonyl moieties. In some embodiments, R1 is C1-C 20 Alkyl, C2-C 20 alkenyl, C2~C 20 Alkynyl, -C(=O)R 1b , -C(=O)R 1z , -C(=O)-( CH=CH) n -R 1a , -C(=O)CH2-[C(=O)CH2] p -[CH2] q -R 1a ,-C(=O)CH2-[CH(OR 1c )-CH2] p -[CH2] q -R1 a ,-C(=O)CH2-[C(=O)CH2] p -[CH(OR 1c )-CH2] r - [CH2] q -R 1a ,-C(=O)CH2-[CH(OR 1c )-CH2] r -[C( =O)CH2] p -[CH2] q -R 1a ,-C(=O)OR 1c ,-C(=O)N(R 1c )2,-C(=O)-CH=CH-C(=O)OR 1c ,-C(=O)-[CH2] q -C(=O)OR 1c ,-C(=O)-CH2CH2-C(=O)OR 1c ,-C(= O)CH2-[C(=O)CH2] p -[CH2] q -C(=O)OR 1c ,-C(=O )-[CH2] q -C(=O)R 1z ,-C(=O)-CH2CH2-C(=O)R 1z ,-C(=O)-CH=CH-[C(=O)] p R 1z ,-C(=O)CH2-[C(= O)CH2] p -[CH2] q -C(=O)R 1z ,-SR 1d ,

Chem.

[0012] In some embodiments, R is one or more R 1a C1 to C optionally substituted with 20 Alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, or heptyl), C1-C 20 The methylene moieties in the alkyl may be one or more. It is substituted with multiple carbonyl moieties. In some embodiments, R is one or more R 1a C1~C substituted with 20 a alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, or heptyl) C1 to C 20 One or more methylene moieties in an alkyl group may be bonded to a carbonyl moiety. is replaced by In some embodiments, R1 is C2-C 20 Alkenyl (e.g., ethenyl, protonyl) The alkyl group is phenyl, butenyl, pentenyl, or hexenyl. In some embodiments, R is one or more R 1aC2 to C optionally substituted with 20 Alkenyl (e.g., ethenyl, propenyl, butenyl, pentenyl, or hexenyl) wherein C2 to C 20 The methylene moieties in an alkenyl may be one or more. is optionally substituted with multiple carbonyl moieties. In some embodiments, R is one or more R 1a C2~C substituted with 20 a alkenyl (e.g., ethenyl, propenyl, butenyl, pentenyl, or hexenyl); In the formula, C2 to C 20 The methylene moieties in the alkenyl may be one or more is optionally substituted at the carbonyl moiety of In some embodiments, R is one or more R 1a C2 to C optionally substituted with 20 Alkenyl (e.g., ethenyl, propenyl, butenyl, pentenyl, or hexenyl) wherein C2 to C 20 The methylene moieties in an alkenyl may be one or more. is substituted with multiple carbonyl moieties. In some embodiments, R is one or more R 1a C2~C substituted with 20 a alkenyl (e.g., ethenyl, propenyl, butenyl, pentenyl, or hexenyl); In the formula, C2 to C 20 The methylene moieties in the alkenyl may be one or more is substituted at the carbonyl moiety of In some embodiments, R1 is C2-C 20 Alkynyl (e.g., ethynyl, pro The alkyl group may be phenyl, butynyl, pentynyl, or hexynyl. In some embodiments, R is one or more R 1aC2 to C optionally substituted with 20 Alkynyl (e.g., ethynyl, propynyl, butynyl, pentynyl, or hexynyl) wherein C2 to C 20 The methylene moieties in an alkenyl may be one or more. is optionally substituted with multiple carbonyl moieties. In some embodiments, R is one or more R 1a C2~C substituted with 20 a alkynyl (e.g., ethynyl, propynyl, butynyl, pentynyl, or hexynyl) In the formula, C2 to C 20 The methylene moieties in the alkenyl may be one or more is optionally substituted at the carbonyl moiety of In some embodiments, R is one or more R 1a C2 to C optionally substituted with 20 Alkynyl (e.g., ethynyl, propynyl, butynyl, pentynyl, or hexynyl) wherein C2 to C 20 The methylene moieties in an alkenyl may be one or more. is substituted with multiple carbonyl moieties. In some embodiments, R is one or more R 1a C2~C substituted with 20 a alkynyl (e.g., ethynyl, propynyl, butynyl, pentynyl, or hexynyl) In the formula, C2 to C 20 The methylene moieties in the alkenyl may be one or more is substituted at the carbonyl moiety of When two or more methylene moieties are replaced by carbonyl moieties, the resulting two or more each carbonyl moiety independently bonded to one or more other available carbonyl moieties adjacent or one or more alkylene moieties, alkene moieties, or alkyne moieties It is understood that the carbonyl may be separated from one or more other resulting carbonyls by In some embodiments, at least two of the resulting carbonyl moieties are In some embodiments, at least two of the resulting carbonyl moieties are Separated by alkylene, alkene, or alkyne moieties. In embodiments, at least two resulting carbonyl moieties are separated by an alkylene moiety. In some embodiments, at least two of the resulting carbonyl moieties are They are separated by methylene moieties.

[0013] In some embodiments, R is —C(═O)R 1b , -C(=O)R 1z , -C( =O)-(CH=CH) n -R 1a , -C(=O)CH2-[C(=O)CH2] p -[ CH2] q -R 1a , -C(=O)CH2-[CH(OR 1c )-CH2] p -[CH2 ] q -R 1a , -C(=O)CH2-[C(=O)CH2] p -[CH(OR 1c )-C H2] r -[CH2] q -R 1a , -C(=O)CH2-[CH(OR 1c )-CH2] r -[C(=O)CH2] p -[CH2] q -R 1a , -C(=O)OR 1c , -C(= O)N(R 1c )2, -C(=O)-CH=CH-C(=O)OR1c , -C(=O)- [CH2] q -C(=O)OR 1c , -C(=O)-CH2CH2-C(=O)OR 1c , -C(=O)CH2-[C(=O)CH2] p -[CH2] q -C(=O)OR 1c , -C(=O)-[CH2] q -C(=O)R 1z , -C(=O)-CH2CH2-C(= O)R 1z , -C(=O)CH2-[C(=O)CH2] p -[CH2] q -C(=O) R 1z , -SR 1d , [ka] is. In some embodiments, R is —C(═O)R 1b is. In some embodiments, R is —C(═O)R 1b where R 1b H, C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, -(CH2 ) q -C(=O)OR 1c , -CH2-C(=O)-(CH2) q -C(=O)OR 1c , -CH2-[C(=O)CH2] p -[CH2] q -C(=O)OR 1c , -CH=C HC(=O)OR 1c , -C(=O)OR 1c , -C(=O)N(R 1c )2, or R 1zwherein C1 to C 20 Alkyl or C2-C 20 Alkenyl or C2-C2 Alkynyl is one or more R 1e is optionally replaced by In some embodiments, R1 is -C(=O)H. In some embodiments, R is —C(═O)R 1b where R 1b is C1 ~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, -(CH2) q -C(=O)OR 1c , -CH2-C(=O)-(CH2) q -C(=O)OR 1c ,- CH2-[C(=O)CH2] p -[CH2] q -C(=O)OR 1c , -CH=CH- C(=O)OR 1c , -C(=O)OR 1c , -C(=O)N(R 1c )2, or R 1z wherein C1 to C 20 Alkyl or C2-C 20 Alkenyl or C2-C 20 a A rucynyl may be one or more R 1e is optionally replaced by In some embodiments, R is —C(═O)R 1b where R 1b is one or multiple R 1e C1 to C optionally substituted with 20 Alkyl, C2-C 20 alkenyl, Or C2~C 20 It is alkynyl. In some embodiments, R is —C(═O)R 1b where R 1bteeth,-( CH2) q -C(=O)OR 1c , -CH2-C(=O)-(CH2) q C(=O)OR 1c , -CH2-[C(=O)CH2] p -[CH2] q -C(=O)OR 1c , -CH =CH-C(=O)OR 1c , -C(=O)OR 1c , or -C(=O)N(R 1c)2 is. In some embodiments, R is —C(═O)R 1c is. In some embodiments, R1 is -C(=O)-(CH2) q -C(=O)OR 1c is. In some embodiments, R1 is -C(=O)-CH2CH2-C(=O)OR 1c is. In some embodiments, R1 is -C(=O)-CH2-C(=O)-(CH2) q -C(=O)OR 1c is. In some embodiments, R1 is -C(=O)-CH2-C(=O)-CH2CH2 -C(=O)OR 1c is. In some embodiments, R1 is -C(=O)-CH=CH-C(=O)OR 1c in be. In some embodiments, R is —C(═O)R 1z is. In some embodiments, R1 is [ka] In some embodiments, R is [ka] In some embodiments, R is [ka] is. In some embodiments, R1 is [ka] is.

[0014] In some embodiments, R is -C(=O)-(CH=CH) n -R 1a , -C( =O)CH2-[C(=O)CH2] p -[CH2] q -R 1a , -C(=O)CH2- [CH(OR 1c )-CH2] p -[CH2] q -R 1a , -C(=O)CH2-[C( =O)CH2] p -[CH(OR 1c )-CH2] r -[CH2] q -R 1a , or -C (=O)CH2-[CH(OR 1c )-CH2] r -[C(=O)CH2] p -[CH2 ] q -R 1a is. In some embodiments, R is -C(=O)-(CH=CH) n -C(=O)OR 1c , -C(=O)CH2-[C(=O)CH2] p -[CH2] q -C(=O)OR1 c , -C(=O)CH2-[CH(OR1c )-CH2] p -[CH2] q -C(=O) OR 1c , -C(=O)CH2-[C(=O)CH2] p -[CH(OR 1c )-CH2 ] r -[CH2] q -C(=O)OR 1c , or -C(=O)CH2-[CH(OR 1c )-CH2] r -[C(=O)CH2] p -[CH2] q -C(=O)OR 1c is. In some embodiments, R is —C(═O)—CH(C(═O)R 1b )-[C( =O)CH2] p -[CH(OR 1c )-CH2] r -[CH2] q -R 1a is. In some embodiments, R is -C(=O)-(CH=CH) n -R 1a is. In some embodiments, R is —C(═O)—R 1a In some embodiments, , R1 is -C(=O)-CH=CH-R 1a is. In some embodiments, R is -C(=O)-(CH=CH) n -C(=O)OR 1c In some embodiments, R is -C(=O)-CH=CH-C(=O) OR 1c is. In some embodiments, R is -C(=O)-(CH=CH) n -C(=O)R1 z In some embodiments, R is —C(═O)—R 1zSome real In an embodiment, R1 is -C(=O)-CH=CH-C(=O)R 1z is. In some embodiments, R1 is [ka] In some embodiments, R is [ka] is. In some embodiments, R1 is -C(=O)CH2-[C(=O)CH2] p -[ CH2] q -R 1a is. In some embodiments, R1 is -C(=O)CH2-[C(=O)CH2] p -R 1a is. In some embodiments, R1 is -C(=O)CH2-[C(=O)CH2] p -C (=O)OR 1c is. In some embodiments, R1 is -C(=O)CH2-[C(=O)CH2] p -C (=O)OR 1c is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] isn't it.

[0015] In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] In some embodiments, R is [ka] In some embodiments, R is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is -C(=O)CH2-[CH2] q -R1a is . In some embodiments, R1 is -C(=O)CH2-[CH2] q -C(=O)O R 1c is. In some embodiments, R1 is -C(=O)-[CH2] q -C(=O)R 1a in be. In some embodiments, R is —C(═O)—CH—C(═O)R 1a is. In some embodiments, R1 is -C(=O)-CH2-C(=O)-OR 1c Yes do. In some embodiments, R1 is -C(=O)-CH2-C(=O)-C(=O)O R 1c is. In some embodiments, R1 is -C(=O)-CH2-C(=O)-C(=O)N (R 1c )2. In some embodiments, R is —C(═O)—CH—C(═O)—N(R 1c ) It is 2. In some embodiments, R is —C(═O)—CH—C(═O)—NH(R 1c ) In some embodiments, R is —C(═O)—CH—C(═O)—N(R 1c ) C(=O)R 1b is. In some embodiments, R is —C(═O)—CH—C(═O)—N(R 1c ) C(=O)R 1z is. In some embodiments, R is —C(═O)—CH—C(═O)—N(R 1c ) C(=O)OR 1c is. In some embodiments, R is -C(=O)-CH-C(=O)-OC(=O) R 1b is. In some embodiments, R is -C(=O)-CH-C(=O)-OC(=O) R 1z is. In some embodiments, R is -C(=O)-CH-C(=O)-OC(=O) OR 1c is. In some embodiments, R is -C(=O)-CH-C(=O)-SC(=O) R 1b is. In some embodiments, R is -C(=O)-CH-C(=O)-SC(=O) R 1z is. In some embodiments, R is -C(=O)-CH-C(=O)-SC(=O) OR 1c is. In some embodiments, R is -C(=O)-CH-C(=O)-SC(=O) N(R 1c )2. In some embodiments, R is —C(═O)—CH—C(═O)—C(═O)R 1b is. In some embodiments, R is —C(═O)—CH—C(═O)—C(═O)R 1z is.

[0016] In some embodiments, R1 is -C(=O)-CH2-C(=O)-SR 1d Yes do. In some embodiments, R is —C(═O)—CH—C(═O)R 1z is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] In some embodiments, R is [ka] In some embodiments, R is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is -[C(=O)CH2] q -C(=O)R 1z Yes do. In some embodiments, R1 is -C(=O)CH2-[C(=O)CH2] p -[ CH2] q -R 1z In some embodiments, R1 is -C(=O)CH2-[ C(=O)CH2] p -R 1z In some embodiments, R is -C(=O) CH2-[CH2] q -R 1z is. In some embodiments, R1 is -C(=O)-CH=CH-[C(=O)] p R1 z is. In some embodiments, R1 is -C(=O)CH2-[CH(OR 1c )-CH2 ] p -[CH2] q -R 1a In some embodiments, R is -C(=O)C H2-[CH(OR 1c )-CH2] p -R 1a In some embodiments, R1 is -C(=O)CH2-[CH2] q -R 1a is. In some embodiments, R1 is -C(=O)CH2-[CH(OR 1c )-CH2 ] p -[CH2] q -C(=O)OR 1c In some embodiments, R is - C(=O)CH2-[CH(OR 1c )-CH2] p -C(=O)OR 1c That is. In some embodiments, R1 is -C(=O)CH2-[CH2] q -C(=O)OR 1c is. In some embodiments, R1 is -C(=O)CH2-[CH(OR 1c )-CH2 ] p -[CH2] q -C(=O)R 1zIn some embodiments, R is -C (=O)CH2-[CH(OR 1c )-CH2] p -C(=O)R 1z Some In this embodiment, R1 is -C(=O)CH2-[CH2] q -C(=O)R 1z is . In some embodiments, R1 is -C(=O)CH2-[C(=O)CH2] p -[ CH(OR 1c )-CH2] r -[CH2] q -R 1a In some embodiments, , R1 is -C(=O)CH2-[CH(OR 1c )-CH2] r -[CH2] q -R1 a In some embodiments, R1 is -C(=O)CH2-[C(=O)CH2 ] p -[CH2] q -R 1a In some embodiments, R is -C(=O)C H2-[C(=O)CH2] p -[CH(OR 1c )-CH2] r -R 1a That is. In some embodiments, R1 is -C(=O)CH2-[CH2] q -R 1a That is. In some embodiments, R1 is -C(=O)CH2-[CH(OR 1c )-CH2] r - R 1a In some embodiments, R is -C(=O)CH-[C(=O)C H2] p -R 1a is. In some embodiments, R1 is -C(=O)CH2-[CH(OR 1c )-CH2 ] r -[C(=O)CH2] p -[CH2] q -R 1a In some embodiments, , R1 is -C(=O)CH2-[C(=O)CH2] p -[CH2] q -R 1a is In some embodiments, R is -C(=O)CH-[CH(OR 1c )-CH2 ] r -[CH2] q -R 1a In some embodiments, R is -C(=O)C H2-[CH(OR 1c )-CH2] r -[C(=O)CH2] p -R 1a That is. In some embodiments, R1 is -C(=O)CH2-[CH2] q -R 1a That is. In some embodiments, R1 is -C(=O)CH2-[C(=O)CH2] p -R 1a in In some embodiments, R is —C(═O)CH—[CH(OR 1c )-C H2] r -R 1a is. In some embodiments, R1 is -C(=O)CH2-[C(=O)CH2] p -[ CH(OR 1c )-CH2] r -[CH2] q -C(=O)OR 1c Some In embodiments, R1 is -C(=O)CH2-[CH(OR 1c )-CH2] r -[CH 2] q -C(=O)OR 1c In some embodiments, R is -C(=O)C H2-[C(=O)CH2] p -[CH2] q -C(=O)OR 1c Some In embodiments, R1 is -C(=O)CH2-[C(=O)CH2] p -[CH(OR1 c )-CH2] r -C(=O)OR 1c In some embodiments, R is -C (=O)CH2-[CH2] q -C(=O)OR 1c In some embodiments, R1 is -C(=O)CH2-[CH(OR 1c )-CH2] r -C(=O)OR 1c in In some embodiments, R is -C(=O)CH-[C(=O)CH] p -C(=O)OR 1c is. In some embodiments, R1 is -C(=O)CH2-[CH(OR 1c )-CH2 ] r -[C(=O)CH2] p -[CH2] q -C(=O)OR 1c Some In embodiments, R1 is -C(=O)CH2-[C(=O)CH2] p -[CH2] q - C(=O)OR 1c In some embodiments, R1 is -C(=O)CH2-[ CH(OR 1c )-CH2] r -[CH2] q -C(=O)OR 1c Some In embodiments, R1 is -C(=O)CH2-[CH(OR 1c )-CH2] r -[C( =O)CH2] p -C(=O)OR 1c In some embodiments, R is -C (=O)CH2-[CH2] q -C(=O)OR 1c In some embodiments, R1 is -C(=O)CH2-[C(=O)CH2] p -C(=O)OR 1c It is. In some embodiments, R1 is -C(=O)CH2-[CH(OR 1c )-CH2] r -C(=O)OR 1c is. In some embodiments, R1 is -C(=O)OR 1c , -C(=O)N(R 1c ) 2. -C(=O)-CH=CH-C(=O)OR 1c is. In some embodiments, R1 is -C(=O)OR 1c is. In some embodiments, R1 is -C(=O)OH. In some embodiments, R1 is -C(=O)OR 1c where R 1c is 1 One or more R 1e C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Arkeny Lu, C2~C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclo Alkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 Al Kill)-(C3~C 12Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C1 2 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), Or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, R1 is -C(=O)OR 1c where R 1c is 1 One or more R 1e C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Arkeny or C2~C 20 It is alkynyl. In some embodiments, R1 is -C(=O)OR 1c where R 1c is 1 One or more R 1e C3 to C, optionally substituted with 12 Cycloalkyl, C3-C 12 F Tetracycloalkyl, C3-C 12 Aryl or C3-C 12 It is heteroaryl. In some embodiments, R1 is -C(=O)OR 1c where R 1c is 1 One or more R 1e optionally substituted with -(C1 to C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterocycloalkyl ), -(C 1~ C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 a Rukill)-(C3~C 12heteroaryl). In some embodiments, R is —C(═O)N(R 1c )2. In some embodiments, R is —C(═O)N(R 1c )2, wherein at least Another R 1c is H. In some embodiments, R is —C(═O)N(R 1c )2, where at least Together with R 1c is one or more R 1e C1 to C, optionally substituted with 20 Alkyl , C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C 3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl , -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 a Rukill)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl)-(C 3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroary (L). In some embodiments, R is —C(═O)N(R 1c )2, where at least Together with R 1c is one or more R 1e C1 to C optionally substituted with 20 Alkyl, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl.

[0017] In some embodiments, R is —C(═O)N(R 1c )2, where at least Together with R 1c is one or more R 1e C3 to C, optionally substituted with 12 Cycloa Lukil, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 It is heteroaryl. In some embodiments, R is —C(═O)N(R 1c )2, where at least Together with R 1c is one or more R 1e optionally substituted with -(C1 to C 20 Al Kill)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C1 2 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), Or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, R1 is -C(=O)-CH=CH-C(=O)OR 1c in be. In some embodiments, R1 is -C(=O)-CH=CH-C(=O)OH . In some embodiments, R1 is -C(=O)-CH=CH-C(=O)OR 1c in where R 1c is one or more R 1e C1 to C, optionally substituted with 20 Archi Lu, C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12cycloalkyl, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroary Le, -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl)-( C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Hetero ant (ru). In some embodiments, R1 is -C(=O)-CH=CH-C(=O)OR 1c in where R 1c is one or more R 1e C1 to C, optionally substituted with 20 Archi Lu, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, R1 is -C(=O)-CH=CH-C(=O)OR 1c in where R 1c is one or more R 1e C3 to C, optionally substituted with 12 Cyclo Alkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C1 2 heteroaryl. In some embodiments, R1 is -C(=O)-CH=CH-C(=O)OR 1c in where R 1c is one or more R 1e optionally substituted with -(C1 to C 20 a Rukill)-(C3~C12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C 1~ C 20 Alkyl)-(C3~C 12 aryl) , or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, R1 is -C(=O)-[CH2] q -C(=O)OR 1c in be. In some embodiments, R1 is -C(=O)-CH2CH2-C(=O)OR 1c in be. In some embodiments, R1 is -C(=O)CH2-[C(=O)CH2] p -[C H2] q -C(=O)OR 1c is. In some embodiments, R1 is -C(=O)-[CH2] q -C(=O)R 1z Yes do. In some embodiments, R is —C(═O)—CHCH—C(═O)R 1z Yes do. In some embodiments, R1 is -C(=O)CH2-[C(=O)CH2] p -[C H2] q -C(=O)R 1z is. In some embodiments, R1 is -SR 1d is. In some embodiments, R1 is -SH. In some embodiments, R1 is -SR 1d where R 1d is one or more R 1e C1 to C, optionally substituted with 20Alkyl, C2-C 20 Alkenyl, C2~ C 20 Alkynyl, C3-C 10 Cycloalkyl, C3-C 12 Cycloalkyl, C3~ C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, - (C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Archi C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~ C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl) is. In some embodiments, R1 is -SR 1d where R 1d is one or more R 1e C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Alkenyl, or C 2~C 20 It is alkynyl. In some embodiments, R1 is -SR 1d where R 1d is one or more R 1e C3 to C, optionally substituted with 10 Cycloalkyl, C3-C 12 Cycloalkane Lu, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 Haitai It's a royal. In some embodiments, R1 is -SR 1d where R 1dis one or more R 1e optionally substituted with -(C1 to C 20 Alkyl)-(C3~C 12 Cycloal Kill), -(C1~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C 1~ C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 alkyl)- (C3~C 12 heteroaryl). In some embodiments, R1 is [ka] (for example, [ka] ) In some embodiments, R is selected from the group consisting of at least one R 1c is H [ka] (for example, [ka] ) In some embodiments, R1 is [ka] (for example, [ka] ) wherein at least one R 1c is one or more R 1e optionally replaced with , C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C3 ~C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 cycloalkyl ), -(C1~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 alkyl)-(C 3~C 12 heteroaryl). In some embodiments, R1 is [ka] (for example, [ka] ) wherein at least one R 1c is one or more R 1e optionally replaced with , C1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 Alkynyl . In some embodiments, R1 is [ka] (for example, [ka] ) wherein at least one R 1c is one or more R 1e optionally replaced with , C3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Ants C3~C 12 It is heteroaryl. In some embodiments, R1 is [ka] (for example, [ka] ) wherein at least one R 1c is one or more R 1e optionally replaced with , -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 a Rukill)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl)-(C 3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroary (L).

[0018] In some embodiments, R1 is [ka] (for example, [ka] ) In some embodiments, R is R 1cis H [ka] (for example, [ka] ) In some embodiments, R1 is [ka] (for example, [ka] ) where R 1c is one or more R 1e C1 to C, optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkane Lu, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroa Reel, -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl) -(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Hetero aryl). In some embodiments, R1 is [ka] (for example, [ka] ) where R 1c is one or more R 1e C1 to C, optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, R1 is [ka] (for example, [ka] ) where R 1c is one or more R 1e C3 to C, optionally substituted with 12 S Chloroalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3~ C 12 It is heteroaryl. In some embodiments, R1 is [ka] (for example, [ka] ) where R 1c is one or more R 1e optionally substituted with -(C1-C2 0 alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3 ~C 12 heterocycloalkyl), -(C1-C 20Alkyl)-(C3~C 12 Ally ru), or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, R1 is [ka] (for example, [ka] ) In some embodiments, R1 is [ka] (for example, [ka] ) where R 1c is H. In some embodiments, R1 is [ka] (for example, [ka] ) where R 1c is one or more R 1e C1 to C, optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkane Lu, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroa Reel, -(C1~C 20Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl) -(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Hetero aryl). In some embodiments, R1 is [ka] (for example, [ka] ) where R 1c is one or more R 1e C1 to C, optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, R1 is [ka] (for example, [ka] ) where R 1c is one or more R 1e C3 to C, optionally substituted with 12 S Chloroalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3~ C 12 It is heteroaryl.

[0019] In some embodiments, R1 is [ka] (for example, [ka] ) where R 1c is one or more R 1e optionally substituted with -(C1-C2 0 alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3 ~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Ally ru), or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, R1 is [ka] (for example, [ka] ) In some embodiments, R1 is —C(═O)—(C1-C 20 alkyl), -C( =O)-(C2~C 20 alkenyl), -C(=O)-(C2-C 20 alkynyl) In the formula, R1 is C1 to C 20 Alkyl, C2-C 20 Alkenyl or C2-C 20 a A rucynyl may be one or more R 1a wherein C1 to C 20 Alkyl, C 2~C 20Alkenyl, or C2-C 20 The methylene moiety or methylene moieties of the alkynyl are It is optionally substituted with one or more carbonyl moieties. In some embodiments, R1 is —C(═O)—(C1-C 20 alkyl), In the formula, C1~C 20 Alkyl is one or more R 1a are optionally substituted with C1 to C 20 One or more methylene moieties in the alkyl may be optionally replaced with one or more carbonyl moieties. It will be exchanged. In some embodiments, R1 is —C(═O)—(C1-C 20 alkyl), In the formula, C1~C 20 The alkyl group has at least two (e.g., two or three) R 1a Place are converted to C1~C 20 At least one methylene moiety of the alkyl is substituted with a carbonyl group will be done. In some embodiments, R is selected from at least two (e.g., two or three) R 1a C1~C substituted with 20 Alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl) ethyl, hexyl, or heptyl) and C1-C 20 At least one methyl group of the alkyl The olefin moiety is substituted with a carbonyl moiety. In some embodiments, R is —C(═O)—CH—C(R 1a )2-(CH2 )2-R 1a or -C(=O)-CH2-C(R 1a )2-CH3. In some embodiments, R is —C(═O)—CH—C(R 1a )2-CH3 be. In some embodiments, R1 is -C(=O)-CH2-C(OR 1c )2-CH3 is. In some embodiments, R1 is -C(=O)-CH2-C(OR 1c )2-CH3 and there are at least two R 1c together with the intervening atom or atoms to which they are attached. , C3~C 12 Forms a heterocycloalkyl. In some embodiments, R1 is [ka] is. In some embodiments, R is —C(═O)—CH—C(R 1a )2-(CH2 )2-R 1a is. In some embodiments, R1 is -C(=O)-CH2-C(OR 1c )2-(CH 2) 2-C(=O)OR 1c is. In some embodiments, R1 is -C(=O)-CH2-C(OR 1c )2-(CH 2) 2-C(=O)OR 1c and there are at least two R 1c are combined C3 to C with one or more intervening atoms 12 Forms a heterocycloalkyl. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is -SR 1d isn't it. In some embodiments, R is H, C 20 Alkyl, C2-C 20 Arkeny -C(=O)-(C1~C 20 alkyl), -C(=O)-(C2-C 20 Arkeny -C(=O)R 1c , -C(=O)R 1z , -C(=O)CH2-[CH(OR1 c )-CH2] p -[CH2] q -R 1a , -C(=O)CH2-[C(=O)CH2] p -[CH(OR 1c )-CH2] r -[CH2] q -R 1a , -C(=O)-CH=C HC(=O)OR 1c , -C(=O)-[CH2] q -C(=O)OR 1c , -C(= O)-[CH2] q -C(=O)R 1a , [ka] is selected from. In some embodiments, R1 is C1-C 20 Alkyl, -C(=O)-(C1-C 20 alkyl), -C(=O)-(C2-C 20 alkenyl), and -C(=O)-[C H2] q -C(=O)R 1a is selected from. In some embodiments, R1 is H, -CH3, [ka] is selected from.

[0020] In some embodiments, R1 is [ka] is selected from. In some embodiments, R1 is H. In some embodiments, R1 is -CH3. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is.

[0021] In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. In some embodiments, R1 is [ka] is. Variable R 1a In some embodiments, at least one R 1a is H. In some embodiments, at least one R 1a is halogen, C1-C 20 Archi Lu, C2~C 20 Alkenyl, -OR1c , -C(=O)OR 1c , -C(=O)N(R 1c )2, -N(R 1c )2, -N(R 1c )C(=O)R 1b , -N(R 1c )C(= O)R 1z , -N(R 1c )C(=O)OR 1c , -OC(=O)R 1b , -OC(=O )R 1z , -OC(=O)OR 1c , -SC(=O)R 1b , -SC(=O)R 1z ,- SC(=O)OR 1c , -SC(=O)N(R 1c )2, -C(=O)R 1b , -C(= O)R 1z , -SR 1d , or R 1z wherein C1 to C 20 Alkyl, C2-C2 0 alkenyl, or C2-C 20 Alkynyl is a group consisting of one or more R 1e optionally replaced by do. In some embodiments, at least one R 1a is halogen, C1-C 20 Archi or C2~C 20 alkenyl, wherein C1-C 20 Alkyl, C2-C 20 a Alkenyl, or C2-C 20 Alkynyl is a group consisting of one or more R 1e is optionally replaced by In some embodiments, at least one R 1a is a halogen (e.g., F, Cl, B r, I). In some embodiments, at least one R 1a is F or Cl In some embodiments, at least one R 1a is F. In some embodiments is at least one R 1a is Cl. In some embodiments, at least one R 1a is C1~C 20 Alkyl (e.g. , methyl, ethyl, propyl, butyl, pentyl, hexyl, or heptyl). In some embodiments, at least one R 1a is one or more R 1e Replaced with C1~C 20 Alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl, xyl, or heptyl). In some embodiments, at least one R 1a is one or more R 1z Replaced with C1~C 20 Alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl, xyl, or heptyl). In some embodiments, at least one R 1a is C2~C 20 Alkenyl (e.g. For example, ethenyl, propenyl, butenyl, pentenyl, or hexenyl. In some embodiments, at least one R 1a is one or more R 1e Replaced with C2~C 20 Alkenyl (e.g., ethenyl, propenyl, butenyl, pentenyl, or hexenyl). In some embodiments, at least one R 1a is one or more R 1z Replaced with C2~C 20 Alkenyl (e.g., ethenyl, propenyl, butenyl, pentenyl, or hexenyl). In some embodiments, at least one R 1a is C2~C 20 Alkynyl (e.g. For example, ethynyl, propynyl, butynyl, pentynyl, or hexynyl. In some embodiments, at least one R 1a is one or more R 1e Replaced with C2~C 20 Alkynyl (e.g., ethynyl, propynyl, butynyl, pentynyl, or hexynyl). In some embodiments, at least one R 1a is one or more R 1z Replaced with C2~C 20 Alkynyl (e.g., ethynyl, propynyl, butynyl, pentynyl, or hexynyl). In some embodiments, at least one R 1a -OR 1c , -C(=O)OR 1c , -C(=O)N(R 1c )2, -N(R 1c )2, -N(R 1c )C(=O)R1 b , -N(R 1c )C(=O)R 1z , -N(R 1c )C(=O)OR 1c , -OC(= O)R 1b , -OC(=O)R 1z , -OC(=O)OR 1c , -SC(=O)R 1b , -SC(=O)R 1z , -SC(=O)OR 1c , -SC(=O)N(R 1c )2, -C (=O)R 1b , -C(=O)R 1z , or -SR 1d is.

[0022] In some embodiments, at least one R 1a HA-OR 1c is. In some embodiments, at least one R 1a is -OH. In some embodiments, at least one R 1a -OR 1c wherein R1 c is C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3 ~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 aryl, C3~C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 Cycloal Kill), -(C1~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C 1~C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 alkyl)- (C3~C 12 heteroaryl), wherein C1-C 20 Alkyl, C2-C 20 a Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Hetero Cycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C2 0 alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3 ~C 12heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Ally ru), or -(C1~C 20 Alkyl)-(C3~C 12 Heteroaryl) is one or Multiple R 1e is optionally replaced by In some embodiments, at least one R 1a -OR 1c wherein R1 c is one or more R 1e C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1a -OR 1c wherein R1 c is one or more R 1e C3 to C, optionally substituted with 12 Cycloalkyl, C3~ C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 Heteroaryl is. In some embodiments, at least one R 1a -OR 1c wherein R1 c is one or more R 1e optionally substituted with -(C1 to C 20 Alkyl)-(C3 ~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterocyclo alkyl), -(C 1~ C 20 Alkyl)-(C3~C 12 aryl), or -(C C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1a is -C(=O)OR 1c is. In some embodiments, at least one R 1a is -C(=O)OH. In some embodiments, at least one R 1a is -C(=O)OR 1c and In the formula, R 1c is C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Archi Nil, C3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterocycloalkyl ), -(C1~C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 a Rukill)-(C3~C 12 heteroaryl), wherein C1-C 20 Alkyl, C2 ~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -( C1~C 20 Alkyl)-(C3~C 12Cycloalkyl), -(C1-C 20 Alkyl )-(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl) , one or more R 1e is optionally replaced by In some embodiments, at least one R 1a is -C(=O)OR 1c and In the formula, R 1c is one or more R 1e C1 to C, optionally substituted with 20 Alkyl, C 2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1a is -C(=O)OR 1c and In the formula, R 1c is one or more R 1e C3 to C, optionally substituted with 12 Cycloalkane Lu, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 Haitai It's a royal. In some embodiments, at least one R 1a is -C(=O)OR 1c and In the formula, R 1c is one or more R 1e optionally substituted with -(C1 to C 20 Alkyl )-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 F -cycloalkyl), -(C 1~ C 20 Alkyl)-(C3~C 12 aryl), or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1a is -C(=O)N(R 1c )2 be. In some embodiments, at least one R 1a is -C(=O)NHR 1c is . In some embodiments, at least one R 1a is -C(=O)NH2. In some embodiments, at least one R 1a is -C(=O)N(R 1c )2 wherein at least one R 1c is C1~C 20 Alkyl, C2-C 20 Arkeny Lu, C2~C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclo Alkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 Al Kill)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C1 2 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), Or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl), wherein C1 ~C 20 Alkyl, C2-C 20 Alkenyl, C2-C20 Alkynyl, C3-C 12 S Chloroalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C1 2 heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 cycloalkyl), - (C1~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 heteroaryl) can be one or more R 1e is optionally replaced by In some embodiments, at least one R 1a is -C(=O)N(R 1c )2 wherein at least one R 1c is one or more R 1e optionally substituted with C 1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1a is -C(=O)N(R 1c )2 wherein at least one R 1c is one or more R 1e optionally substituted with C 3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl , or C3~C 12 It is heteroaryl. In some embodiments, at least one R 1a is -C(=O)N(R 1c )2 wherein at least one R 1c is one or more R 1e optionally replaced by - (C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Archi C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~ C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl) is. In some embodiments, at least one R 1a -N(R 1c )2. In some embodiments, at least one R 1a is -NH2. In some embodiments, at least one R 1a Ha-NHR 1c is. In some embodiments, at least one R 1a is -(R 1c )2, wherein: At least one R 1c is C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C 3~C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 alkyl)-(C 3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterothymic -(C1-C alkyl) 20 Alkyl)-(C3~C12 aryl), or -(C1 ~C 20 Alkyl)-(C3~C 12 heteroaryl), wherein C1-C 20 Al Kill, C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 cycloalkyl , C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Hetero ant Rule, -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C2 0 alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl)- (C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroa Reel) is one or more R 1e is optionally replaced by In some embodiments, at least one R 1a is N(R 1c )2, wherein: At least one R 1c is one or more R 1e C1 to C, optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1a is N(R 1c )2, wherein: At least one R 1c is one or more R 1e C3 to C, optionally substituted with 12 S Chloroalkyl, C3-C 12Heterocycloalkyl, C3-C 12 Aryl or C3~ C 12 It is heteroaryl. In some embodiments, at least one R 1a is -N(R 1c )2, wherein , at least one R 1c is one or more R 1e optionally substituted with -(C1 to C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 alkyl)-(C 3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Ants (C1 to C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1a is -N(R 1c )C(=O)R1 b is. In some embodiments, at least one R 1a is -N(R 1c )C(=O)H be. In some embodiments, at least one R 1a is -N(R 1c )C(=O)R1 b where R 1b is C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, -(CH2) q -C(=O)OR 1c , -CH2-C(=O)-(CH 2) q -C(=O)OR 1c , -CH2-[C(=O)CH2] p-[CH2] q -C( =O)OR 1c , -CH=CH-C(=O)OR 1c , -C(=O)OR 1c , -C(= O)N(R 1c )2, or R 1z wherein C1 to C 20 Alkyl or C2-C2 0 alkenyl or C2-C 20 Alkynyl is a group consisting of one or more R 1e is optionally replaced by . In some embodiments, at least one R 1a is -N(R 1c )C(=O)R1 b where R 1b is one or more R 1e C1 to C, optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1a is -N(R 1c )C(=O)R1 b where R 1b is -(CH2) q -C(=O)OR 1c , -CH2-C(=O )-(CH2) q -C(=O)OR 1c , -CH2-[C(=O)CH2] p -[CH2 ] q -C(=O)OR 1c , -CH=CH-C(=O)OR 1c , -C(=O)OR 1c , or -C(=O)N(R 1c)2 is. In some embodiments, at least one R 1a is -N(R 1c )C(=O)R1 z is. In some embodiments, at least one R 1a teeth [ka] is. In some embodiments, at least one R 1a teeth [ka] is. In some embodiments, at least one R 1a teeth [ka] is. In some embodiments, at least one R 1a teeth [ka] is. In some embodiments, at least one R 1a teeth [ka] is. In some embodiments, at least one R 1a teeth [ka] is. In some embodiments, at least one R 1a teeth [ka] is. In some embodiments, at least one R1a teeth [ka] is.

[0023] In some embodiments, at least one R 1a is -NHC(=O)R 1b is . In some embodiments, at least one R 1a is -N(R 1c )C(=O)R1 b where R 1c is C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C 3~C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 alkyl)-(C 3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterothymic -(C1-C alkyl) 20 Alkyl)-(C3~C 12 aryl), or -(C1 ~C 20 Alkyl)-(C3~C 12 heteroaryl), wherein C1-C 20 Al Kill, C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 cycloalkyl , C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Hetero ant Rule, -(C1~C20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C2 0 alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl)- (C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroa Reel) is one or more R 1e is optionally replaced by In some embodiments, at least one R 1a is -N(R 1c )C(=O)R1 b where R 1c is one or more R 1e C1 to C, optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1a is -N(R 1c )C(=O)R1 b where R 1c is one or more R 1e C3 to C, optionally substituted with 12 S Chloroalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3~ C 12 It is heteroaryl. In some embodiments, at least one R 1a is -N(R 1c )C(=O)R1 b where R 1c is one or more R 1e optionally substituted with -(C1-C2 0 alkyl)-(C3~C 12 Cycloalkyl), -(C1-C20 Alkyl)-(C3 ~C 12 heterocycloalkyl), -(C 1~ C 20 Alkyl)-(C3~C 12 Ally ru), or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1a is -N(R 1c )C(=O)OR 1c is. In some embodiments, at least one R 1a is -NHC(=O)OR 1c Yes do. In some embodiments, at least one R 1a is -N(R 1c )C(=O)OH is. In some embodiments, at least one R 1a is -N(R 1c )C(=O)OR 1c wherein at least one R 1c is C1~C 20 Alkyl, C2-C 20 a Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Hetero Cycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C2 0 alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3 ~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Ally ru), or -(C1~C20 Alkyl)-(C3~C 12 heteroaryl), wherein , C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C3 ~C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 cycloalkyl ), -(C1~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 alkyl)-(C 3~C 12 heteroaryl) can be one or more R 1e is optionally replaced by In some embodiments, at least one R 1a is -N(R 1c )C(=O)OR 1c wherein at least one R 1c is one or more R 1e optionally replaced by C1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 Alkynyl do. In some embodiments, at least one R 1a is -N(R 1c )C(=O)OR 1c wherein at least one R 1c is one or more R 1e optionally replaced by C3~C 12Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 a Reel or C3~C 12 It is heteroaryl. In some embodiments, at least one R 1a is -N(R 1c )C(=O)OR 1c wherein at least one R 1c is one or more R 1e optionally replaced by Ta, -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl)-( C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Hetero ant (ru). In some embodiments, at least one R 1a is -OC(=O)R 1b is. In some embodiments, at least one R 1a is -OC(=O)H. In some embodiments, at least one R 1a is -OC(=O)R 1b and In the formula, R 1b is C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Archi Nyl, -(CH2) q -C(=O)OR 1c , -CH2-C(=O)-(CH2) q -C (=O)OR 1c , -CH2-[C(=O)CH2] p -[CH2] q-C(=O)OR 1c , -CH=CH-C(=O)OR 1c , -C(=O)OR 1c , -C(=O)N(R 1c )2, or R 1z wherein C1 to C 20 Alkyl or C2-C 20 Arkeny C2~C 20 Alkynyl is a group consisting of one or more R 1e is optionally replaced by In some embodiments, at least one R 1a is -OC(=O)R 1b and In the formula, R 1b is one or more R 1e C1 to C, optionally substituted with 20 Alkyl, C 2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1a is -OC(=O)R 1b and In the formula, R 1b is -(CH2) q -C(=O)OR 1c , -CH2-C(=O)-(CH 2) q C(=O)OR 1c , -CH2-[C(=O)CH2] p -[CH2] q -C(= O)OR 1c , -CH=CH-C(=O)OR 1c , -C(=O)OR 1c , or -C( =O)N(R 1c)2 is. In some embodiments, at least one R 1a is -OC(=O)R 1z is. In some embodiments, at least one R 1a teeth [ka] is. In some embodiments, at least one R 1a teeth [ka] is. In some embodiments, at least one R 1a teeth [ka] is. In some embodiments, at least one R 1a teeth [ka] is. In some embodiments, at least one R 1a is -OC(=O)OR 1c is . In some embodiments, at least one R 1a is -OC(=O)OH. In some embodiments, at least one R 1a is -OC(=O)OR 1c and , where R 1c is C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Al Quinyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C1 2 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C1 2cycloalkyl), -(C1-C 20 Alkyl)-(C3~C12 Heterocycloalkane -(C1~C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 heteroaryl), wherein C1-C 20 Alkyl, C 2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3~ C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, - (C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Archi C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~ C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl) is one or more R 1e is optionally replaced by In some embodiments, at least one R 1a is -OC(=O)OR 1c and , where R 1c is one or more R 1e C1 to C, optionally substituted with 20 Alkyl, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1a is -OC(=O)OR 1c and , where R 1c is one or more R 1eC3 to C, optionally substituted with 12 Cycloal Kill, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 F It is a teraryl. In some embodiments, at least one R 1a is -OC(=O)OR 1c and , where R 1c is one or more R 1e optionally substituted with -(C1 to C 20 Archi C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C 1~ C 20 Alkyl)-(C3~C 12 aryl), or Ha-(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1a is -SC(=O)R 1b is. In some embodiments, at least one R 1a is -SC(=O)H. In some embodiments, at least one R 1a is -SC(=O)R 1b and In the formula, R 1b is C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Archi Nyl, -(CH2) q -C(=O)OR 1c , -CH2-C(=O)-(CH2) q -C (=O)OR 1c , -CH2-[C(=O)CH2] p-[CH2] q -C(=O)OR 1c , -CH=CH-C(=O)OR 1c , -C(=O)OR 1c , -C(=O)N(R 1c )2, or R 1z wherein C1 to C 20 Alkyl or C2-C 20 Arkeny C2~C 20 Alkynyl is a group consisting of one or more R 1e is optionally replaced by In some embodiments, at least one R 1a is -SC(=O)R 1b and In the formula, R 1b is one or more R 1e C1 to C, optionally substituted with 20 Alkyl, C 2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1a is -SC(=O)R 1b and In the formula, R 1b is -(CH2) q -C(=O)OR 1c , -CH2-C(=O)-(CH 2) q -C(=O)OR 1c , -CH2-[C(=O)CH2] p -[CH2] q -C( =O)OR 1c , -CH=CH-C(=O)OR 1c , -C(=O)OR 1c , or -C (=O)N(R 1c)2 is. In some embodiments, at least one R 1a is -SC(=O)R 1z is. In some embodiments, at least one R1a teeth [ka] is. In some embodiments, at least one R 1a teeth [ka] is.

[0024] In some embodiments, at least one R 1a teeth [ka] is. In some embodiments, at least one R 1a teeth [ka] is. In some embodiments, at least one R 1a is -SC(=O)OR 1c is . In some embodiments, at least one R 1a is -SC(=O)OH. In some embodiments, at least one R 1a is -SC(=O)OR 1c and , where R 1c is C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Al Quinyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C1 2 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C1 2cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterocycloalkane -(C1~C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 heteroaryl), wherein C1-C 20 Alkyl, C 2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3~ C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, - (C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Archi C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~ C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl) is one or more R 1e is optionally replaced by In some embodiments, at least one R 1a is -SC(=O)OR 1c and , where R 1c is one or more R 1e C1 to C, optionally substituted with 20 Alkyl, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1a is -SC(=O)OR 1c and , where R 1c is one or more R 1e C3 to C, optionally substituted with 12 Cycloal Kill, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 F It is a teraryl. In some embodiments, at least one R 1a is -SC(=O)OR 1c and , where R 1c is one or more R 1e optionally substituted with -(C1 to C 20 Archi C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C 1~ C 20 Alkyl)-(C3~C 12 aryl), or Ha-(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1a is -SC(=O)N(R 1c )2 is. In some embodiments, at least one R 1a is -SC(=O)NHR 1c Yes do. In some embodiments, at least one R 1a is -SC(=O)NH2. In some embodiments, at least one R 1a is -SC(=O)N(R 1c )2 wherein at least one R 1c is C1~C 20 Alkyl, C2-C 20 Arke Nil, C2~C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Heterothymic alkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 a Rukill)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl) , or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl), wherein C 1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 cycloalkyl), -(C1~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C2 0 alkyl)-(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~ C 12 heteroaryl) can be one or more R 1e is optionally replaced by In some embodiments, at least one R 1a is -SC(=O)N(R 1c )2 wherein at least one R 1cis one or more R 1e optionally replaced by C1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1a is -SC(=O)N(R 1c )2 wherein at least one R 1c is one or more R 1e optionally replaced by C3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Ally C3~C 12 It is heteroaryl. In some embodiments, at least one R 1a is -SC(=O)N(R 1c )2 wherein at least one R 1c is one or more R 1e optionally replaced by -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Al Kill)-(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3 ~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl ) In some embodiments, at least one R 1a is -C(=O)R 1b is. In some embodiments, at least one R 1a is -C(=O)H. In some embodiments, at least one R 1a is -C(=O)R1b and the formula Medium, R 1b is C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkini Le, -(CH2) q -C(=O)OR 1c , -CH2-C(=O)-(CH2) q -C( =O)OR 1c , -CH2-[C(=O)CH2] p -[CH2] q -C(=O)OR1 c , -CH=CH-C(=O)OR 1c , -C(=O)OR 1c , -C(=O)N(R1 c )2, or R 1z wherein C1 to C 20 Alkyl or C2-C 20 Alkenyl Or C2~C 20 Alkynyl is a group consisting of one or more R 1e is optionally replaced by In some embodiments, at least one R 1a is -C(=O)R 1b and the formula Medium, R 1b is one or more R 1e C1 to C, optionally substituted with 20 Alkyl, C2 ~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1a is -C(=O)R 1b and the formula Medium, R 1b is -(CH2) q -C(=O)OR 1c , -CH2-C(=O)-(CH2 ) q -C(=O)OR 1c , -CH2-[C(=O)CH2]p -[CH2] q -C(= O)OR 1c , -CH=CH-C(=O)OR 1c , -C(=O)OR 1c , or -C( =O)N(R 1c)2 is. In some embodiments, at least one R 1a is -C(=O)CH2C(=O) OR 1c is. In some embodiments, at least one R 1a is -C(=O)-CH=CH-C (=O)OR 1c is. In some embodiments, at least one R 1a is -C(=O)R 1z is. In some embodiments, at least one R 1a teeth [ka] In some embodiments, at least one R 1a teeth [ka] In some embodiments, at least one R 1a teeth [ka] is. In some embodiments, at least one R 1a teeth [ka] is. In some embodiments, at least one R 1a Ha-SR 1d is. In some embodiments, at least one R 1a Ha-SR 1d is. In some embodiments, at least one R 1a is -SH. In some embodiments, at least one R 1a -SR 1d wherein R1 d is one or more R 1e C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 10 Cycloalkyl, C3-C 12 Shik alkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 cycloalkyl), -( C1~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 a Rukill)-(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C1 2 heteroaryl). In some embodiments, at least one R 1a -SR 1d wherein R1 d is one or more R 1e C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1a -SR1d wherein R1 d is one or more R 1e C3 to C, optionally substituted with 10 Cycloalkyl, C3~ C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, or is C3~C 12 It is heteroaryl. In some embodiments, at least one R 1a -SR 1d wherein R1 d is one or more R 1e optionally substituted with -(C1 to C 20 Alkyl)-(C3 ~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterocyclo alkyl), -(C 1~ C 20 Alkyl)-(C3~C 12 aryl), or -(C C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1a is R 1z is. In some embodiments, at least one R 1a teeth [ka] is. In some embodiments, at least one R 1a teeth [ka] is. In some embodiments, at least one R1a teeth [ka] is. In some embodiments, at least one R 1a teeth [ka] is. In some embodiments, at least two R 1a -OR 1c and two R1 c together with the intervening atom or atoms to which they are attached, form a C3-C 12 Heterocyclo Forms an alkyl. In some embodiments, at least two R 1a HA-OR 1c and at least 1 R 1a is -C(=O)OR 1c is. In some embodiments, at least two R 1a HA-OR 1c and at least 1 R 1a is -C(=O)OH or -C(=O)OCH3. In some embodiments, at least two R 1a HA-OR 1c and at least 1 R 1a is -C(=O)OH or -C(=O)OCH3, and two R 1c Is that C3-C together with one or more intervening atoms to which they are bonded 12 Heterocycloalkyl Form. In some embodiments, at least one R 1a is -N(R 1c )C(=O)OR 1c is. In some embodiments, at least two R 1a is -N(R 1c )C(=O)OR 1c is. In some embodiments, R 1a teeth [ka] is.

[0025] Variable R 1b In some embodiments, at least one R 1b is H. In some embodiments, at least one R 1b is one or more R 1e Optionally Substituted, C1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 Archi It's Nil. In some embodiments, at least one R 1b is C1~C 20 Alkyl (e.g. , methyl, ethyl, propyl, butyl, pentyl, hexyl, or heptyl). In some embodiments, at least one R 1b is one or more R 1e Replaced with C1~C 20 Alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl, xyl, or heptyl). In some embodiments, at least one R 1b is one or more R 1z Replaced with C1~C 20 Alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl, xyl, or heptyl). In some embodiments, at least one R 1b is C2~C 20 Alkenyl (e.g. For example, ethenyl, propenyl, butenyl, pentenyl, or hexenyl. In some embodiments, at least one R 1b is one or more R 1e Replaced with C2~C 20 Alkenyl (e.g., ethenyl, propenyl, butenyl, pentenyl, or hexenyl). In some embodiments, at least one R 1b is one or more R 1z Replaced with C2~C 20 Alkenyl (e.g., ethenyl, propenyl, butenyl, pentenyl, or hexenyl). In some embodiments, at least one R 1b is C2~C 20 Alkynyl (e.g. For example, ethynyl, propynyl, butynyl, pentynyl, or hexynyl. In some embodiments, at least one R 1b is one or more R 1e Replaced with C2~C 20 Alkynyl (e.g., ethynyl, propynyl, butynyl, pentynyl, or hexynyl). In some embodiments, at least one R 1b is one or more R 1z Replaced with C2~C 20 Alkynyl (e.g., ethynyl, propynyl, butynyl, pentynyl, or hexynyl). In some embodiments, at least one R 1b is -(CH2) q -C(=O)O R 1c, -CH2-C(=O)-(CH2) q -C(=O)OR 1c , -CH2-[C( =O)CH2] p -[CH2] q -C(=O)OR 1c , -CH=CH-C(=O)OR 1c , -C(=O)OR 1c , -C(=O)N(R 1c)2 or R 1z is. In some embodiments, at least one R 1b is -(CH2) q -C(=O)O R 1c is. In some embodiments, at least one R 1b is -(CH2) q -C(=O)O It's H. In some embodiments, at least one R 1b is -(CH2) q -C(=O)O R 1c where R 1c is one or more R 1e C1-C2 optionally substituted with 0 alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloa Rukill, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Haitai Aryl, -(C1-C 20 Alkyl)-(C3~C 12 cycloalkyl), -(C1 ~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 Archi C3~C 12 aryl), or -(C1-C 20Alkyl)-(C3~C 12 F (terearyl). In some embodiments, at least one R 1b is -(CH2) q -C(=O)O R 1c where R 1c is one or more R 1e C1-C2 optionally substituted with 0 alkyl, C2-C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1b is -(CH2) q -C(=O)O R 1c where R 1c is one or more R 1e C3-C1 optionally substituted with 2Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, or C 3~C 12 It is heteroaryl. In some embodiments, at least one R 1b is -(CH2) q -C(=O)O R 1c where R 1c is one or more R 1e optionally substituted with -(C1~ C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 alkyl)-( C3~C 12 heterocycloalkyl), -(C 1~ C 20 Alkyl)-(C3~C 12 a reel), or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1b is -CH2CH2-C(=O)O R 1c is. In some embodiments, at least one R 1b is -CH2CH2-C(=O)O It's H. In some embodiments, at least one R 1b is -CH2CH2-C(=O)O R 1c where R 1c is one or more R 1e C1-C2 optionally substituted with 0 alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloa Rukill, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Haitai Aryl, -(C1-C 20 Alkyl)-(C3~C 12 cycloalkyl), -(C1 ~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 Archi C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 F (terearyl). In some embodiments, at least one R 1b is -CH2CH2-C(=O)O R 1c where R 1c is one or more R 1e C1-C2 optionally substituted with 0 alkyl, C2-C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1b is -CH2CH2-C(=O)O R 1c where R 1c is one or more R 1e C3-C1 optionally substituted with 2Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, or C 3~C 12 It is heteroaryl. In some embodiments, at least one R 1b is -CH2CH2-C(=O)O R 1c where R 1c is one or more R 1e optionally substituted with -(C1~ C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 alkyl)-( C3~C 12 heterocycloalkyl), -(C 1~ C 20 Alkyl)-(C3~C 12 a reel), or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1b is -(CH2) q -C(=O)R 1c is. In some embodiments, at least one R 1b is -(CH2) q -C(=O)R 1c where R 1c is one or more R 1e C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Alkenyl, C2-C 20Alkynyl, C3-C 12 Cycloal Kill, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Hetero Aryl, -(C1-C 20 Alkyl)-(C3~C 12 cycloalkyl), -(C1 C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl )-(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Haitai (Royal). In some embodiments, at least one R 1b is -(CH2) q -C(=O)R 1c where R 1c is one or more R 1e C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1b is -(CH2) q -C(=O)R 1c where R 1c is one or more R 1e C3 to C, optionally substituted with 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3 ~C 12 It is heteroaryl. In some embodiments, at least one R 1b is -(CH2) q -C(=O)R 1c where R 1c is one or more R 1e optionally substituted with -(C1 to C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 alkyl)-(C 3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Ants (C1 to C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1b is -CH2-C(=O)-(CH 2) q -C(=O)OR 1c is. In some embodiments, at least one R 1b is -CH2-C(=O)-(CH 2) q -C(=O)OH. In some embodiments, at least one R 1b is -CH2-C(=O)-(CH 2) q -C(=O)OR 1c where R 1c is one or more R 1e Place it arbitrarily with Replaced, C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Ally Lu, C3~C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 Cyclo alkyl), -(C1-C 20Alkyl)-(C3~C 12 heterocycloalkyl), - (C1~C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 Alkyl )-(C3~C 12 heteroaryl). In some embodiments, at least one R 1b is -CH2-C(=O)-(CH 2) q -C(=O)OR 1c where R 1c is one or more R 1e Place it arbitrarily with Replaced, C1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 Alkini It is. In some embodiments, at least one R 1b is -CH2-C(=O)-(CH 2) q -C(=O)OR 1c where R 1c is one or more R 1e Place it arbitrarily with Replaced, C3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 It is heteroaryl. In some embodiments, at least one R 1b is -CH2-C(=O)-(CH 2) q -C(=O)OR 1c where R 1c is one or more R 1e Place it arbitrarily with Replaced, -(C1~C 20 Alkyl)-(C3~C 12 cycloalkyl), -(C1 C 20Alkyl)-(C3~C 12 heterocycloalkyl), -(C 1~ C 20 Alkyl )-(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Haitai (Royal). In some embodiments, at least one R 1b is -CH2-[C(=O)CH2 ] p -[CH2] q -C(=O)OR 1c is. In some embodiments, at least one R 1b is -CH2-[C(=O)CH2 ] p -[CH2] q -C(=O)OH. In some embodiments, at least one R 1b is -CH2-[C(=O)CH2 ] p -[CH2] q -C(=O)OR 1c where R 1c is one or more R1 e C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3~ C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~ C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterocycloa Rukill), -(C1~C 20 Alkyl)-(C3~C 12aryl), or -(C1-C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1b is -CH2-[C(=O)CH2 ] p -[CH2] q -C(=O)OR 1c where R 1c is one or more R1 e C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1b is -CH2-[C(=O)CH2 ] p -[CH2] q -C(=O)OR 1c where R 1c is one or more R1 e C3 to C, optionally substituted with 12 Cycloalkyl, C3-C 12 Heterocycloalkane Lu, C3~C 12 Aryl or C3-C 12 It is heteroaryl. In some embodiments, at least one R 1b is -CH2-[C(=O)CH2 ] p -[CH2] q -C(=O)OR 1c where R 1c is one or more R1 e optionally substituted with -(C1 to C 20 Alkyl)-(C3~C 12 Cycloalkyl) , -(C1~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1~ C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3 ~C 12 heteroaryl). In some embodiments, at least one R 1b is -CH2-C(=O)-CH2 CH2-C(=O)OR 1c is. In some embodiments, at least one R 1b is -CH2-C(=O)-CH2 CH2-C(=O)OH. In some embodiments, at least one R 1b is -CH2-C(=O)-CH2 CH2-C(=O)OR 1c where R 1c is one or more R 1e Place it arbitrarily with Replaced, C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Ally Lu, C3~C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 Cyclo alkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), - (C1~C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 Alkyl )-(C3~C 12 heteroaryl). In some embodiments, at least one R 1bis -CH2-C(=O)-CH2 CH2-C(=O)OR 1c where R 1c is one or more R 1e Place it arbitrarily with Replaced, C1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 Alkini It is. In some embodiments, at least one R 1b is -CH2-C(=O)-CH2 CH2-C(=O)OR 1c where R 1c is one or more R 1e Place it arbitrarily with Replaced, C3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 It is heteroaryl. In some embodiments, at least one R 1b is -CH2-C(=O)-CH2 CH2-C(=O)OR 1c where R 1c is one or more R 1e Place it arbitrarily with Replaced, -(C1~C 20 Alkyl)-(C3~C 12 cycloalkyl), -(C1 C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C 1~ C 20 Alkyl )-(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Haitai (Royal). In some embodiments, at least one R 1b is -CH=CH-C(=O)OR 1c is. In some embodiments, at least one R 1b is -CH=CH-C(=O)OH is.

[0026] In some embodiments, at least one R 1b is -CH=CH-C(=O)OR 1c where R 1c is one or more R 1e C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloal Kill, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Hetero Aryl, -(C1-C 20 Alkyl)-(C3~C 12 cycloalkyl), -(C1 C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl )-(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Haitai (Royal). In some embodiments, at least one R 1b is -CH=CH-C(=O)OR 1c where R 1c is one or more R 1e C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1bis -CH=CH-C(=O)OR 1c where R 1c is one or more R 1e C3 to C, optionally substituted with 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3 ~C 12 It is heteroaryl. In some embodiments, at least one R 1b is -CH=CH-C(=O)OR 1c where R 1c is one or more R 1e optionally substituted with -(C1 to C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 alkyl)-(C 3~C 12 heterocycloalkyl), -(C 1~ C 20 Alkyl)-(C3~C 12 Ants (C1 to C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1b is -C(R 1e )=C(R 1e ) -C(=O)OR 1c is. In some embodiments, at least one R 1b is -C(R 1e )=C(R 1e ) -C(=O)OH. In some embodiments, at least one R 1b is C(R 1e )=C(R 1e )- C(=O)OR 1c where R1c is one or more R 1e optionally replaced with , C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C3 ~C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 cycloalkyl ), -(C1~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 alkyl)-(C 3~C 12 heteroaryl). In some embodiments, at least one R 1b is -C(R 1e )=C(R 1e ) -C(=O)OR 1c where R 1c is one or more R 1e optionally replaced by C1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 Alkynyl do. In some embodiments, at least one R 1b is -CH=CH-C(=O)OR 1c where R 1c is one or more R 1e C3 to C, optionally substituted with 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12Aryl or C3 ~C 12 It is heteroaryl. In some embodiments, at least one R 1b is -C(R 1e )=C(R 1e ) -C(=O)OR 1c where R 1c is one or more R 1e optionally replaced by Ta, -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl)-( C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Hetero ant (ru). In some embodiments, at least one R 1b is -C(=O)OR 1c is. In some embodiments, at least one R 1b is -C(=O)OH. In some embodiments, at least one R 1b is -C(=O)OR 1c and In the formula, R 1c is one or more R 1e C1 to C, optionally substituted with 20 Alkyl, C 2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3~ C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, - (C1~C 20 Alkyl)-(C3~C12 Cycloalkyl), -(C1-C 20 Archi C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~ C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl) is. In some embodiments, at least one R 1b is -C(=O)OR 1c and In the formula, R 1c is one or more R 1e C1 to C, optionally substituted with 20 Alkyl, C 2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1b is -C(=O)OR 1c and In the formula, R 1c is one or more R 1e C3 to C, optionally substituted with 12 Cycloalkane Lu, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 Haitai It's a royal. In some embodiments, at least one R 1b is -C(=O)OR 1c and In the formula, R 1c is one or more R 1e optionally substituted with -(C1 to C 20 Alkyl )-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 F -cycloalkyl), -(C 1~ C20 Alkyl)-(C3~C 12 aryl), or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1b is -C(=O)N(R 1c )2 be. In some embodiments, at least one R 1b is -C(=O)NHR 1c is . In some embodiments, at least one R 1b is -C(=O)NH2. In some embodiments, at least one R 1b is -C(=O)N(R 1c )2 wherein at least one R 1c is one or more R 1e optionally substituted with C 1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 cycloalkyl), -(C1~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C2 0 alkyl)-(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~ C 12 heteroaryl). In some embodiments, at least one R 1bis -C(=O)N(R 1c )2 wherein at least one R 1c is one or more R 1e optionally substituted with C 1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1b is -C(=O)OR 1c and In the formula, R 1c is one or more R 1e C3 to C, optionally substituted with 12 Cycloalkane Lu, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 Haitai It's a royal. In some embodiments, at least one R 1b is -C(=O)N(R 1c )2 wherein at least one R 1c is one or more R 1e optionally replaced by - (C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Archi C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~ C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl) is. In some embodiments, at least one R 1b is R 1z is. In some embodiments, at least one R 1b teeth [ka] is. In some embodiments, at least one R 1b teeth [ka] is. In some embodiments, at least one R 1b teeth [ka] is. In some embodiments, at least one R 1b teeth [ka] is. Variable R 1c In some embodiments, at least one R 1c is H. In some embodiments, at least one R 1c are independently C1 to C 20 Archi Lu, C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 cycloalkyl, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroary Le, -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl)-( C3~C 12aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Hetero ant wherein C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 a Rucynyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterocycloar Kill), -(C1~C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C2 0 alkyl)-(C3~C 12 heteroaryl) can be one or more R 1e Optionally replace with Or two R 1c together with the intervening atom or atoms to which they are attached. , C3~C 12 Cycloalkyl or C3-C 12 forming a heterocycloalkyl, , C3~C 12 Cycloalkyl or C3-C 12 Heterocycloalkyl can be one or more R 1e is optionally replaced by In some embodiments, at least one R 1c is one or more R 1e Optionally Substituted, C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl , C3~C 12 Cycloalkyl, C3-C12 Heterocycloalkyl, C3-C 12 Ants C3~C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 Shik -(C1-C alkyl) 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1~C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 Archi C3~C 12 heteroaryl). In some embodiments, at least one R 1c is one or more R 1e Optionally Substituted, C1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 Archi It's Nil. In some embodiments, at least one R 1c is C1~C 20 Alkyl (e.g. , methyl, ethyl, propyl, butyl, pentyl, hexyl, or heptyl). In some embodiments, at least one R 1c is one or more R 1e Replaced with C1~C 20 Alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl, xyl, or heptyl). In some embodiments, at least one R 1c is one or more R 1z Replaced with C1~C 20 Alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl, xyl, or heptyl). In some embodiments, at least one R 1c is C2~C 20 Alkenyl (e.g. For example, ethenyl, propenyl, butenyl, pentenyl, or hexenyl. In some embodiments, at least one R 1c is one or more R 1e Replaced with C2~C 20 Alkenyl (e.g., ethenyl, propenyl, butenyl, pentenyl, or hexenyl). In some embodiments, at least one R 1c is one or more R 1z Replaced with C2~C 20 Alkenyl (e.g., ethenyl, propenyl, butenyl, pentenyl, or hexenyl). In some embodiments, at least one R 1c is C2~C 20 Alkynyl (e.g. For example, ethynyl, propynyl, butynyl, pentynyl, or hexynyl. In some embodiments, at least one R 1c is one or more R 1e Replaced with C2~C 20 Alkynyl (e.g., ethynyl, propynyl, butynyl, pentynyl, or hexynyl). In some embodiments, at least one R 1c is one or more R 1z Replaced with C2~C 20 Alkynyl (e.g., ethynyl, propynyl, butynyl, pentynyl, or hexynyl). In some embodiments, at least one R 1c is one or more R 1e Optionally Substituted, C3-C 12Cycloalkyl, C3-C 12 Heterocycloalkyl, C3~ C 12 Aryl or C3-C 12 It is heteroaryl. In some embodiments, at least one R 1c is one or more R 1e Optionally Substituted C3~C 12 In some embodiments, at least one R 1c is C3~C 12 In some embodiments, at least Another R 1c is one or more R 1e C3~C substituted with 12 Cycloalkyl In some embodiments, at least one R 1c is one or more R 1z Replace with C3~C 12 It is cycloalkyl. In some embodiments, at least one R 1c is one or more R 1e Optionally Substituted C3~C 12 In some embodiments, at least one of the aryl, ... Together with R 1c is C3~C 12 In some embodiments, the aryl group is heterocycloalkyl. is at least one R 1c is one or more R 1e C3~C substituted with 12 Hetero In some embodiments, at least one R 1c is one or Multiple R 1z C3~C substituted with 12 It is heterocycloalkyl. In some embodiments, at least one R 1cis one or more R 1e Optionally Substituted C3~C 12 In some embodiments, at least one R 1c is C3~C 12 In some embodiments, at least one R is aryl. c is one or more R 1e C3~C substituted with 12 Some implementations In the form, at least one R 1c is one or more R 1z C3~C substituted with 12 It is aryl. In some embodiments, at least one R 1c is one or more R 1e Optionally Substituted C3~C 12 In some embodiments, at least one R 1c is C3~C 12 In some embodiments, at least one of Another R 1c is one or more R 1e C3~C substituted with 12 Heteroaryl In some embodiments, at least one R 1c is one or more R 1z Replace with C3~C 12 It is heteroaryl. In some embodiments, at least one R 1c is one or more R 1e Optionally Substituted, -(C1~C 20 Alkyl)-(C3~C 12 cycloalkyl), -(C1 ~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1~ C 20 Archi C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 F (terearyl). In some embodiments, at least one R 1c is one or more R 1e Optionally Substituted -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl). In some embodiments, at least one R 1c is -(C1~C 20 Alkyl)-(C3 ~C 12 In some embodiments, at least one R 1c teeth , one or more R 1e -(C1~C 20 Alkyl)-(C3~C 12 Shik In some embodiments, at least one R 1c is one or more R in Numbers 1z -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl) is. In some embodiments, at least one R 1c is one or more R 1e Optionally Substituted -(C1~C 20 Alkyl)-(C3~C 12 heterocycloalkyl) In some embodiments, at least one R 1c is -(C1~C 20 alkyl)- (C3~C 12 In some embodiments, at least one R1c is one or more R 1e -(C1~C 20 Alkyl)-(C3 ~C 12 In some embodiments, at least one R 1c is one or more R 1z -(C1~C 20 Alkyl)-(C3~C1 2 heterocycloalkyl). In some embodiments, at least one R 1c is one or more R 1e Optionally Substituted -(C1~C 20 Alkyl)-(C3~C 12 aryl). In embodiments, at least one R 1c is -(C1~C 20 Alkyl)-(C3~C1 2aryl). In some embodiments, at least one R 1c is one or more R in Numbers 1e -(C1~C 20 Alkyl)-(C3~C 12 aryl) In some embodiments, at least one R 1c is one or more R 1z Replaced with Reta-(C1~C 20 Alkyl)-(C3~C 12 aryl). In some embodiments, at least one R 1c is one or more R 1e Optionally Substituted -(C1~C 20 Alkyl)-(C3~C 12 Heteroaryl). In some embodiments, at least one R 1c is -(C1~C 20 Alkyl)-(C3 ~C 12 In some embodiments, at least one R 1c teeth , one or more R 1e -(C1~C 20 Alkyl)-(C3~C 12 Haitai In some embodiments, at least one R 1c is one or more R in Numbers 1z -(C1~C 20 Alkyl)-(C3~C 12 Heteroaryl) is. In some embodiments, at least two R 1c are one or C3 to C with multiple intervening atoms 12 Cycloalkyl or C3-C 12 Heterocycloar Form a kill, in which C3~C 12 Cycloalkyl or C3-C 12 Heterocycloalkane A rule consists of one or more R 1e is optionally replaced by In some embodiments, at least two R 1a are one or C3 to C with multiple intervening atoms 12 Cycloalkyl or C3-C 12 Heterocycloar Form a kill. In some embodiments, at least two R 1c are one or One or more R 1e C3 to C optionally substituted with 12 Cycloa Forming Rukil.

[0027] In some embodiments, at least two R 1a are one or C3 to C with multiple intervening atoms 12 Forms a cycloalkyl. In some embodiments, at least two R 1c are one or One or more R 1e C3 to C optionally substituted with 12 Heterogeneity Forms a chloroalkyl. In some embodiments, at least two R 1a are one or C3 to C with multiple intervening atoms 12 Forms a heterocycloalkyl. In some embodiments, R 1c teeth [ka] is. Variable R 1d In some embodiments, at least one R 1d is H. In some embodiments, at least one R 1d is one or more R 1e Optionally Substituted, C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl , C3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Ants C3~C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 Shik -(C1-C alkyl) 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1~C 20 Alkyl)-(C3~C 12aryl), or -(C1-C 20 Archi C3~C 12 heteroaryl). In some embodiments, at least one R 1d is one or more R 1e Optionally Substituted, C1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 Archi It's Nil. In some embodiments, at least one R 1d is C1~C 20 Alkyl (e.g. , methyl, ethyl, propyl, butyl, pentyl, hexyl, or heptyl). In some embodiments, at least one R 1d is one or more R 1e Replaced with C1~C 20 Alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl, xyl, or heptyl). In some embodiments, at least one R 1d is one or more R 1z Replaced with C1~C 20 Alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl, xyl, or heptyl). In some embodiments, at least one R 1d is C2~C 20 Alkenyl (e.g. For example, ethenyl, propenyl, butenyl, pentenyl, or hexenyl. In some embodiments, at least one R 1d is one or more R 1e Replaced with C2~C 20 Alkenyl (e.g., ethenyl, propenyl, butenyl, pentenyl, or hexenyl). In some embodiments, at least one R 1d is one or more R 1z Replaced with C2~C 20 Alkenyl (e.g., ethenyl, propenyl, butenyl, pentenyl, or hexenyl). In some embodiments, at least one R 1d is C2~C 20 Alkynyl (e.g. For example, ethynyl, propynyl, butynyl, pentynyl, or hexynyl. In some embodiments, at least one R 1d is one or more R 1e Replaced with C2~C 20 Alkynyl (e.g., ethynyl, propynyl, butynyl, pentynyl, or hexynyl). In some embodiments, at least one R 1d is one or more R 1z Replaced with C2~C 20 Alkynyl (e.g., ethynyl, propynyl, butynyl, pentynyl, or hexynyl). In some embodiments, at least one R 1d is one or more R 1e Optionally Substituted, C3-C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3~ C 12 Aryl or C3-C 12 It is heteroaryl. In some embodiments, at least one R 1d is one or more R 1e Optionally Substituted C3~C 12 In some embodiments, at least one R 1d is C3~C12 In some embodiments, at least Another R 1d is one or more R 1e C3~C substituted with 12 Cycloalkyl In some embodiments, at least one R 1d is one or more R 1z Replace with C3~C 12 It is cycloalkyl. In some embodiments, at least one R 1d is one or more R 1e Optionally Substituted C3~C 12 In some embodiments, at least one of the aryl, ... Together with R 1d is C3~C 12 In some embodiments, the aryl group is heterocycloalkyl. is at least one R 1d is one or more R 1e C3~C substituted with 12 Hetero In some embodiments, at least one R 1d is one or Multiple R 1z C3~C substituted with 12 It is heterocycloalkyl. In some embodiments, at least one R 1d is one or more R 1e Optionally Substituted C3~C 12 In some embodiments, at least one R 1d is C3~C 12 In some embodiments, at least one R is aryl. d is one or more R 1e C3~C substituted with 12 Some implementations In the form, at least one R1d is one or more R 1z C3~C substituted with 12 It is aryl. In some embodiments, at least one R 1d is one or more R 1e Optionally Substituted C3~C 12 In some embodiments, at least one R 1d is C3~C 12 In some embodiments, at least one of Another R 1d is one or more R 1e C3~C substituted with 12 Heteroaryl In some embodiments, at least one R 1d is one or more R 1z Replace with C3~C 12 It is heteroaryl. In some embodiments, at least one R 1d is one or more R 1e Optionally Substituted, -(C1~C 20 Alkyl)-(C3~C 12 cycloalkyl), -(C1 ~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C 1~ C 20 Archi C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 F (terearyl). In some embodiments, at least one R 1d is one or more R 1e Optionally Substituted -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl). In some embodiments, at least one R 1d is -(C1~C 20 Alkyl)-(C3 ~C 12 In some embodiments, at least one R 1d teeth , one or more R 1e -(C1~C 20 Alkyl)-(C3~C 12 Shik In some embodiments, at least one R 1d is one or more R in Numbers 1z -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl) is. In some embodiments, at least one R 1d is one or more R 1e Optionally Substituted -(C1~C 20 Alkyl)-(C3~C 12 heterocycloalkyl) In some embodiments, at least one R 1d is -(C1~C 20 alkyl)- (C3~C 12 In some embodiments, at least one R 1d is one or more R 1e -(C1~C 20 Alkyl)-(C3 ~C 12 In some embodiments, at least one R 1d is one or more R 1z -(C1~C 20 Alkyl)-(C3~C1 2 heterocycloalkyl). In some embodiments, at least one R 1dis one or more R 1e Optionally Substituted -(C1~C 20 Alkyl)-(C3~C 12 aryl). In embodiments, at least one R 1d is -(C1~C 20 Alkyl)-(C3~C1 2aryl). In some embodiments, at least one R 1d is one or more R in Numbers 1e -(C1~C 20 Alkyl)-(C3~C 12 aryl) In some embodiments, at least one R 1d is one or more R 1z Replaced with Reta-(C1~C 20 Alkyl)-(C3~C 12 aryl). In some embodiments, at least one R 1d is one or more R 1e Optionally Substituted -(C1~C 20 Alkyl)-(C3~C 12 Heteroaryl). In some embodiments, at least one R 1d is -(C1~C 20 Alkyl)-(C3 ~C 12 In some embodiments, at least one R 1d teeth , one or more R 1e -(C1~C 20 Alkyl)-(C3~C 12 Haitai In some embodiments, at least one R 1d is one or more R in Numbers 1z -(C1~C 20 Alkyl)-(C3~C 12Heteroaryl) is.

[0028] Variable R 1e In some embodiments, at least one R 1e is H. In some embodiments, at least one R 1e are independently halogen, C1-C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, -OR 1g , -C( =O)OR 1g , -C(=O)N(R 1g )2, -N(R 1g )2, -N(R 1g )C( =O)R 1f , -N(R 1g )C(=NH)R 1f , -N(R 1g )C(=O)R 1z , -N(R 1g )C(=O)OR 1g , -OC(=O)R 1f , -OC(=O)R 1z ,- OC(=O)OR 1g , -SR 1g , -N + (R 1g )3, -SC(=O)R 1f , -S C(=O)R 1z , -SC(=O)OR 1g , -SC(=O)N(R 1g )2, -C(= O)R 1f , -C(=O)R 1z , C3~C 12 Cycloalkyl, C3-C 12 Heterogeneity Chloroalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, or R 1z and , where C1~C20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C 3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl , or C3~C 12 Heteroaryl can be one or more R 1f or R 1z optionally replaced by can be. In some embodiments, at least one R 1e are independently halogen, C1-C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, -OR 1g , -C( =O)OR 1g , -C(=O)N(R 1g ) 2、 -N(R 1g )2, -N(R 1g )C( =O)R 1f , -N(R 1g )C(=NH)R 1f , -N(R 1g )C(=O)R 1z , -N(R 1g )C(=O)OR 1g , -OC(=O)R 1f , -OC(=O)R 1z ,- OC(=O)OR 1g , -SR 1g , -N + (R 1g )3, -SC(=O)R 1f , -S C(=O)R 1z , -SC(=O)OR 1g , -SC(=O)N(R 1g )2, -C(= O)R 1f , -C(=O)R 1z , C3~C 12 Cycloalkyl, C3-C12 Heterogeneity Chloroalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, or R 1z and , where C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C 3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl , or C3~C 12 Heteroaryl can be one or more R 1f is optionally replaced by In some embodiments, at least one R 1e are independently halogen, C1-C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, -OR 1g , -C( =O)OR 1g , -C(=O)N(R 1g ) 2、 -N(R 1g )2, -N(R 1g )C( =O)R 1f , -N(R 1g )C(=NH)R 1f , -N(R 1g )C(=O)R 1z , -N(R 1g )C(=O)OR 1g , -OC(=O)R 1f , -OC(=O)R 1z ,- OC(=O)OR 1g , -SR 1g , -N + (R 1g )3, -SC(=O)R 1f , -S C(=O)R 1z , -SC(=O)OR 1g , -SC(=O)N(R1g )2, -C(= O)R 1f , -C(=O)R 1z , C3~C 12 Cycloalkyl, C3-C 12 Heterogeneity Chloroalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, or R 1z and , where C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C 3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl , or C3~C 12 Heteroaryl can be one or more R 1z is optionally replaced by In some embodiments, at least one R 1e is halogen, C1-C 20 Archi Lu, C2~C 20 Alkenyl, C2-C 20 Alkynyl, -OR 1g , -C(=O)OR 1g , -C(=O)N(R 1g )2, -N(R 1g )2, -N(R 1g )C(=O)R1 f , -N(R 1g )C(=O)R 1z , -N(R 1g )C(=O)OR 1g , -OC(= O)R 1f , -OC(=O)R 1z , -OC(=O)OR 1g , -SR 1g , -N + (R 1g )3, -SC(=O)R 1f , -SC(=O)R 1z, -SC(=O)OR 1g ,- SC(=O)N(R 1g )2, -C(=O)R 1f , -C(=O)R 1z , or R 1z in In the formula, C1 to C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 Archi Nil is one or more R 1z is optionally replaced by In some embodiments, at least one R 1e is a halogen (e.g., F, Cl, B r, I). In some embodiments, at least one R 1e is F or Cl. In an embodiment, at least one R 1e is F. In some embodiments, at least One R 1e is Cl. In some embodiments, at least one R 1e is one or more R 1z Optionally Substituted, C1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 Archi It's Nil. In some embodiments, at least one R 1e is C1~C 20 Alkyl (e.g. , methyl, ethyl, propyl, butyl, pentyl, hexyl, or heptyl). In some embodiments, at least one R 1e is one or more R 1z Replaced with C1~C 20 Alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl, xyl, or heptyl). In some embodiments, at least one R 1e is C2~C 20 Alkenyl (e.g. For example, ethenyl, propenyl, butenyl, pentenyl, or hexenyl. In some embodiments, at least one R 1e is one or more R 1z Replaced with C2~C 20 Alkenyl (e.g., ethenyl, propenyl, butenyl, pentenyl, or hexenyl). In some embodiments, at least one R 1e is C2~C 20 Alkynyl (e.g. For example, ethynyl, propynyl, butynyl, pentynyl, or hexynyl. In some embodiments, at least one R 1e is one or more R 1z Replaced with C2~C 20 Alkynyl (e.g., ethynyl, propynyl, butynyl, pentynyl, or hexynyl). In some embodiments, at least one R 1e -OR 1g , -C(=O)OR 1g , -C(=O)N(R 1g )2, -N(R 1g )2, -N(R 1g )C(=O)R1 z , -N(R 1g )C(=O)R 1g , -OC(=O)R 1f , -OC(=O)R 1z , -OC(=O)OR 1g , -SR 1g , -N + (R 1g )3, -SC(=O)R 1f ,- SC(=O)R 1z , -SC(=O)OR1g , -SC(=O)N(R 1g )2, -C( =O)R 1f , -C(=O)R 1z , or R 1z is. In some embodiments, at least one R 1e -OR 1g , -C(=O)OR 1g , -C(=O)N(R 1g )2, -N(R 1g )2, -N(R 1g )C(=O)R1 f , -N(R 1g )C(=O)R 1z , -N(R 1g )C(=O)OR 1g , -OC(= O)R 1f , -OC(=O)R 1z , -OC(=O)OR 1g , -SR 1g , -N + (R 1g )3, -SC(=O)R 1f , -SC(=O)R 1z , -SC(=O)OR 1g ,- SC(=O)N(R 1g )2, -C(=O)R 1f , or -C(=O)R 1z is. In some embodiments, at least one R 1e HA-OR 1g is. In some embodiments, at least one R 1e is -OH. In some embodiments, at least one R 1e -OR 1g wherein R1 g is one or more R 1z C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Haitai Cycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 alkyl)-(C 3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Ants (C1 to C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1e -OR 1g wherein R1 g is one or more R 1z C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1e -OR 1g wherein R1 g is one or more R 1z C3 to C, optionally substituted with 12 Cycloalkyl, C3~ C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 Heteroaryl is. In some embodiments, at least one R 1e -OR 1g wherein R1 g is one or more R 1zoptionally substituted with -(C1 to C 20 Alkyl)-(C3 ~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterocyclo alkyl), -(C 1~ C 20 Alkyl)-(C3~C 12 aryl), or -(C C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1e is -C(=O)OR 1g is. In some embodiments, at least one R 1e is -C(=O)OH. In some embodiments, at least one R 1e is -C(=O)OR 1g and In the formula, R 1g is one or more R 1z C1 to C, optionally substituted with 20 Alkyl, C 2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3~ C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, - (C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Archi C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~ C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl) is. In some embodiments, at least one R 1e is -C(=O)OR 1g and In the formula, R 1g is one or more R 1z C1 to C, optionally substituted with 20 Alkyl, C 2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1e is -C(=O)OR 1g and In the formula, R 1g is one or more R 1z C3 to C, optionally substituted with 12 Cycloalkane Lu, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 Haitai It's a royal. In some embodiments, at least one R 1e is -C(=O)OR 1g and In the formula, R 1g is one or more R 1z optionally substituted with -(C1 to C 20 Alkyl )-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 F -cycloalkyl), -(C 1~ C 20 Alkyl)-(C3~C 12 aryl), or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1e is -C(=O)N(R 1g )2 be. In some embodiments, at least one R 1e is -C(=O)NHR 1g is . In some embodiments, at least one R 1e is -C(=O)NH2. In some embodiments, at least one R 1e is -C(=O)N(R 1g )2 wherein at least one R 1g is one or more R 1z optionally substituted with C 1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 cycloalkyl), -(C1~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C2 0 alkyl)-(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~ C 12 heteroaryl). In some embodiments, at least one R 1e is -C(=O)N(R 1g )2 wherein at least one R 1g is one or more R 1z optionally substituted with C 1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R1e is -C(=O)N(R 1g )2 wherein at least one R 1g is one or more R 1z optionally substituted with C 3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl , or C3~C 12 It is heteroaryl. In some embodiments, at least one R 1e is -C(=O)N(R 1g )2 wherein at least one R 1g is one or more R 1z optionally replaced by - (C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Archi C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~ C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl) is. In some embodiments, at least one R 1e -N(R 1g )2. In some embodiments, at least one R 1e Ha-NHR 1g is. In some embodiments, at least one R 1e is -NH2. In some embodiments, at least one R 1e is -N(R 1g )2, wherein , at least one R 1g is one or more R 1z C1 to C, optionally substituted with20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloal Kill, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Hetero Aryl, -(C1-C 20 Alkyl)-(C3~C 12 cycloalkyl), -(C1 C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl )-(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Haitai (Royal). In some embodiments, at least one R 1e is -N(R 1g )2, wherein , at least one R 1g is one or more R 1z C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1e is -N(R 1g )2, wherein , at least one R 1g is one or more R 1z C3 to C, optionally substituted with 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3 ~C 12 It is heteroaryl. In some embodiments, at least one R 1eis -N(R 1g )2, wherein , at least one R 1g is one or more R 1z optionally substituted with -(C1 to C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 alkyl)-(C 3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Ants (C1 to C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1e is -N(R 1g )C(=O)R1 f is. In some embodiments, at least one R 1e is -NHC(=O)R 1f is . In some embodiments, at least one R 1e is -N(R1g)C(=O)H be. In some embodiments, at least one R 1e is -NHC(=O)H. In some embodiments, at least one R 1e is -N(R 1g )C(=O)R1 f where R 1g is one or more R 1z C1 to C, optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkane Lu, C3~C 12 Heterocycloalkyl, C3-C 12Aryl, C3-C 12 Heteroa Reel, -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl) -(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Hetero aryl). In some embodiments, at least one R 1e is -N(R 1g )C(=O)R1 f where R 1g is one or more R 1z C1 to C, optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1e is -N(R 1g )C(=O)R1 f where R 1g is one or more R 1z C3 to C, optionally substituted with 12 S Chloroalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3~ C 12 It is heteroaryl. In some embodiments, at least one R 1e is -N(R 1g )C(=O)R1 f where R 1g is one or more R 1z optionally substituted with -(C1-C2 0 alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3 ~C 12 heterocycloalkyl), -(C 1~ C 20 Alkyl)-(C3~C 12 Ally ru), or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1e is -N(R 1g )C(=O)R1 f where R 1f is C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, -CHC(=O)OR 1g , -CH=CH-C(=O)OR 1g ,- C(=O)OR 1g , -C(=O)N(R 1g )2, or R 1z wherein C1 to C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 Alkynyl is one or more R 1z is optionally replaced by In some embodiments, at least one R 1e is -N(R 1g )C(=O)R1 f where R 1f is one or more R 1z C1 to C, optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1e is -N(R1g )C(=O)R1 f where R 1f -CH2C(=O)OR 1g , -CH=CH-C(=O)OR1 g , -C(=O)OR 1g , -C(=O)N(R 1g )2, or R 1z is. In some embodiments, at least one R 1e is -N(R 1g )C(=O)R1 f where R 1f is -CH2C(=O)OR 1g , -CH=CH-C(=O)OR 1g , -C(=O)OR 1g , or -C(=O)N(R 1g )2. In some embodiments, at least one R 1e is -N(R 1g )C(=O)R1 z is.

[0029] In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e is -N(R 1g )C(=O)OR 1g is. In some embodiments, at least one R 1e is -N(R 1g )C(=O)OH is. In some embodiments, at least one R 1e is -NHC(=O)OR 1g Yes do. In some embodiments, at least one R 1e is -NHC(=O)OH. In some embodiments, at least one R 1e is -N(R 1g )C(=O)OR 1g wherein at least one R 1g is one or more R 1z optionally replaced by C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3~ C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C 3~C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 Cycloalkane -(C1~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1 ~C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 alkyl)-( C3~C 12 heteroaryl). In some embodiments, at least one R 1e is -N(R 1g )C(=O)OR 1g wherein at least one R 1g is one or more R 1z optionally replaced by C1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 Alkynyl do. In some embodiments, at least one R 1e is -N(R 1g )C(=O)OR 1g wherein at least one R1g is one or more R 1z optionally replaced by C3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 a Reel or C3~C 12 It is heteroaryl. In some embodiments, at least one R 1e is -N(R 1g )C(=O)OR 1g wherein at least one R 1g is one or more R 1z optionally replaced by Ta, -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl)-( C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Hetero ant (ru). In some embodiments, at least one R 1e is -OC(=O)R 1f is. In some embodiments, at least one R 1e is -OC(=O)H. In some embodiments, at least one R 1e is -OC(=O)R 1f and In the formula, R 1f is C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Archi Nyl, -CH2C(=O)OR 1g , -CH=CH-C(=O)OR 1g , -C(=O) OR1g , -C(=O)N(R 1g )2, or R 1z wherein C1 to C 20 Archi Lu, C2~C 20 Alkenyl, or C2-C 20 Alkynyl is a group consisting of one or more R 1z in It is optionally substituted. In some embodiments, at least one R 1e is -OC(=O)R 1f and In the formula, R 1f is one or more R 1z C1 to C, optionally substituted with 20 Alkyl, C 2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1e is -OC(=O)R 1f and In the formula, R 1f -CH2C(=O)OR 1g , -CH=CH-C(=O)OR 1g , -C( =O)OR 1g , -C(=O)N(R 1g )2, or R 1z is. In some embodiments, at least one R 1e is -OC(=O)R 1f and In the formula, R 1f is -CH2C(=O)OR 1g , -CH=CH-C(=O)OR 1g , -C (=O)OR 1g , or -C(=O)N(R 1g )2. In some embodiments, at least one R 1e is -OC(=O)R 1z is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e is -OC(=O)OR 1g is . In some embodiments, at least one R 1e is -OC(=O)OH. In some embodiments, at least one R 1e is -OC(=O)OR 1g and , where R 1g is one or more R 1z C1 to C, optionally substituted with 20 Alkyl, C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3 ~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 heteroaryl, -(C1~C 20Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Al Kill)-(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3 ~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl ) In some embodiments, at least one R 1e is -OC(=O)OR 1g and , where R 1g is one or more R 1z C1 to C, optionally substituted with 20 Alkyl, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1e is -OC(=O)OR 1g and , where R 1g is one or more R 1z C3 to C, optionally substituted with 12 Cycloal Kill, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 F It is a teraryl. In some embodiments, at least one R 1e is -OC(=O)OR 1g and , where R 1g is one or more R 1z optionally substituted with -(C1 to C 20 Archi C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), or Ha-(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1e Ha-SR 1g is. In some embodiments, at least one R 1e is -SH. In some embodiments, at least one R 1e -SR 1g wherein R1 g is one or more R 1z C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Haitai Cycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 alkyl)-(C 3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Ants (C1 to C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1e -SR 1g wherein R1 g is one or more R 1z C1 to C, optionally substituted with 20 Alkyl, C2-C20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1e -SR 1g wherein R1 g is one or more R 1z C3 to C, optionally substituted with 12 Cycloalkyl, C3~ C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 Heteroaryl is. In some embodiments, at least one R 1e -SR 1g wherein R1 g is one or more R 1z optionally substituted with -(C1 to C 20 Alkyl)-(C3 ~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterocyclo alkyl), -(C 1~ C 20 Alkyl)-(C3~C 12 aryl), or -(C C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1e -N + (R 1g )3. In some embodiments, at least one R 1e -N + H(R 1g )2. In some embodiments, at least one R 1e Ha-N + H2R 1g is. In some embodiments, at least one R 1e Ha-N + It is H3. In some embodiments, at least one R 1e -N + (R 1g )3, and the formula Medium, at least one R 1g is one or more R 1z C1-C2 optionally substituted with 0 alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloa Lukil, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Haitai Aryl, -(C1-C 20 Alkyl)-(C3~C 12 cycloalkyl), -(C1 ~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 Archi C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 F (terearyl).

[0030] In some embodiments, at least one R 1e -N + (R 1g )3, and the formula Medium, at least one R 1g is one or more R 1z C1-C2 optionally substituted with 0 alkyl, C2-C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1e -N + (R 1g)3, and the formula Medium, at least one R 1g is one or more R 1z C3-C1 optionally substituted with 2Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, or C 3~C 12 It is heteroaryl. In some embodiments, at least one R 1e -N + (R 1g )3, and the formula Medium, at least one R 1g is one or more R 1z optionally substituted with -(C1~ C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 alkyl)-( C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 a reel), or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1e is -SC(=O)R 1f is. In some embodiments, at least one R 1e is -SC(=O)H. In some embodiments, at least one R 1e is -SC(=O)R 1f and In the formula, R 1f is C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Archi Nyl, -CH2C(=O)OR 1g , -CH=CH-C(=O)OR 1g , -C(=O) OR1g , -C(=O)N(R 1g )2, or R 1z wherein C1 to C 20 Archi Lu, C2~C 20 Alkenyl, or C2-C 20 Alkynyl is a group consisting of one or more R 1z in It is optionally substituted. In some embodiments, at least one R 1e is -SC(=O)R 1f and In the formula, R 1f is one or more R 1z C1 to C, optionally substituted with 20 Alkyl, C 2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1e is -SC(=O)R 1f and In the formula, R 1f -CH2C(=O)OR 1g , -CH=CH-C(=O)OR 1g , -C( =O)OR 1g , -C(=O)N(R 1g )2, or R 1z is. In some embodiments, at least one R 1e is -SC(=O)R 1f and In the formula, R 1f is -CH2C(=O)OR 1g , -CH=CH-C(=O)OR 1g , -C (=O)OR 1g , or -C(=O)N(R 1g )2. In some embodiments, at least one R 1e is -SC(=O)R 1z is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e is -SC(=O)OR 1g is . In some embodiments, at least one R 1e is -SC(=O)OH. In some embodiments, at least one R 1e is -SC(=O)OR 1g and , where R 1g is one or more R 1z C1 to C, optionally substituted with 20 Alkyl, C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3 ~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 heteroaryl, -(C1~C 20Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Al Kill)-(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3 ~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl ) In some embodiments, at least one R 1e is -SC(=O)OR 1g and , where R 1g is one or more R 1z C1 to C, optionally substituted with 20 Alkyl, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1e is -SC(=O)OR 1g and , where R 1g is one or more R 1z C3 to C, optionally substituted with 12 Cycloal Kill, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 F It is a teraryl. In some embodiments, at least one R 1e is -SC(=O)OR 1g and , where R 1g is one or more R 1z optionally substituted with -(C1 to C 20 Archi C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), or Ha-(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1e is -SC(=O)N(R 1g )2 is. In some embodiments, at least one R 1e is -SC(=O)NHR 1g Yes do. In some embodiments, at least one R 1e is -SC(=O)NH2. In some embodiments, at least one R 1e is -SC(=O)N(R 1g )2 wherein at least one R 1g is one or more R 1z optionally replaced by C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C1 2Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C3~ C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 Cycloalkyl) , -(C1~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3 ~C 12 heteroaryl). In some embodiments, at least one R 1e is -SC(=O)N(R 1g )2 wherein at least one R 1g is one or more R 1z optionally replaced by C1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1e is -SC(=O)N(R 1g )2 wherein at least one R 1g is one or more R 1z optionally replaced by C3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Ally C3~C 12 It is heteroaryl. In some embodiments, at least one R 1e is -SC(=O)N(R 1g )2 wherein at least one R 1g is one or more R 1z optionally replaced by -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Al Kill)-(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3 ~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl ) In some embodiments, at least one R 1e is -C(=O)R 1f is. In some embodiments, at least one R 1e is -C(=O)H. In some embodiments, at least one R 1e is -C(=O)R 1f and the formula Medium, R 1f is C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkini -CH2C(=O)OR 1g , -CH=CH-C(=O)OR 1g , -C(=O)O R 1g , -C(=O)N(R 1g )2, or R 1z wherein C1 to C 20 Alkyl , C2~C 20 Alkenyl, or C2-C 20 Alkynyl is a group consisting of one or more R 1z At the discretion of It is replaced by intention. In some embodiments, at least one R 1e is -C(=O)R 1f and the formula Medium, R 1f is one or more R 1z C1 to C, optionally substituted with 20 Alkyl, C2 ~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1e is -C(=O)R 1f and the formula Medium, R 1f is -CH2C(=O)OR 1g , -CH=CH-C(=O)OR 1g , -C( =O)OR 1g , -C(=O)N(R 1g )2, or R 1z is. In some embodiments, at least one R 1eis -SC(=O)R 1f and In the formula, R 1f is -CH2C(=O)OR 1g , -CH=CH-C(=O)OR 1g , -C (=O)OR 1g , or -C(=O)N(R 1g )2. In some embodiments, at least one R 1e is -C(=O)R 1z is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e are independently C3 to C 12 Cyclo Alkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 F C3-C 12 Cycloalkyl, C3-C12 Heterocycloa Rukill, C3~C 12 Aryl or C3-C 12 Heteroaryl is one or more R 1f or R 1z is optionally replaced by In some embodiments, at least one R 1e are independently C3 to C 12 Cyclo Alkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 F C3-C 12 Cycloalkyl, C3-C 12 Heterocycloa Rukill, C3~C 12 Aryl or C3-C 12 Heteroaryl is one or more R 1f is optionally replaced by In some embodiments, at least one R 1e are independently C3 to C 12 Cyclo Alkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 F C3-C 12 Cycloalkyl, C3-C 12 Heterocycloa Rukill, C3~C 12 Aryl or C3-C 12 Heteroaryl is one or more R 1f is optionally replaced by In some embodiments, at least one R 1e are independently C3 to C 12 Cyclo Alkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 F It is a teraryl. In some embodiments, at least one R 1e independently, one or more R1 f or R 1z C3 to C optionally substituted with 12 It is cycloalkyl. In some embodiments, at least one R 1e independently, one or more R1 f C3 to C optionally substituted with 12 It is cycloalkyl. In some embodiments, at least one R 1e independently, one or more R1 z C3 to C optionally substituted with 12 It is cycloalkyl. In some embodiments, at least one R 1e are independently C3 to C 12 Cyclo It is alkyl. In some embodiments, at least one R 1e independently, one or more R1 f or R 1z C3 to C optionally substituted with 12 It is heterocycloalkyl. In some embodiments, at least one R 1e independently, one or more R1 f C3 to C optionally substituted with 12 It is heterocycloalkyl. In some embodiments, at least one R 1e independently, one or more R1 z C3 to C optionally substituted with 12 It is heterocycloalkyl. In some embodiments, at least one R 1e are independently C3 to C 12 Hetero It is cycloalkyl. In some embodiments, at least one R 1e independently, one or more R1 f or R 1z C3 to C optionally substituted with 12 It is aryl. In some embodiments, at least one R 1e independently, one or more R1 f C3 to C optionally substituted with 12 It is aryl. In some embodiments, at least one R 1e independently, one or more R1 z C3 to C optionally substituted with 12 It is aryl. In some embodiments, at least one R 1e are independently C3 to C 12 Ally It is. In some embodiments, at least one R 1e independently, one or more R1 f or R 1z C3 to C optionally substituted with 12 It is heteroaryl. In some embodiments, at least one R 1e independently, one or more R1 f C3 to C optionally substituted with 12 It is heteroaryl. In some embodiments, at least one R 1e independently, one or more R1 z C3 to C optionally substituted with 12 It is heteroaryl. In some embodiments, at least one R 1e are independently C3 to C 12 Hetero It is aryl.

[0031] In some embodiments, at least one R 1e is R 1z is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e teeth [ka] is. In some embodiments, at least one R 1e teeth [ka] is. Variable R 1f In some embodiments, at least one R 1f is H. In some embodiments, at least one R 1f are independently C1 to C 20 Alkyl , C2~C 20 Alkenyl, C2-C 20 Alkynyl, -OR 1g , -CH2C(=O) OR 1g , -CH=CH-C(=O)OR 1g , -C(=O)OR 1g , -C(=O)N (R 1g )2, -N(R 1g )2, or R 1zwherein C1 to C 20 Alkyl, C 2~C 20 Alkenyl, or C2-C 20 Alkynyl is one or more -OR 1g At the discretion of It is replaced by intention. In some embodiments, at least one R 1f are independently C1 to C 20 Alkyl , C2~C 20 Alkenyl, C2-C 20 Alkynyl, -OR 1g , -CH2C(=O) OR 1g , -CH=CH-C(=O)OR 1g , -C(=O)OR 1g , -C(=O)N (R 1g )2, -N(R 1g )2, or R 1z wherein C1 to C 20 Alkyl, C 2~C 20 Alkenyl, or C2-C 20 Alkynyl is one or more -OR 1g At the discretion of It is replaced by intention. In some embodiments, at least one R 1f are independently C1 to C 20 Alkyl , C2~C 20 Alkenyl, C2-C 20 Alkynyl, -OR 1g , -CH2C(=O) OR 1g , -CH=CH-C(=O)OR 1g , -C(=O)OR 1g , -C(=O)N (R 1g )2, -N(R 1g )2, or R 1z wherein C1 to C 20 Alkyl, C 2~C 20 Alkenyl, or C2-C 20 Alkynyl is a group consisting of one or more -R1z Any is replaced by In some embodiments, at least one R 1f is C1~C 20 Alkyl, C2~ C 20 Alkenyl, C2-C 20 Alkynyl, -CHC(=O)OR 1g , -CH=C HC(=O)OR 1g , -C(=O)OR 1g , -C(=O)N(R 1g )2, or R 1z wherein C1 to C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 Alkynyl is a group consisting of one or more R 1z is optionally replaced by In some embodiments, at least one R 1f -OR 1g or R 1z C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Alkenyl, or C2 ~C 20 It is alkynyl. In some embodiments, at least one R 1f -OR 1g At the discretion of C1~C, arbitrarily replaced 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 a It's Rukinir. In some embodiments, at least one R 1f is C1~C 20 Alkyl, C2~ C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1f is one or more R1z Optionally Substituted, C1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 Archi It's Nil. In some embodiments, at least one R 1f is C1~C 20 Alkyl (e.g. , methyl, ethyl, propyl, butyl, pentyl, hexyl, or heptyl). In some embodiments, at least one R 1f -OR 1g or R 1z C1~C substituted with 20 Alkyl (e.g., methyl, ethyl, propyl, butyl) , pentyl, hexyl, or heptyl). In some embodiments, at least one R 1f -OR 1g Place Replaced C1~C 20 Alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl) , hexyl, or heptyl). In some embodiments, at least one R 1f is one or more R 1z Replaced with C1~C 20 Alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl, xyl, or heptyl). In some embodiments, at least one R 1f is C2~C 20 Alkenyl (e.g. For example, ethenyl, propenyl, butenyl, pentenyl, or hexenyl. In some embodiments, at least one R 1f -OR 1g or R 1z C2~C substituted with20 Alkenyl (e.g., ethenyl, propenyl, butenyl) , pentenyl, or hexenyl). In some embodiments, at least one R 1f -OR 1g Place Replaced C2~C 20 Alkenyl (e.g., ethenyl, propenyl, butenyl, pentenyl) hexenyl, or hexenyl). In some embodiments, at least one R 1f is one or more R 1z Replaced with C2~C 20 Alkenyl (e.g., ethenyl, propenyl, butenyl, pentenyl, or hexenyl). In some embodiments, at least one R 1f is C2~C 20 Alkynyl (e.g. For example, ethynyl, propynyl, butynyl, pentynyl, or hexynyl. In some embodiments, at least one R 1f -OR 1g or R 1z C2~C substituted with 20 Alkynyl (e.g., ethynyl, propynyl, butynyl) , pentynyl, or hexynyl). In some embodiments, at least one R 1f -OR 1g Place Replaced C2~C 20 Alkynyl (e.g., ethynyl, propynyl, butynyl, pentynyl) hexynyl). In some embodiments, at least one R 1f is one or more R 1z Replaced with C2~C 20Alkynyl (e.g., ethynyl, propynyl, butynyl, pentynyl, or hexynyl). In some embodiments, at least one R 1f HA-OR 1g is. In some embodiments, at least one R 1f -OR 1g wherein R1 g is one or more R 1z C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Haitai Cycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 alkyl)-(C 3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Ants (C1 to C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1f -OR 1g wherein R1 g is one or more R 1z C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1f -OR 1g wherein R1 g is one or more R 1z C3 to C, optionally substituted with 12 Cycloalkyl, C3~ C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 Heteroaryl is. In some embodiments, at least one R 1f -OR 1g wherein R1 g is one or more R 1z optionally substituted with -(C1 to C 20 Alkyl)-(C3 ~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterocyclo alkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), or -(C1 C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1f is -CH2C(=O)OR 1g , -CH=CH-C(=O)OR 1g , -C(=O)OR 1g , -C(=O)N(R 1g ) 2, or R 1z is. In some embodiments, at least one R 1f is -CH2C(=O)OR 1g , -CH=CH-C(=O)OR 1g , -C(=O)OR 1g , or -C(=O)N(R1 g )2. In some embodiments, at least one R 1fis -CH2C(=O)OR 1g in be. In some embodiments, at least one R 1f is -CH2C(=O)OH . In some embodiments, at least one R 1f is -CH2C(=O)OR 1g in where R 1g is one or more R 1z C1 to C, optionally substituted with 20 Archi Lu, C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 cycloalkyl, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroary Le, -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl)-( C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Hetero ant (ru). In some embodiments, at least one R 1f is -CH2C(=O)OR 1g in where R 1g is one or more R 1z C1 to C, optionally substituted with 20 Archi Lu, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1fis -CH2C(=O)OR 1g in where R 1g is one or more R 1z C3 to C, optionally substituted with 12 Cyclo Alkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C1 2 heteroaryl. In some embodiments, at least one R 1f is -CH2C(=O)OR 1g in where R 1g is one or more R 1z optionally substituted with -(C1 to C 20 a Rukill)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl) , or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1f is -CH=CH-C(=O)OR 1g is. In some embodiments, at least one R 1e is -CH=CH-C(=O)OH is. In some embodiments, at least one R 1e is -CH=CH-C(=O)OR 1g where R 1g is one or more R 1z C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Alkenyl, C2-C 20Alkynyl, C3-C 12 Cycloal Kill, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Hetero Aryl, -(C1-C 20 Alkyl)-(C3~C 12 cycloalkyl), -(C1 C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl )-(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Haitai (Royal). In some embodiments, at least one R 1e is -CH=CH-C(=O)OR 1g where R 1g is one or more R 1z C1 to C optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1e is -CH=CH-C(=O)OR 1g where R 1g is one or more R 1z C3 to C, optionally substituted with 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3 ~C 12 It is heteroaryl. In some embodiments, at least one R 1e is -CH=CH-C(=O)OR 1g where R 1gis one or more R 1z optionally substituted with -(C1 to C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 alkyl)-(C 3~C 12 heterocycloalkyl), -(C 1~ C 20 Alkyl)-(C3~C 12 Ants (C1 to C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1f is -C(=O)OR 1g is. In some embodiments, at least one R 1e is -C(=O)OH. In some embodiments, at least one R 1e is -C(=O)OR 1g and In the formula, R 1g is one or more R 1z C1 to C, optionally substituted with 20 Alkyl, C 2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3~ C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, - (C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Archi C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~ C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12Heteroaryl) is.

[0032] In some embodiments, at least one R 1e is -C(=O)OR 1g and In the formula, R 1g is one or more R 1z C1 to C, optionally substituted with 20 Alkyl, C 2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one R 1e is -C(=O)OR 1g and In the formula, R 1g is one or more R 1z C3 to C, optionally substituted with 12 Cycloalkane Lu, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 Haitai It's a royal. In some embodiments, at least one R 1e is -C(=O)OR 1g and In the formula, R 1g is one or more R 1z optionally substituted with -(C1 to C 20 Alkyl )-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 F -cycloalkyl), -(C 1~ C 20 Alkyl)-(C3~C 12 aryl), or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1f is -C(=O)N(R1g )2 be. In some embodiments, at least one R 1f is -C(=O)NHR 1g is . In some embodiments, at least one R 1f is -C(=O)NH2. In some embodiments, at least one R 1f is -C(=O)N(R 1g )2 wherein at least one R 1g is one or more R 1z optionally substituted with C 1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 cycloalkyl), -(C1~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C2 0 alkyl)-(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~ C 12 heteroaryl). In some embodiments, at least one R 1f is -C(=O)N(R 1g )2 wherein at least one R 1g is one or more R 1z optionally substituted with C 1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20It is alkynyl. In some embodiments, at least one R 1f is -C(=O)N(R 1g )2 wherein at least one R 1g is one or more R 1z optionally substituted with C 3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl , or C3~C 12 It is heteroaryl. In some embodiments, at least one R 1f is -C(=O)N(R 1g )2 wherein at least one R 1g is one or more R 1z optionally replaced by - (C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Archi C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~ C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl) is. In some embodiments, at least one R 1f -N(R 1g )2. In some embodiments, at least one R 1f is -N(R 1g )2, wherein , R 1g is one or more R 1z C1 to C, optionally substituted with 20 Alkyl, C2~ C 20 Alkenyl, C2-C 20 Alkynyl, C3-C12 Cycloalkyl, C3-C1 2Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C 1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 alkyl) -(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C1 2aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroaryl do. In some embodiments, at least one —N(R 1g )2 is -OR 1g and In the formula, R 1g is one or more R 1z C1 to C, optionally substituted with 20 Alkyl, C 2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one —N(R 1g )2 is -OR 1g and In the formula, R 1g is one or more R 1z C3 to C, optionally substituted with 12 Cycloalkane Lu, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 Haitai It's a royal. In some embodiments, at least one —N(R 1g )2 is -OR 1g and In the formula, R 1g is one or more R 1z optionally substituted with -(C1 to C 20 Alkyl )-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 F -cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, at least one R 1f is R 1z is. In some embodiments, at least one R 1f teeth [ka] is. In some embodiments, at least one R 1f teeth [ka] is. In some embodiments, at least one R 1f teeth [ka] is. In some embodiments, at least one R 1f teeth [ka] is. In some embodiments, at least one R 1f is H, -OSi(R 1g )3, also is -C(=O)OR 1g is. In some embodiments, at least one R 1f is -OSi(R1g )3, or - C(=O)OR 1g is. In some embodiments, at least one R 1f is -OSi(R 1g )3 or -C (=O)OR 1g wherein at least one R 1g is C1~C 20 Alkyl do. In some embodiments, at least one R 1f is -OSi(R 1g )3 or -C (=O)OR 1g where each R 1g are independently C1 to C 20 Alkyl (e.g. , methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, or t-butyl Chill). In some embodiments, at least one R 1f is -OSi(R 1g )3, In the formula, each R 1g are independently C1 to C 20 Alkyl (e.g., methyl, ethyl, n-propyl) The alkyl group is propyl, i-propyl, n-butyl, s-butyl, or t-butyl. In some embodiments, at least one R 1f is -OSi(R 1g )3, In the formula, each R 1g is independently methyl or t-butyl. In some embodiments, at least one R 1f teeth [ka] is. In some embodiments, at least one R 1f is -C(=O)OR 1g and In the formula, R 1g are independently C1 to C 20 Alkyl (e.g., methyl, ethyl, n-propyl) The alkyl esters are butyl, i-propyl, n-butyl, s-butyl, or t-butyl. In some embodiments, at least one R 1f is -C(=O)OR 1g and In the formula, R 1g is t-butyl. In some embodiments, at least one R 1f teeth [ka] is. Variable R 1g In some embodiments, at least one R 1g is H. In some embodiments, at least one R 1g is one or more R 1z Optionally Substituted, C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl , C3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Ants C3~C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 Shik -(C1-C alkyl) 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1~C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 Archi C3~C 12 heteroaryl). In some embodiments, at least one R 1g is one or more R 1z Optionally Substituted, C1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 Archi It's Nil. In some embodiments, at least one R 1g is C1~C 20 Alkyl (e.g. , methyl, ethyl, propyl, butyl, pentyl, hexyl, or heptyl). In some embodiments, at least one R 1g is one or more R 1z Replaced with C1~C 20 Alkyl (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, or heptyl). In some embodiments, at least one R 1g is C2~C 20 Alkenyl (e.g. For example, ethenyl, propenyl, butenyl, pentenyl, or hexenyl. In some embodiments, at least one R 1g is one or more R 1z Replaced with C2~C 20 Alkenyl (e.g., ethenyl, propenyl, butenyl, pentenyl) , or hexenyl). In some embodiments, at least one R 1g is C2~C 20 Alkynyl (e.g. For example, ethynyl, propynyl, butynyl, pentynyl, or hexynyl. In some embodiments, at least one R 1g is one or more R 1z Replaced with C2~C 20Alkynyl (e.g., ethynyl, propynyl, butynyl, pentynyl) , or hexynyl). In some embodiments, at least one R 1g is one or more R 1z Optionally Substituted, C3-C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3~ C 12 Aryl or C3-C 12 It is heteroaryl. In some embodiments, at least one R 1g is one or more R 1z Optionally Substituted C3~C 12 In some embodiments, at least one R 1g is C3~C 12 In some embodiments, at least Another R 1g is one or more R 1z C3~C substituted with 12 Cycloalkyl do. In some embodiments, at least one R 1g is one or more R 1z Optionally Substituted C3~C 12 In some embodiments, at least one of the aryl, ... Together with R 1g is C3~C 12 In some embodiments, the aryl group is heterocycloalkyl. is at least one R 1g is one or more R 1z C3~C substituted with 12 Hetero It is cycloalkyl. In some embodiments, at least one R 1g is one or more R 1z Optionally Substituted C3~C12 In some embodiments, at least one R 1g is C3~C 12 In some embodiments, at least one R is aryl. g is one or more R 1z C3~C substituted with 12 It is aryl. In some embodiments, at least one R 1g is one or more R 1z Optionally Substituted C3~C 12 In some embodiments, at least one R 1g is C3~C 12 In some embodiments, at least one of Another R 1g is one or more R 1z C3~C substituted with 12 Heteroaryl do. In some embodiments, at least one R 1g is one or more R 1z Optionally Substituted, -(C1~C 20 Alkyl)-(C3~C 12 cycloalkyl), -(C1 ~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C 1~ C 20 Archi C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 F (terearyl). In some embodiments, at least one R 1g is one or more R 1z Optionally Substituted -(C1~C 20 Alkyl)-(C3~C 12Cycloalkyl). In some embodiments, at least one R 1g is -(C1~C 20 Alkyl)-(C3 ~C 12 In some embodiments, at least one R 1g teeth , one or more R 1z -(C1~C 20 Alkyl)-(C3~C 12 Shik (alkyl). In some embodiments, at least one R 1g is one or more R 1z Optionally Substituted -(C1~C 20 Alkyl)-(C3~C 12 heterocycloalkyl) In some embodiments, at least one R 1g is -(C1~C 20 alkyl)- (C3~C 12 In some embodiments, at least one R 1g is one or more R 1z -(C1~C 20 Alkyl)-(C3 ~C 12 heterocycloalkyl). In some embodiments, at least one R 1g is one or more R 1z Optionally Substituted -(C1~C 20 Alkyl)-(C3~C 12 aryl). In embodiments, at least one R 1g is -(C1~C 20 Alkyl)-(C3~C1 2aryl). In some embodiments, at least one R 1g is one or more R in Numbers1z -(C1~C 20 Alkyl)-(C3~C 12 aryl) . In some embodiments, at least one R 1g is one or more R 1z Optionally Substituted -(C1~C 20 Alkyl)-(C3~C 12 Heteroaryl). In some embodiments, at least one R 1g is -(C1~C 20 Alkyl)-(C3 ~C 12 In some embodiments, at least one R 1g teeth , one or more R 1z -(C1~C 20 Alkyl)-(C3~C 12 Haitai (Royal).

[0033] Variable R 1z In some embodiments, at least one R 1z teeth, [ka] is. In some embodiments, at least one R 1z teeth, [ka] is. In some embodiments, at least one R 1z teeth [ka] is. In some embodiments, at least one R 1z teeth [ka] is. In some embodiments, at least one R 1z teeth [ka] is. In some embodiments, at least one R 1z teeth [ka] is. In some embodiments, one or more R 1z All of [ka] is. In some embodiments, one or more R 1z All of [ka] is. In some embodiments, one or more R 1z All of [ka] is.

[0034] In some embodiments, one or more R 1z All of [ka] is. In some embodiments, two or more R 1z At least one of [ka] and two or more R 1z At least one of [ka] is. In some embodiments, two or more R 1z At least one of [ka] and two or more R 1z At least one of [ka] is. In some embodiments, two or more R 1z At least one of [ka] and two or more R 1z At least one of [ka] is. In some embodiments, at least one R 1z teeth [ka] is. In some embodiments, one or more R 1z All of [ka] is. In some embodiments, at least one R 1z teeth [ka] is. In some embodiments, one or more R 1z All of [ka] is. In some embodiments, at least one R 1z teeth [ka] is. In some embodiments, one or more R 1z All of [ka] is. In some embodiments, at least one R 1z teeth [ka] is. In some embodiments, one or more R 1z All of [ka] is. In some embodiments, at least one R 1z teeth [ka] is. In some embodiments, one or more R 1z All of [ka] is. In some embodiments, at least one R 1z teeth [ka] is. In some embodiments, one or more R 1z All of [ka] is. In some embodiments, at least one R 1z teeth [ka] is. In some embodiments, one or more R 1z All of [ka] is. In some embodiments, at least one R 1z teeth [ka] is. In some embodiments, one or more R 1z All of [ka] is. In some embodiments, at least one R 1z teeth [ka] is. In some embodiments, one or more R1z All of [ka] is. In some embodiments, at least one R 1z teeth [ka] is. In some embodiments, each R 1z teeth [ka] is.

[0035] Variables n, p, q, and r In some embodiments, n is 0 to 20, 0 to 15, 0 to 10, 0 to 6, 0 to 4, or is between 0 and 2. In some embodiments, n is 1 to 20, 2 to 20, 3 to 20, 4 to 20, or 5 to 20. , 6~20, 7~20, 8~20, 9~20, 10~20, 11~20, 12~20, 1 3~20, 14~20, 15~20, 16~20, 17~20, 18~20, or 19~ It is 20. In some embodiments, n is 0. In some embodiments, n is 1 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10). In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is In some embodiments, n is 6. In some embodiments, n is 7. In some embodiments, n is 8. In some embodiments, n is 9. In some embodiments, n is 10. do. In some embodiments, n is 11 to 20 (e.g., 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20). In some embodiments, n is 11. In some embodiments, n is 12. In some embodiments, n is 13. In some embodiments, n is 14. In some embodiments, n is 15. In some embodiments, n is 16. In some embodiments, n is 17. In some embodiments, n is 18. In some embodiments, n is 19. In some embodiments, n is 20. In some embodiments, p is 0 to 20, 0 to 15, 0 to 10, 0 to 6, 0 to 4, or is between 0 and 2. In some embodiments, p is 1 to 20, 2 to 20, 3 to 20, 4 to 20, 5 to 20 , 6~20, 7~20, 8~20, 9~20, 10~20, 11~20, 12~20, 1 3~20, 14~20, 15~20, 16~20, 17~20, 18~20, or 19~ It is 20. In some embodiments, p is 0. In some embodiments, p is 1 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, In some embodiments, p is 1. In some embodiments, p is 2. In some embodiments, p is 2. In some embodiments, p is 3. In some embodiments, p is 4. In some embodiments, p is 5. In some embodiments, p is In some embodiments, p is 6. In some embodiments, p is 7. In some embodiments, p is 8. In some embodiments, p is 9. In some embodiments, p is 10. do. In some embodiments, p is 11 to 20 (e.g., 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20). In some embodiments, p is 11. In some embodiments, p is 12. In some embodiments, p is 13. In some embodiments, p is 14. In some embodiments, p is 15. In some embodiments, p is 16. In some embodiments, p is 17. In some embodiments, p is 18. In some embodiments, p is 19. In some embodiments, p is 20. In some embodiments, q is 0 to 20, 0 to 15, 0 to 10, 0 to 6, 0 to 4, or is between 0 and 2. In some embodiments, q is 1 to 20, 2 to 20, 3 to 20, 4 to 20, or 5 to 20 , 6~20, 7~20, 8~20, 9~20, 10~20, 11~20, 12~20, 1 3~20, 14~20, 15~20, 16~20, 17~20, 18~20, or 19~ It is 20. In some embodiments, q is 0. In some embodiments, q is 1 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, In some embodiments, q is 1. In some embodiments, q is 2. In some embodiments, q is 2. In some embodiments, q is 3. In some embodiments, q is 4. In some embodiments, q is 5. In some embodiments, q is In some embodiments, q is 6. In some embodiments, q is 7. In some embodiments, q is 8. In some embodiments, q is 9. In some embodiments, q is 10. do. In some embodiments, r is 11 to 20 (e.g., 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20). In some embodiments, r is 11. In some embodiments, r is 12. In some embodiments, r is 13. In some embodiments, r is 14. In some embodiments, r is 15. In some embodiments, r is 16. In some embodiments, r is 17. In some embodiments, r is 18. In some embodiments, r is 19. In some embodiments, r is 20. In some embodiments, r is 0 to 20, 0 to 15, 0 to 10, 0 to 6, 0 to 4, or is between 0 and 2. In some embodiments, r is 1 to 20, 2 to 20, 3 to 20, 4 to 20, or 5 to 20 , 6~20, 7~20, 8~20, 9~20, 10~20, 11~20, 12~20, 1 3~20, 14~20, 15~20, 16~20, 17~20, 18~20, or 19~ It is 20. In some embodiments, r is 0. In some embodiments, r is 1 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10). In some embodiments, r is 1. In some embodiments, r is 2. In some embodiments, r is 3. In some embodiments, r is 4. In some embodiments, r is 5. In some embodiments, r is In some embodiments, r is 6. In some embodiments, r is 7. In some embodiments, r is 8. In some embodiments, r is 9. In some embodiments, r is 10. do. In some embodiments, r is 11 to 20 (e.g., 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20). In some embodiments, r is 11. In some embodiments, r is 12. In some embodiments, r is 13. In some embodiments, r is 14. In some embodiments, r is 15. In some embodiments, r is 16. In some embodiments, r is 17. In some embodiments, r is 18. In some embodiments, r is 19. In some embodiments, r is 20.

[0036] Variable R2 In some embodiments, R2 is H. In some embodiments, R2 is -C(=O)R 1b , -C(=O)OR 1c , -C (=O)N(R 1c )2, -C(=O)R 1z , -C(=O)-CH=CH-C(=O) OR 1c , -C(=O)-CH2-CH2-C(=O)OR 1c , [ka] -C(=O)-CH=CH-C(=O)-R 1z , -C(=O)-CH2-CH2-C( =O)-R 1z , [ka] is. In some embodiments, R2 is -C(=O)R 1b is. In some embodiments, R2 is -C(=O)H. In some embodiments, R2 is -C(=O)R 1b where R 1b is C1 ~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, -(CH2) q -C(=O)OR 1c , -CH2-C(=O)-(CH2) q -C(=O)OR 1c ,- CH2-[C(=O)CH2] p -[CH2] q -C(=O)OR 1c , -CH=CH- C(=O)OR 1c , -C(=O)OR 1c , -C(=O)N(R 1c )2, or R 1z wherein C1 to C 20 Alkyl or C2-C 20 Alkenyl or C2-C 20 a A rucynyl may be one or more R 1e is optionally replaced by In some embodiments, R2 is -C(=O)R 1b where R 1b is one or multiple R 1e C1 to C optionally substituted with 20 Alkyl, C2-C 20 alkenyl, Or C2~C 20 It is alkynyl. In some embodiments, R2 is -C(=O)R 1b where R 1b teeth,-( CH2) q -C(=O)OR 1c , -CH2-C(=O)-(CH2) q -C(=O)O R1c , -CH2-[C(=O)CH2] p -[CH2] q -C(=O)OR 1c , -C H=CH-C(=O)OR 1c , -C(=O)OR 1c , or -C(=O)N(R 1c ) It is 2. In some embodiments, R2 is -(CH2) q -C(=O)OR 1c is. In some embodiments, R2 is -CH2CH2-C(=O)OR 1c is. In some embodiments, R2 is -CH2-C(=O)-(CH2) q -C(=O) OR 1c is. In some embodiments, R2 is -CH2-C(=O)-CH2CH2-C(=O) OR 1c is. In some embodiments, R2 is -C(=O)-CH=CH-C(=O)OR 1c in be. In some embodiments, R2 is -C(=O)R 1z is. In some embodiments, R2 is [ka] is. In some embodiments, R2 is [ka] is. In some embodiments, R2 is [ka] is. In some embodiments, R2 is [ka] is. In some embodiments, R2 is -C(=O)OR 1c is. In some embodiments, R2 is -C(=O)OH. In some embodiments, R2 is -C(=O)OR 1c where R 1c is 1 One or more R 1e C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Arkeny Lu, C2~C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclo Alkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 Al Kill)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C1 2 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), Or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, R2 is -C(=O)OR 1c where R 1c is 1 One or more R 1e C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Arkeny or C2~C 20 It is alkynyl. In some embodiments, R2 is -C(=O)OR 1c where R 1cis 1 One or more R 1e C3 to C, optionally substituted with 12 Cycloalkyl, C3-C 12 F Tetracycloalkyl, C3-C 12 Aryl or C3-C 12 It is heteroaryl. In some embodiments, R2 is -C(=O)OR 1c where R 1c is 1 One or more R 1e optionally substituted with -(C1 to C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterocycloalkyl ), -(C1~C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 a Rukill)-(C3~C 12 heteroaryl). In some embodiments, R2 is —C(═O)N(R 1c )2. In some embodiments, R2 is —C(═O)N(R 1c )2, wherein at least Another R 1c is H. In some embodiments, R2 is —C(═O)N(R 1c )2, where at least Together with R 1c is one or more R 1e C1 to C, optionally substituted with 20 Alkyl , C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C 3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12Heteroaryl , -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 a Rukill)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl)-(C 3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroary (L). In some embodiments, R2 is —C(═O)N(R 1c )2, where at least Together with R 1c is one or more R 1e C1 to C optionally substituted with 20 Alkyl, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, R2 is —C(═O)N(R 1c )2, where at least Together with R 1c is one or more R 1e C3 to C, optionally substituted with 12 Cycloa Lukil, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 It is heteroaryl. In some embodiments, R2 is —C(═O)N(R 1c )2, where at least Together with R 1c is one or more R 1e optionally substituted with -(C1 to C 20 Al Kill)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C1 2 heterocycloalkyl), -(C1-C20 Alkyl)-(C3~C 12 aryl), Or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, R2 is -C(=O)-CH=CH-C(=O)OR 1c in be. In some embodiments, R2 is -C(=O)-CH=CH-C(=O)OH . In some embodiments, R2 is -C(=O)-CH=CH-C(=O)OR 1c in where R 1c is one or more R 1e C1 to C, optionally substituted with 20 Archi Lu, C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 cycloalkyl, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroary Le, -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl)-( C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Hetero ant (ru). In some embodiments, R2 is -C(=O)-CH=CH-C(=O)OR 1c in where R 1c is one or more R 1e C1 to C, optionally substituted with 20 Archi Lu, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, R2 is -C(=O)-CH=CH-C(=O)OR 1c in where R 1c is one or more R 1e C3 to C, optionally substituted with 12 Cyclo Alkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C1 2 heteroaryl. In some embodiments, R2 is -C(=O)-CH=CH-C(=O)OR 1c in where R 1c is one or more R 1e optionally substituted with -(C1 to C 20 a Rukill)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl) , or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, R2 is -C(=O)-CH2-CH2-C(=O)OR1 c is. In some embodiments, R2 is -C(=O)-CH2-CH2-C(=O)OH. be. In some embodiments, R2 is -C(=O)-CH2-CH2-C(=O)OR1 c where R 1c is one or more R 1e C1 to C, optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkane Lu, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroa Reel, -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl) -(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Hetero aryl). In some embodiments, R2 is -C(=O)-CH2-CH2-C(=O)OR1 c where R 1c is one or more R 1e C1 to C, optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, R2 is -C(=O)-CH2-CH2-C(=O)OR1 c where R 1c is one or more R 1e C3 to C, optionally substituted with 12 S Chloroalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3~ C 12 It is heteroaryl. In some embodiments, R2 is -C(=O)-CH2-CH2-C(=O)OR1 cwhere R 1c is one or more R 1e optionally substituted with -(C1-C2 0 alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3 ~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Ally ru), or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl).

[0037] In some embodiments, R2 is [ka] (for example, [ka] ) In some embodiments, R2 is selected from the group consisting of at least one R 1c is H [ka] (for example, [ka] ) In some embodiments, R2 is [ka] (for example [ka] ) wherein at least one R 1c is one or more R 1eoptionally replaced with , C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C3 ~C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 cycloalkyl ), -(C1~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 alkyl)-(C 3~C 12 heteroaryl). In some embodiments, R2 is [ka] (for example [ka] ) wherein at least one R 1c is one or more R 1e optionally replaced with C1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, R2 is [ka] (for example [ka] ) wherein at least one R 1c is one or more R 1e optionally replaced with , C3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Ants C3~C 12 It is heteroaryl. In some embodiments, R2 is [ka] (for example [ka] ) wherein at least one R 1c is one or more R 1e optionally replaced with , -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 a Rukill)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl)-(C 3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroary (L). In some embodiments, R2 is [ka] (for example, [ka] ) In some embodiments, R2 is [ka] (for example, [ka] and R 1c is H. In some embodiments, R2 is [ka] (for example [ka] ) where R 1c is one or more R 1e C1 to C, optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkane Lu, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroa Reel, -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl) -(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Hetero aryl). In some embodiments, R2 is [ka] (for example [ka] ) where R 1c is one or more R 1e C1 to C, optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, R2 is [ka] (for example [ka] ) where R 1c is one or more R 1e C3 to C, optionally substituted with 12 S Chloroalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3~ C 12 It is heteroaryl. In some embodiments, R2 is [ka] (for example [ka] ) where R 1c is one or more R 1e optionally substituted with -(C1-C2 0 alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3 ~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Ally ru), or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl).

[0038] In some embodiments, R2 is [ka] (for example, [ka] ) In some embodiments, R2 is [ka] (for example, [ka] ) and R 1c is H. In some embodiments, R2 is [ka] (for example [ka] ) where R 1c is one or more R 1e C1 to C, optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkane Lu, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroa Reel, -(C1~C 20 Alkyl)-(C3~C12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl) -(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Hetero aryl). In some embodiments, R2 is [ka] (for example [ka] ) where R 1c is one or more R 1e C1 to C, optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, R2 is [ka] (for example [ka] ) where R 1c is one or more R 1e C3 to C, optionally substituted with 12 S Chloroalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3~ C 12 It is heteroaryl. In some embodiments, R2 is [ka] (for example [ka] ) where R 1c is one or more R 1e optionally substituted with -(C1-C2 0 alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3 ~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Ally ru), or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, R2 is [ka] (for example, [ka] ) In some embodiments, R2 is -C(=O)-CH=CH-C(=O)-R 1z in be. In some embodiments, R2 is -C(=O)-CH=CH-C(=O)-R 1z in where R 1z teeth, [ka] is. In some embodiments, R2 is -C(=O)-CH=CH-C(=O)-R 1z in where R 1z teeth, [ka] is. In some embodiments, R2 is -C(=O)-CH=CH-C(=O)-R 1z in where R 1z teeth, [ka] is. In some embodiments, R2 is -C(=O)-CH=CH-C(=O)-R 1z in where R 1z teeth, [ka] is. In some embodiments, R2 is -C(=O)-CH2-CH2-C(=O)R 1z is. In some embodiments, R2 is -C(=O)-CH2-CH2-C(=O)-R1 z where R 1z teeth, [ka] is. In some embodiments, R2 is -C(=O)-CH2-CH2-C(=O)-R1 z where R 1z teeth, [ka] is. In some embodiments, R2 is -C(=O)-CH2-CH2-C(=O)-R1 z where R 1zteeth, [ka] is. In some embodiments, R2 is -C(=O)-CH2-CH2-C(=O)-R1 z where R 1z teeth, [ka] is. In some embodiments, R2 is [ka] is. In some embodiments, R2 is [ka] and at least one X is -OR 1c , -SR 1c , or -N(R 1c )2 In some embodiments, R2 is [ka] and at least two Xs are -OR 1c , -SR 1c , or -N(R 1c )2 In some embodiments, R2 is [ka] and each X is independently -OR 1c , -SR 1c , or -N(R 1c )2.

[0039] In some embodiments, R2 is [ka] and at least one X is -OR 1c is. In some embodiments, R2 is [ka] and at least two Xs are -OR 1c is. In some embodiments, R2 is [ka] and each X is independently -OR 1c is. In some embodiments, R2 is [ka] and at least one X is -SR 1c is. In some embodiments, R2 is [ka] and at least two Xs are -SR 1c is. In some embodiments, R2 is [ka] and each X is independently -SR 1c is. In some embodiments, R2 is [ka] and at least one X is -N(R 1c )2. In some embodiments, R2 is [ka] and at least two Xs are -N(R 1c )2. In some embodiments, R2 is [ka] and each X is independently -N(R 1c )2. In some embodiments, R2 is [ka] is. In some embodiments, R2 is [ka] is. In some embodiments, R2 is [ka] wherein at least one X is [ka] (for example, [ka] ) or [ka] (for example, [ka] ) In some embodiments, R2 is [ka] wherein at least two X's are [ka] (for example, [ka] ) or [ka] (for example, [ka] ) In some embodiments, R2 is [ka] and each X is independently [ka] (for example, [ka] ) or [ka] (for example, [ka] )

[0040] In some embodiments, R2 is [ka] wherein at least one X is [ka] or R 1z is. In some embodiments, R2 is [ka] and one of the two X's is [ka] or R 1z is. In some embodiments, R2 is [ka] and each X is [ka] or R 1z is. In some embodiments, R2 is [ka] At least one X is [ka] (for example, [ka] ) In some embodiments, R2 is [ka] and there are at least two Xs [ka] (for example, [ka] ) In some embodiments, R2 is [ka] and each X is [ka] (for example, [ka] ) In some embodiments, R2 is [ka] and at least one X is [ka] (for example, [ka] )

[0041] In some embodiments, R2 is [ka] and there are at least two Xs [ka] (for example, [ka] ) In some embodiments, R2 is [ka] and each X is [ka] (for example, [ka] ) In some embodiments, R2 is [ka] and at least one X is [ka] (for example, [ka] ), or [ka] (for example, [ka] ) In some embodiments, R2 is [ka] and one of the two X's is [ka] (for example, [ka] ), or [ka] (for example, [ka] ) In some embodiments, R2 is [ka] and each X is [ka] (for example, [ka] ), or [ka] (for example, [ka] ) In some embodiments, R2 is [ka] and at least one X is R 1z (for example, [ka] (for example, [ka] ) or [ka] ) In some embodiments, R2 is [ka] and one of the two Xs is R 1z (for example, [ka] (for example, [ka] ) or [ka] is. In some embodiments, R2 is [ka] and each X is R 1z (for example, [ka] (for example, [ka] ) or [ka] ) In some embodiments, R2 is [ka] is. In some embodiments, R2 is [ka] and at least one X is -OR 1c , -SR 1c , or -N(R 1c )2 In some embodiments, R2 is [ka] and two of the three Xs are -OR 1c , -SR 1c , or -N(R 1c )2

[0042] In some embodiments, R2 is [ka] and each X is independently -OR 1c , -SR 1c , or -N(R 1c )2. In some embodiments, R2 is [ka] and at least one X is -OR 1c is. In some embodiments, R2 is [ka] and two of the three Xs are -OR 1c is. In some embodiments, R2 is [ka] and each X is independently -OR 1c is. In some embodiments, R2 is [ka] and at least one X is -SR 1c is. In some embodiments, R2 is [ka] and two of the three Xs are -SR 1c is. In some embodiments, R2 is [ka] and each X is independently -SR 1c is. In some embodiments, R2 is [ka] and at least one X is -N(R 1c )2. In some embodiments, R2 is [ka] and two of the three Xs are -N(R 1c )2. In some embodiments, R2 is [ka] and each X is independently -N(R 1c )2. In some embodiments, R2 is [ka] and at least one X is [ka] (for example, [ka] ) or [ka] (for example, [ka] ) In some embodiments, R2 is [ka] and one of the two X's is [ka] (for example, [ka] ) or [ka] (for example, [ka] ) In some embodiments, R2 is [ka] and each X is independently [ka] (for example, [ka] ) or [ka] (for example, [ka] ) In some embodiments, R2 is [ka] and at least one X is [ka] or R 1z is. In some embodiments, R2 is [ka] and two of the three X's are [ka]

[0043] In some embodiments, R2 is [ka] and each X is [ka] or R 1z is. In some embodiments, R2 is [ka] and at least one X is [ka] (for example, [ka] ) In some embodiments, R2 is [ka] and two of the three Xs are [ka] (for example, [ka] ) In some embodiments, R2 is [ka] and each X is [ka] (for example, [ka] ) In some embodiments, R2 is [ka] and at least one X is [ka] (for example, [ka] ) In some embodiments, R2 is [ka] and two of the three Xs are [ka] (for example, [ka] ) In some embodiments, R2 is [ka] and each X is [ka] (for example, [ka] ) In some embodiments, R2 is [ka] and at least one X is [ka] (for example, [ka] ), or [ka] (for example, [ka] ) In some embodiments, R2 is [ka] and two of the three X's are [ka] (for example, [ka] ), or [ka] (for example, [ka] )

[0044] In some embodiments, R2 is [ka] and each X is [ka] (for example, [ka] ), or [ka] (for example, [ka] ) In some embodiments, R2 is [ka] and at least one X is R 1z (for example, [ka] (for example, [ka] ) or [ka] ) In some embodiments, R2 is [ka] and two of the three Xs are R 1z (for example, [ka] (for example, [ka] ) or [ka] ) In some embodiments, R2 is [ka] and each X is R 1z (for example, [ka] (for example, [ka] ) or [ka] ) In some embodiments, R2 is -C(=O)R 1b where R 1b is one or multiple R 1e C1 to C optionally substituted with 20 It is alkyl. In some embodiments, R2 is -C(=O)R 1b where R 1b is one or multiple R 1e C1 to C optionally substituted with 20 alkyl and at least one R 1e H, oxo, C1-C 20 Alkyl, -N(R 1f )2, or C3~C 12 Ants wherein C1 to C 20 Alkyl or C3-C 12 Aryl or C3-C 12 Heteroaryl is one or more R 1f is optionally replaced by In some embodiments, R2 is -C(=O)R 1b where R 1b is one or multiple R 1e C1 to C optionally substituted with20 alkyl and at least one R 1e H, oxo, C1-C 20 Alkyl, or -N(R 1f )2. In some embodiments, R2 is -C(=O)R 1b where R 1b is one or multiple R 1e C1 to C optionally substituted with 20 alkyl and at least one R 1e is oxo, C1-C 20 Alkyl, or -N(R 1f )2. In some embodiments, R2 is -C(=O)R 1b where R 1b is one or multiple R 1e C1 to C optionally substituted with 20 alkyl and at least one R 1e is -N(R 1f )2. In some embodiments, R2 is -C(=O)R 1b where R 1b is one or multiple R 1e C1 to C optionally substituted with 20 alkyl and at least one R 1e -NHR 1f is. In some embodiments, R2 is -C(=O)R 1b where R 1b is plural R 1e C1 to C optionally substituted with 20 alkyl and at least one R 1e teeth, oxo and at least one R 1e is -N(R 1f )2. In some embodiments, R2 is -C(=O)R1b where R 1b is plural R 1e C1 to C optionally substituted with 20 alkyl and at least one R 1e teeth, oxo and at least one R 1e -NHR 1f is. In some embodiments, R2 is -C(=O)R 1b where R 1b There are two R 1e C1 to C optionally substituted with 20 alkyl and one R 1e is oxo and one R 1e is -N(R 1f )2. In some embodiments, R2 is -C(=O)R 1b where R 1b There are two R 1e C1 to C optionally substituted with 20 alkyl and one R 1e is oxo and one R 1e is NHR 1f is. In some embodiments, R2 is -C(=O)R 1b where R 1b There are three More than R 1e C1 to C optionally substituted with 20 alkyl and at least one R 1e is oxo and at least one R 1e is -N(R 1f )2 and at least 1 R 1e is C1~C 20 It is alkyl. In some embodiments, R2 is —C(═O)—(C(R 1e )2) 0-19 -C(R 1e )3. In some embodiments, R2 is —C(═O)—C(R 1e )3. In some embodiments, R2 is -C(=O)-CH2R 1e is. In some embodiments, R2 is —C(═O)—CH(R 1e )2. In some embodiments, R2 is —C(═O)—C(R 1e )2-C(R 1e )3 do. In some embodiments, R2 is -C(=O)-CHR 1e -CH2R 1e is. In some embodiments, R2 is —Si(R 1g )3. In some embodiments, R2 is —Si(R 1g ) 3, wherein each R 1g is German Stand up and play C1~C 20 Alkyl or C3-C 12 It is aryl. In some embodiments, R2 is —Si(R 1g ) 3, wherein each R 1g is German In other words, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i- butyl, t-butyl, or phenyl. In some embodiments, R2 is —Si(R 1g ) 3, wherein each R 1g is German Stand up and play C1~C 20 It is alkyl. In some embodiments, R2 is —Si(R 1g ) 3, wherein each R 1g is German In other words, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i- butyl, or t-butyl. In some embodiments, R2 is —Si(R 1g ) 3, wherein each R 1g is German Typically, it is methyl or t-butyl. In some embodiments, R2 is [ka] is. In some embodiments, R2 is [ka] isn't it. In some embodiments, R2 is H, -C(=O)R 1b , -C(=O)R 1z ,- C(=O)-CH2-CH2-C(=O)OR 1c , and [ka] is selected from. In some embodiments, R2 is H and -C(=O)R 1b is selected from. In some embodiments, R2 is H, [ka] is selected from. In some embodiments, R2 is H and [ka] is selected from.

[0045] In some embodiments, R2 is H. In some embodiments, R2 is [ka] is. In some embodiments, R2 is [ka] is. In some embodiments, R2 is [ka] is. In some embodiments, R2 is [ka] is. In some embodiments, R2 is [ka] is. In some embodiments, R2 is [ka] is. In some embodiments, R2 is [ka] is. In some embodiments, R2 is [ka] is. In some embodiments, R2 is [ka] is. Variable R3 In some embodiments, R3 is H. In some embodiments, R3 is -C(=O)R1b , -C(=O)OR 1c , -C (=O)N(R 1c )2, -C(=O)R 1z , -C(=O)-CH=CH-C(=O) OR 1c , -C(=O)-CH2-CH2-C(=O)OR 1c , [ka] -C(=O)-CH=CH-C(=O)-R 1z , -C(=O)-CH2-CH2-C( =O)-R 1z , [ka] is. In some embodiments, R3 is -C(=O)R 1b is. In some embodiments, R3 is -C(=O)H. In some embodiments, R3 is -C(=O)R 1b where R 1b is C1 ~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, -(CH2) q -C(=O)OR 1c , -CH2-C(=O)-(CH2) q -C(=O)OR 1c ,- CH2-[C(=O)CH2] p -[CH2] q -C(=O)OR 1c , -CH=CH- C(=O)OR 1c , -C(=O)OR 1c , -C(=O)N(R 1c )2, or R 1z wherein C1 to C 20Alkyl or C2-C 20 Alkenyl or C2-C 20 a A rucynyl may be one or more R 1e is optionally replaced by In some embodiments, R3 is -C(=O)R 1b where R 1b is one or multiple R 1e C1 to C optionally substituted with 20 Alkyl, C2-C 20 alkenyl, Or C2~C 20 It is alkynyl. In some embodiments, R3 is -C(=O)R 1b where R 1b teeth,-( CH2) q -C(=O)OR 1c , -CH2-C(=O)-(CH2) q -C(=O)O R 1c , -CH2-[C(=O)CH2] p -[CH2] q -C(=O)OR 1c , -C H=CH-C(=O)OR 1c , -C(=O)OR 1c , or -C(=O)N(R 1c) It is 2. In some embodiments, R3 is -(CH2) q -C(=O)OR 1c is. In some embodiments, R3 is -CH2CH2-C(=O)OR 1c is. In some embodiments, R3 is -CH2-C(=O)-(CH2) q -C(=O) OR 1c is. In some embodiments, R3 is -CH2-C(=O)-CH2CH2-C(=O) OR 1c is. In some embodiments, R3 is -C(=O)-CH=CH-C(=O)OR 1c in be. In some embodiments, R3 is -C(=O)R 1z is. In some embodiments, R3 is [ka] is. In some embodiments, R3 is [ka] is. In some embodiments, R3 is [ka] is. In some embodiments, R3 is [ka] is. In some embodiments, R3 is -C(=O)OR 1c is. In some embodiments, R3 is -C(=O)OH. In some embodiments, R3 is -C(=O)OR 1c where R 1c is 1 One or more R 1e C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Arkeny Lu, C2~C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocyclo Alkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl, -(C1-C 20 Al Kill)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C1 2 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), Or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, R3 is -C(=O)OR 1c where R 1c is 1 One or more R 1e C1 to C, optionally substituted with 20 Alkyl, C2-C 20 Arkeny or C2~C 20 It is alkynyl. In some embodiments, R3 is -C(=O)OR 1c where R 1c is 1 One or more R 1e C3 to C, optionally substituted with 12 Cycloalkyl, C3-C 12 F Tetracycloalkyl, C3-C 12 Aryl or C3-C 12 It is heteroaryl. In some embodiments, R3 is -C(=O)OR 1c where R 1c is 1 One or more R 1e optionally substituted with -(C1 to C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Heterocycloalkyl ), -(C1~C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 a Rukill)-(C3~C12 heteroaryl). In some embodiments, R3 is —C(═O)N(R 1c )2. In some embodiments, R3 is —C(═O)N(R 1c )2, where at least Another R 1c is H. In some embodiments, R3 is -C(=O)N(R 1c )2, where at least Together with R 1c is one or more R 1e C1 to C, optionally substituted with 20 Alkyl , C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C 3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroaryl , -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 a Rukill)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl)-(C 3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroary (L). In some embodiments, R3 is -C(=O)N(R 1c )2, where at least Together with R 1c is one or more R 1e C1 to C optionally substituted with 20 Alkyl, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, R3 is -C(=O)N(R 1c )2, where at least Together with R 1c is one or more R 1e C3 to C, optionally substituted with 12 Cycloa Lukil, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 It is heteroaryl. In some embodiments, R3 is -C(=O)N(R 1c )2, where at least Together with R 1c is one or more R 1e optionally substituted with -(C1 to C 20 Al Kill)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C1 2 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl), Or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, R3 is -C(=O)-CH=CH-C(=O)OR 1c in be. In some embodiments, R3 is -C(=O)-CH=CH-C(=O)OH . In some embodiments, R3 is -C(=O)-CH=CH-C(=O)OR 1c in where R 1c is one or more R 1e C1 to C, optionally substituted with 20 Archi Lu, C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 cycloalkyl, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroary Le, -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl)-( C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Hetero ant (ru). In some embodiments, R3 is -C(=O)-CH=CH-C(=O)OR 1c in where R 1c is one or more R 1e C1 to C, optionally substituted with 20 Archi Lu, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, R3 is -C(=O)-CH=CH-C(=O)OR 1c in where R 1c is one or more R 1e C3 to C, optionally substituted with 12 Cyclo Alkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C1 2 heteroaryl. In some embodiments, R3 is -C(=O)-CH=CH-C(=O)OR 1c in where R 1c is one or more R 1e optionally substituted with -(C1 to C 20 a Rukill)-(C3~C 12Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 aryl) , or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, R3 is -C(=O)-CH2-CH2-C(=O)OR1 c is. In some embodiments, R3 is -C(=O)-CH2-CH2-C(=O)OH. be. In some embodiments, R3 is -C(=O)-CH2-CH2-C(=O)OR1 c where R 1c is one or more R 1e C1 to C, optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkane Lu, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroa Reel, -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl) -(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Hetero aryl). In some embodiments, R3 is -C(=O)-CH2-CH2-C(=O)OR1 c where R 1c is one or more R 1e C1 to C, optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, R3 is -C(=O)-CH2-CH2-C(=O)OR1 c where R 1c is one or more R 1e C3 to C, optionally substituted with 12 S Chloroalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3~ C 12 It is heteroaryl. In some embodiments, R3 is -C(=O)-CH2-CH2-C(=O)OR1 c where R 1c is one or more R 1e optionally substituted with -(C1-C2 0 alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3 ~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Ally ru), or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl).

[0046] In some embodiments, R3 is [ka] (for example, [ka] ) In some embodiments, R3 is [ka] (for example, [ka] ) wherein at least one R 1c is H. In some embodiments, R3 is [ka] (for example [ka] ) wherein at least one R 1c is one or more R 1e optionally replaced with , C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C3 ~C 12 Heteroaryl, -(C1-C 20 Alkyl)-(C3~C 12 cycloalkyl ), -(C1~C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C C 20 Alkyl)-(C3~C 12 aryl), or -(C1-C 20 alkyl)-(C 3~C 12 heteroaryl). In some embodiments, R3 is [ka] (for example [ka] ) wherein at least one R 1c is one or more R 1e optionally replaced with C1~C 20 Alkyl, C2-C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, R3 is [ka] (for example [ka] ) wherein at least one R 1c is one or more R 1e optionally replaced with , C3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Ants C3~C 12 It is heteroaryl. In some embodiments, R3 is [ka] (for example [ka] ) wherein at least one R 1c is one or more R 1e optionally replaced with , -(C1~C 20Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 a Rukill)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl)-(C 3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Heteroary (L). In some embodiments, R3 is [ka] (for example, [ka] ) In some embodiments, R3 is [ka] (for example, [ka] ) and R 1c is H. In some embodiments, R3 is [ka] (for example [ka] ) where R 1c is one or more R 1e C1 to C, optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12Cycloalkane Lu, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroa Reel, -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl) -(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Hetero aryl). In some embodiments, R3 is [ka] (for example [ka] ) where R 1c is one or more R 1e C1 to C, optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl.

[0047] In some embodiments, R3 is [ka] (for example [ka] ) where R 1c is one or more R 1e C3 to C, optionally substituted with 12 S Chloroalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3~ C 12 It is heteroaryl. In some embodiments, R3 is [ka] (for example [ka] ) where R 1c is one or more R 1e optionally substituted with -(C1-C2 0 alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3 ~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Ally ru), or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, R3 is [ka] (for example, [ka] ) In some embodiments, R3 is [ka] (for example, [ka] ) and R 1c is H. In some embodiments, R3 is [ka] (for example [ka] ) where R 1c is one or more R 1e C1 to C, optionally substituted with 20 a Rukill, C2~C 20 Alkenyl, C2-C 20 Alkynyl, C3-C 12 Cycloalkane Lu, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 Heteroa Reel, -(C1~C 20 Alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 heterocycloalkyl), -(C1-C 20 alkyl) -(C3~C 12 aryl), or -(C1-C 20 Alkyl)-(C3~C 12 Hetero aryl). In some embodiments, R3 is [ka] (for example [ka] ) where R 1c is one or more R 1e C1 to C, optionally substituted with 20a Rukill, C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, R3 is [ka] (for example [ka] ) where R 1c is one or more R 1e C3 to C, optionally substituted with 12 S Chloroalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3~ C 12 It is heteroaryl. In some embodiments, R3 is [ka] (for example [ka] ) where R 1c is one or more R 1e optionally substituted with -(C1-C2 0 alkyl)-(C3~C 12 Cycloalkyl), -(C1-C 20 Alkyl)-(C3 ~C 12 heterocycloalkyl), -(C1-C 20 Alkyl)-(C3~C 12 Ally ru), or -(C1~C 20 Alkyl)-(C3~C 12 heteroaryl). In some embodiments, R3 is [ka] (for example, [ka] ) In some embodiments, R3 is -C(=O)-CH=CH-C(=O)-R 1z in be. In some embodiments, R3 is -C(=O)-CH=CH-C(=O)-R 1z in where R 1z teeth, [ka] is. In some embodiments, R3 is -C(=O)-CH=CH-C(=O)-R 1z in where R 1z teeth, [ka] is. In some embodiments, R3 is -C(=O)-CH=CH-C(=O)-R 1z in where R 1z teeth, [ka] is. In some embodiments, R3 is -C(=O)-CH=CH-C(=O)-R 1z in where R 1z teeth, [ka] is. In some embodiments, R3 is -C(=O)-CH2-CH2-C(=O)-R1 z is. In some embodiments, R3 is -C(=O)-CH2-CH2-C(=O)-R1 z where R 1z teeth, [ka] is.

[0048] In some embodiments, R3 is -C(=O)-CH2-CH2-C(=O)-R1 z where R 1z teeth, [ka] is. In some embodiments, R3 is -C(=O)-CH2-CH2-C(=O)-R1 z where R 1z teeth, [ka] is. In some embodiments, R3 is -C(=O)-CH2-CH2-C(=O)-R1 z where R 1z teeth, [ka] is. In some embodiments, R3 is [ka] is. In some embodiments, R3 is [ka] and at least one X is -OR 1c , -SR 1c , or -N(R 1c )2 In some embodiments, R3 is [ka] and one of the two Xs is -OR 1c , -SR 1c , or -N(R 1c )2 In some embodiments, R3 is [ka] and each X is independently -OR 1c , -SR 1c , or -N(R 1c )2. In some embodiments, R3 is [ka] and at least one X is -OR 1c is. In some embodiments, R3 is [ka] and one of the two Xs is -OR 1c is. In some embodiments, R3 is [ka] and each X is independently -OR 1c is. In some embodiments, R3 is [ka] and at least one X is -SR 1c is. In some embodiments, R3 is [ka] and one of the two Xs is -SR 1c is. In some embodiments, R3 is [ka] and each X is independently -SR 1c is. In some embodiments, R3 is [ka] and at least one X is -N(R 1c )2. In some embodiments, R3 is [ka] and one of the two Xs is -N(R 1c )2. In some embodiments, R3 is [ka] and each X is independently -N(R 1c )2. In some embodiments, R3 is [ka] is. In some embodiments, R3 is [ka] is. In some embodiments, R3 is [ka] wherein at least one X is [ka] (for example, [ka] ) or [ka] (for example, [ka] )

[0049] In some embodiments, R3 is [ka] and one of the two X's is [ka] (for example, [ka] ) or [ka] (for example, [ka] ) In some embodiments, R3 is [ka] and each X is independently [ka] (for example, [ka] ) or [ka] (for example, [ka] ) In some embodiments, R3 is [ka] and at least one X is [ka] or R 1z is. In some embodiments, R3 is [ka] and one of the two Xs is [ka] or R 1z is. In some embodiments, R3 is [ka] and each X is [ka] or R 1z is. In some embodiments, R3 is [ka] and at least one X is [ka] (for example, [ka] ) In some embodiments, R3 is [ka] and one of the two Xs is [ka] (for example, [ka] ) In some embodiments, R3 is [ka] and each X is [ka] (for example, [ka] )

[0050] In some embodiments, R3 is [ka] and at least one X is [ka] (for example, [ka] ) In some embodiments, R3 is [ka] and one of the two Xs is [ka] (for example, [ka] ) In some embodiments, R3 is [ka] and each X is [ka] (for example, [ka] ) In some embodiments, R3 is [ka] and at least one X is [ka] (for example, [ka] ) or [ka] (for example, [ka] ) In some embodiments, R3 is [ka] and one of the two Xs is [ka] (for example, [ka] ) or [ka] (for example, [ka] ) In some embodiments, R3 is [ka] and each X is [ka] (for example, [ka] ) or [ka] (for example, [ka] )

[0051] In some embodiments, R3 is [ka] and at least one X is R 1z (for example, [ka] (for example, [ka] ) or [ka] ) In some embodiments, R3 is [ka] and one of the two Xs is R 1z (for example, [ka] (for example, [ka] ) or [ka] ) In some embodiments, R3 is [ka] and each X is R 1z (for example, [ka] (for example, [ka] ) or [ka] ) In some embodiments, R3 is [ka] is. In some embodiments, R3 is [ka] and at least one X is -OR 1c , -SR 1c , or -N(R 1c )2 In some embodiments, R3 is [ka] and two of the three Xs are -OR 1c , -SR 1c , or -N(R 1c )2 In some embodiments, R3 is [ka] and each X is independently -OR 1c , -SR 1c , or -N(R 1c )2. In some embodiments, R3 is [ka] and at least one X is -OR 1c is. In some embodiments, R3 is [ka] and two of the three Xs are -OR 1c is. In some embodiments, R3 is [ka] and each X is independently -OR 1c is. In some embodiments, R3 is [ka] and at least one X is -SR 1c is. In some embodiments, R3 is [ka] and two of the three Xs are -SR 1c is.

[0052] In some embodiments, R3 is [ka] and each X is independently -SR 1c is. In some embodiments, R3 is [ka] and at least one X is -N(R 1c )2. In some embodiments, R3 is [ka] and two of the three Xs are -N(R 1c )2. In some embodiments, R3 is [ka] and each X is independently -N(R 1c )2. In some embodiments, [ka] and R3 has at least one X [ka] (for example, [ka] ) or [ka] (for example, [ka] ) In some embodiments, [ka] and R3 is one of the two Xs. [ka] (for example, [ka] ) or [ka] (for example, [ka] ) In some embodiments, R3 is [ka] and each X is independently [ka] (for example, [ka] ) or [ka] (for example, [ka] ) In some embodiments, R3 is [ka] and at least one X is [ka] or R 1z is. In some embodiments, R3 is [ka] and two of the three Xs are [ka] or R 1z is. In some embodiments, R3 is [ka] and each X is [ka] or R 1z is. In some embodiments, R3 is [ka] and at least one X is [ka] (for example, [ka] ) In some embodiments, R3 is [ka] and two of the three Xs are [ka] (for example, [ka] ) In some embodiments, R3 is [ka] and each X is [ka] (for example, [ka] ) In some embodiments, R3 is [ka] and at least one X is [ka] (for example, [ka] ) In some embodiments, R3 is [ka] and two of the three Xs are [ka] (for example, [ka] )

[0053] In some embodiments, R3 is [ka] and each X is [ka] (for example, [ka] ) In some embodiments, R3 is [ka] and at least one X is [ka] (for example, [ka] ) or [ka] (for example, [ka] ) In some embodiments, R3 is [ka] and two of the three Xs are [ka] (for example, [ka] ) or [ka] (for example, [ka] ) In some embodiments, R3 is [ka] and each X is [ka] (for example, [ka] ) or [ka] (for example, [ka] ) In some embodiments, R3 is [ka] and at least one X is R 1z (for example, [ka] (for example, [ka] ) or [ka] ) In some embodiments, R3 is [ka] and two of the three Xs are R 1z (for example, [ka] (for example, [ka] ) or [ka] ) In some embodiments, R3 is [ka] and each X is R 1z (for example, [ka] (for example, [ka] ) or [ka] )

[0054] In some embodiments, R3 is -C(=O)R1b where R 1b is one or multiple R 1e C1 to C optionally substituted with 20 It is alkyl. In some embodiments, R3 is -C(=O)R 1b where R 1b is one or multiple R 1e C1 to C optionally substituted with 20 alkyl and at least one R 1e H, oxo, C1-C 20 Alkyl, -N(R 1f )2, or C3~C 12 Ants wherein C1 to C 20 Alkyl or C3-C 12 Aryl or C3-C 12 Heteroaryl can be one or more R 1f is optionally replaced by In some embodiments, R3 is -C(=O)R 1b where R 1b is one or multiple R 1e C1 to C optionally substituted with 20 alkyl and at least one R 1e H, oxo, C1-C 20 Alkyl, or -N(R 1f )2. In some embodiments, R3 is -C(=O)R 1b where R 1b is one or multiple R 1e C1 to C optionally substituted with 20 alkyl and at least one R 1e is oxo, C1-C 20 Alkyl, or -N(R 1f )2. In some embodiments, R3 is -C(=O)R 1bwhere R 1b is one or multiple R 1e C1 to C optionally substituted with 20 alkyl and at least one R 1e is -N(R 1f )2. In some embodiments, R3 is -C(=O)R 1b where R 1b is one or multiple R 1e C1 to C optionally substituted with 20 alkyl and at least one R 1e -NHR 1f is. In some embodiments, R3 is -C(=O)R 1b where R 1b is plural R 1e C1 to C optionally substituted with 20 alkyl and at least one R 1e teeth, oxo and at least one R 1e is -N(R 1f )2. In some embodiments, R3 is -C(=O)R 1b where R 1b is plural R 1e C1 to C optionally substituted with 20 alkyl and at least one R 1e teeth, oxo and at least one R 1e -NHR 1f is. In some embodiments, R3 is -C(=O)R 1b where R 1b There are two R 1e C1 to C optionally substituted with 20 alkyl and one R 1e is oxo and one R 1e is -N(R1f )2. In some embodiments, R3 is -C(=O)R 1b where R 1b There are two R 1e C1 to C optionally substituted with 20 alkyl and one R 1e is oxo and one R 1e -NHR 1f is. In some embodiments, R3 is -C(=O)R 1b where R 1b There are three More than R 1e C1 to C optionally substituted with 20 alkyl and at least one R 1e is oxo and at least one R 1e is -N(R 1f )2 and at least 1 R 1e is C1~C 20 It is alkyl. In some embodiments, R3 is —C(═O)—(C(R 1e )2) 0-19 -C(R 1e )3. In some embodiments, R3 is —C(═O)—C(R 1e )3. In some embodiments, R3 is -C(=O)-CH2R 1e is. In some embodiments, R3 is —C(═O)—CH(R 1e )2. In some embodiments, R3 is —C(═O)—C(R 1e )2-C(R 1e )3 do. In some embodiments, R3 is -C(=O)-CHR 1e -CH2R 1e is. In some embodiments, R3 is —Si(R1g )3. In some embodiments, R3 is -Si(R 1g ) 3, wherein each R 1g is German Stand up and play C1~C 20 Alkyl or C3-C 12 It is aryl. In some embodiments, R3 is -Si(R 1g ) 3, wherein each R 1g is German In other words, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i- butyl, t-butyl, or phenyl. In some embodiments, R3 is -Si(R 1g ) 3, wherein each R 1g is German Stand up and play C1~C 20 It is alkyl. In some embodiments, R3 is -Si(R 1g ) 3, wherein each R 1g is German In other words, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i- butyl, or t-butyl. In some embodiments, R3 is -Si(R 1g ) 3, wherein each R 1g is German Typically, it is methyl or t-butyl. In some embodiments, R3 is [ka] is. In some embodiments, R3 is [ka] isn't it. In some embodiments, R3 is H, -C(=O)R 1b , and -C(=O)-CH 2-CH2-C(=O)OR 1c is selected from. In some embodiments, R3 is selected from H. In some embodiments, R3 is H, [ka] is selected from. In some embodiments, R3 is [ka] is. In some embodiments, R3 is [ka] is. In some embodiments, R3 is [ka] is. In some embodiments, R3 is [ka] is. In some embodiments, R3 is [ka] is. Variable X In some embodiments, at least one X is -OR 1c is. In some embodiments, at least one X is -SR 1c is. In some embodiments, at least one X is —N(R 1c )2. In some embodiments, at least one X is [ka] is. In some embodiments, at least one X is [ka] is. In some embodiments, at least one X is [ka] is. In some embodiments, at least one X is [ka] is. In some embodiments, at least one X is [ka] is. In some embodiments, at least one X is [ka] is. In some embodiments, at least one X is [ka] is. In some embodiments, at least one X is [ka] is.

[0055] In some embodiments, at least one X is [ka] is. In some embodiments, at least one X is [ka] is. In some embodiments, at least one X is [ka] is. In some embodiments, at least one X is [ka] is. In some embodiments, at least one X is [ka] is. In some embodiments, at least one X is [ka] is. In some embodiments, at least one X is R 1z is. In some embodiments, at least one X is [ka] is. In some embodiments, at least one X is [ka] is. In some embodiments, at least one X is [ka] is. In some embodiments, at least one X is [ka] is. In some embodiments, two X's, together with the intervening atom or atoms to which they are attached, , C5~C 12 Heterocycloalkyl or C5-C 12 forming a heteroaryl, , C5~C 12 Heterocycloalkyl or C5-C 12 Heteroaryl can be one or more R 1a is optionally replaced by In some embodiments, two Xs are bonded to one or more intervening atoms. Along with C5~C 12 Heterocycloalkyl or C5-C 12 Forming heteroaryl . In some embodiments, two Xs are bonded to one or more intervening atoms. together with one or more R 1a C5-C optionally substituted with 12 Heterocycloalkyl Form. In some embodiments, two Xs are bonded to one or more intervening atoms. Along with C5~C 12 Forms a heterocycloalkyl. In some embodiments, two Xs are bonded to one or more intervening atoms. together with one or more R 1a C5-C optionally substituted with 12 Forming a heteroaryl do. In some embodiments, two Xs are bonded to one or more intervening atoms. Along with C5~C 12 Forming a heteroaryl. Variable T In some embodiments, at least one T is a bond. In some embodiments, at least one T is C1 to C 20 It is alkyl. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 It is alkyl. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl, wherein at least one R 1e is H, halogen, C1~C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Alkynyl, -OR 1g , -C(=O)OR 1g , -C(=O)N(R 1g )2, -N(R 1g )2, -N(R1 g )C(=O)R 1f , -N(R 1g )C(=NH)R 1f , -N(R 1g )C(=O) R 1z , -N(R 1g )C(=O)OR 1g , -OC(=O)R 1f , -OC(=O)R 1z , -OC(=O)OR 1g , -SR 1g , -N + (R 1g )3, -SC(=O)R1 f , -SC(=O)R 1z , -SC(=O)OR 1g , -SC(=O)N(R 1g )2, -C(=O)R 1f , -C(=O)R 1z , C3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl, C3-C 12 heteroaryl, or R z wherein C1 to C 20 Alkyl, C2-C 20 Alkenyl, C2-C 20 Archi Nil, C3~C 12 Cycloalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 Heteroaryl can be one or more R 1f or R 1z Any is replaced by In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl, wherein at least one R 1e is H. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl, wherein at least one R 1e is a halogen. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl and at least one R 1e is C1~C 20 Alkyl , C2~C 20 Alkenyl, or C2-C 20 It is alkynyl. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl, wherein at least one R 1e is C1~C 20 Al It's a kill. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl, wherein at least one R 1e is C2~C 20 Al It's a kill. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl, wherein at least one R 1e is C2~C 20 Al It's Kinil. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl and at least one R 1e is C1~C 20 Alkyl , C2~C 20 Alkenyl, C2-C 20 Alkynyl, wherein C1-C 20 Archi Lu, C2~C 20 Alkenyl, C2-C 20 Alkynyl is a group consisting of one or more R 1f or R 1z is optionally replaced by In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl and at least one R 1e is C1~C 20 Alkyl , C2~C 20 Alkenyl, C2-C 20Alkynyl, wherein C1-C 20 Archi Lu, C2~C 20 Alkenyl, C2-C 20 Alkynyl is a group consisting of one or more R 1f Any is replaced by In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl and at least one R 1e is C1~C 20 Alkyl , C2~C 20 Alkenyl, C2-C 20 Alkynyl, wherein C1-C 20 Archi Lu, C2~C 20 Alkenyl, C2-C 20 Alkynyl is a group consisting of one or more R 1z Any is replaced by In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl and at least one R 1e is one or more R 1f or R 1z C1 to C optionally substituted with 20 It is alkyl. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl and at least one R 1e is one or more R 1f C1 to C optionally substituted with 20 It is alkyl. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl and at least one R1e is one or more R 1z C1 to C optionally substituted with 20 It is alkyl. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl, wherein at least one R 1e is C2~C 20 Al It's a kill. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl and at least one R 1e is one or more R 1f or R 1z C2 to C optionally substituted with 20 It is alkenyl. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl and at least one R 1e is one or more R 1f C2 to C optionally substituted with 20 It is alkenyl. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl and at least one R 1e is one or more R 1z C2 to C optionally substituted with 20 It is alkenyl. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl, wherein at least one R 1e is C2~C 20Al It's Kinil. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl and at least one R 1e is one or more R 1f or R 1z C2 to C optionally substituted with 20 It is alkynyl. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl and at least one R 1e is one or more R 1f C2 to C optionally substituted with 20 It is alkynyl. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl and at least one R 1e is one or more R 1z C2 to C optionally substituted with 20 It is alkynyl. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl, wherein at least one R 1e -OR 1g or -C(=O)OR 1g is. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl, wherein at least one R 1e is OH. In some embodiments, at least one T is selected from one or more R1e Optionally replace with C1~C 20 alkyl, wherein at least one R 1e -C(=O)OH is. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl, wherein at least one R 1e is -C(=O)N (R 1g )2, -N(R 1g )2, -N(R 1g )C(=O)R 1f , -N(R 1g )C (=NH)R 1f , -N(R 1g )C(=O)R 1z , or -N(R 1g )C(=O)O R 1g is. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl, wherein at least one R 1e is -OC(=O) R 1f , -OC(=O)R 1z , or -OC(=O)OR 1g is. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl, wherein at least one R 1e -SR 1g ,- N + (R 1g )3, -SC(=O)R 1f , -SC(=O)R 1z , -SC(=O)OR 1g , or -SC(=O)N(R 1g)2. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl, wherein at least one R 1e is -C(=O)R1 f or -C(=O)R 1z is. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl, wherein at least one R 1e is C3~C 12 S Chloroalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3~ C 12 Heteroaryl, wherein C3-C 12 Cycloalkyl, C3-C 12 Hetero Cycloalkyl, C3-C 12 Aryl or C3-C 12 Heteroaryl is one or Multiple R 1f or R 1z is optionally replaced by In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl, wherein at least one R 1e is C3~C 12 S Chloroalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3~ C 12 Heteroaryl, wherein C3-C 12 Cycloalkyl, C3-C 12 Hetero Cycloalkyl, C3-C 12 Aryl or C3-C12 Heteroaryl is one or Multiple R 1f is optionally replaced by

[0056] In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl, wherein at least one R 1e is C3~C 12 S Chloroalkyl, C3-C 12 Heterocycloalkyl, C3-C 12 Aryl or C3~ C 12 Heteroaryl, wherein C3-C 12 Cycloalkyl, C3-C 12 Hetero Cycloalkyl, C3-C 12 Aryl or C3-C 12 Heteroaryl is one or Multiple R 1f is optionally replaced by In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl and at least one R 1e is C3~C 12 Cycloa Lukil, C3~C 12 Heterocycloalkyl, C3-C 12 Aryl or C3-C 12 It is heteroaryl. In some embodiments, at least one T is selected from one or more R 1e Optionally replace with C1~C 20 alkyl, wherein at least one R 1e is R 1z is. In some embodiments, T is one or more R 1e C1~C2 replaced by 0 alkyl. In some embodiments, T is [ka] is. Example of the relationship between variables R1, R2, and R3 In some embodiments, one of R1, R2, and R3 is one or more [ka] In some embodiments, R1 is one or more [ka] [ka] In some embodiments, R1 is one or more [ka] [ka] In some embodiments, R1 is one or more [ka] [ka] In some embodiments, two of R1, R2, and R3 are one or more [ka] In some embodiments, R1 and R2 each represent one or more [ka] [ka] In some embodiments, R1 and R3 each represent one or more [ka] [ka] In some embodiments, R2 and R3 each represent one or more [ka] [ka] In some embodiments, all of R, R, and R are one or more [ka] In some embodiments, one of R and R is one or more [ka] In some embodiments, R1 is one or more [ka] [ka] In some embodiments, R2 is one or more [ka] [ka] In some embodiments, R1 and R2 each represent one or more [ka] In some embodiments, one of R and R is one or more [ka] In some embodiments, R1 is one or more [ka] [ka] In some embodiments, R3 is one or more [ka] [ka] In some embodiments, R1 and R3 each represent one or more [ka] In some embodiments, one of R2 and R3 is one or more [ka] In some embodiments, R2 is one or more [ka] [ka]

[0057] In some embodiments, R3 is one or more [ka] [ka] In some embodiments, R2 and R3 each represent one or more [ka] In some embodiments, at least one of R2 and R3 is -C(=O)R 1b ,- C(=O)OR 1c , -C(=O)N(R 1c )2, -C(=O)R 1z , -C(=O) -CH=CH-C(=O)OR 1c , -C(=O)-CH2-CH2-C(=O)OR1 c , [ka] -C(=O)-CH=CH-C(=O)-R 1z , -C(=O)-CH2-CH2-C( =O)-R 1z , or [ka] is. In some embodiments, at least one of R2 and R3 is -C(=O)R 1b ,- C(=O)OR 1c , -C(=O)N(R 1c )2, -C(=O)R 1z , -C(=O) -CH=CH-C(=O)OR 1c , -C(=O)-CH2-CH2-C(=O)OR1 c , or [ka] is. In some embodiments, at least one of R2 and R3 is -C(=O)R1 b is. In some embodiments, at least one of R2 and R3 is -C(=O)OR 1c is. In some embodiments, at least one of R2 and R3 is —C(═O)N(R 1c )2. In some embodiments, at least one of R2 and R3 is -C(=O)R z is. In some embodiments, at least one of R2 and R3 is -C(=O)-CH=C HC(=O)OR 1c is. In some embodiments, at least one of R2 and R3 is -C(=O)-CH2- CH2-C(=O)OR 1c is. In some embodiments, at least one of R2 and R3 is [ka] is. In some embodiments, at least one of R2 and R3 is -C(=O)-CH=C HC(=O)-R 1z or -C(=O)-CH2-CH2-C(=O)-R 1z is . In some embodiments, at least one of R2 and R3 is -C(=O)-CH=C HC(=O)-R 1z is. In some embodiments, at least one of R2 and R3 is -C(=O)-CH2- CH2-C(=O)-R 1z is. In some embodiments, at least one of R2 and R3 is [ka] is. In some embodiments, one of R2 and R3 is -C(=O)R 1b , -C(=O) OR 1c , -C(=O)N(R 1c )2, -C(=O)R 1z , -C(=O)-CH=C HC(=O)OR 1c , -C(=O)-CH2-CH2-C(=O)OR 1c , [ka] -C(=O)-CH=CH-C(=O)-R 1z , -C(=O)-CH2-CH2-C( =O)-R 1z , or [ka] is. In some embodiments, one of R2 and R3 is -C(=O)R 1b , -C(=O) OR 1c , -C(=O)N(R 1c )2, -C(=O)R 1z , -C(=O)-CH=C HC(=O)OR 1c , -C(=O)-CH2-CH2-C(=O)OR 1c , or [ka] is. In some embodiments, one of R2 and R3 is -C(=O)R 1b is. In some embodiments, one of R2 and R3 is -C(=O)OR 1c is. In some embodiments, one of R2 and R3 is —C(═O)N(R 1c )2 is. In some embodiments, one of R2 and R3 is -C(=O)R 1z is. In some embodiments, one of R2 and R3 is -C(=O)-CH=CH- C(=O)OR 1c is. In some embodiments, one of R2 and R3 is -C(=O)-CH2-CH 2-C(=O)OR 1c is. In some embodiments, one of R2 and R3 is [ka] is. In some embodiments, one of R2 and R3 is -C(=O)-CH=CH-C(= O)-R 1z or -C(=O)-CH2-CH2-C(=O)-R 1z is. In some embodiments, one of R2 and R3 is -C(=O)-CH=CH- C(=O)-R 1z is. In some embodiments, one of R2 and R3 is -C(=O)-CH2-CH 2-C(=O)-R 1z is. In some embodiments, one of R2 and R3 is [ka] is. In some embodiments, each of R2 and R3 is -C(=O)R 1b , -C(= O)OR 1c , -C(=O)N(R 1c )2, -C(=O)R 1z , -C(=O)-CH =CH-C(=O)OR 1c , -C(=O)-CH2-CH2-C(=O)OR 1c , [ka] -C(=O)-CH=CH-C(=O)-R 1z , -C(=O)-CH2-CH2-C( =O)-R 1z , or [ka] is. In some embodiments, each of R2 and R3 is -C(=O)R 1b , -C(= O)OR 1c , -C(=O)N(R 1c )2, -C(=O)R 1z , -C(=O)-CH =CH-C(=O)OR 1c , -C(=O)-CH2-CH2-C(=O)OR 1c ,also teeth [ka] is. In some embodiments, each of R2 and R3 is -C(=O)R 1b is. In some embodiments, each of R2 and R3 is -C(=O)OR 1c is. In some embodiments, each of R2 and R3 is -C(=O)N(R 1c )2 be. In some embodiments, each of R2 and R3 is -C(=O)R 1z is. In some embodiments, each of R2 and R3 is -C(=O)-CH=CH-C (=O)OR 1c is. In some embodiments, each of R2 and R3 is -C(=O)-CH2-CH2 -C(=O)OR 1c is. In some embodiments, each of R2 and R3 is [ka] is. In some embodiments, each of R2 and R3 is -C(=O)-CH=CH-C (=O)-R 1z or -C(=O)-CH2-CH2-C(=O)-R 1z is. In some embodiments, each of R2 and R3 is -C(=O)-CH=CH-C (=O)-R 1z is. In some embodiments, each of R2 and R3 is -C(=O)-CH2-CH2 -C(=O)-R 1z is. In some embodiments, each of R2 and R3 is [ka] is. In some embodiments, R1 is -SR 1d Instead, R2 is [ka] isn't it. In some embodiments, R1 is -SR 1d Instead, R3 is [ka] isn't it.

[0058] In some embodiments, R2 is [ka] Instead, R3 is [ka] isn't it. In some embodiments, R1 is -SR 1d Instead, R2 is [ka] Instead, R3 is [ka] isn't it. Exemplary Formulas and Compounds In some embodiments, R is H, C 20 Alkyl, C2-C 20 Arkeny -C(=O)-(C1~C 20 alkyl), -C(=O)-(C2-C 20 Arkeny -C(=O)R 1c , -C(=O)R 1z , -C(=O)CH2-[CH(OR1 c )-CH2] p -[CH2] q -R 1a , -C(=O)CH2-[C(=O)CH2] p -[CH(OR 1c )-CH2] r -[CH2] q -R 1a , -C(=O)-CH=C HC(=O)OR1c , -C(=O)-[CH2] q -C(=O)OR 1c , -C(= O)-[CH2] q -C(=O)R 1a , [ka] and R2 is selected from H, —C(═O)R 1b , -C(=O)R 1z , -C(=O)- CH2-CH2-C(=O)OR 1c , and [ka] and R3 is selected from H, —C(═O)R 1b , and -C(=O)-CH2-CH2- C(=O)OR 1c is selected from. In some embodiments, R1 is C1-C 20 Alkyl, -C(=O)-(C1-C 20 alkyl), -C(=O)-(C2-C 20 alkenyl), and -C(=O)-[C H2] q -C(=O)R 1a and R2 is selected from H and —C(═O)R 1b Selected from and R3 is selected from H. In some embodiments, R1 is H, -CH3, [ka] and R2 is selected from [ka] and R3 is selected from [ka] is selected from. In some embodiments, R1 is [ka] R2 is selected from H and [ka] and R3 is selected from H. In some embodiments, the compound has formula (I-1) or (I-2): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has the formula (I-1): or a solvate. In some embodiments, the compound has the formula (I-2): or a solvate. In some embodiments, the compound has formula (Iaa), (Iab), (Iac), or (Ib). Iad) [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has the formula (Iaa): or a solvate. In some embodiments, the compound has the formula (Iab): or a solvate. In some embodiments, the compound has the formula (Iac): or a solvate. In some embodiments, the compound has the formula (Iad): or a solvate. In some embodiments, the compound has the formula (Iaa-1), (Iaa-2), (Iab- 1), (Iab-2), (Iac-1), (Iac-2), (Iad-1), or (Ia d-2) [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has formula (Iaa-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Iaa-2): It is a salt or solvate thereof. In some embodiments, the compound has formula (Iab-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Iab-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Iac-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Iac-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Iad-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Iad-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Iae), (Iaf), (Iag), or (Ib). Iah) [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has the formula (Iae): or a solvate. In some embodiments, the compound has the formula (Iaf): or a solvate. In some embodiments, the compound has the formula (Iag): or a solvate. In some embodiments, the compound has the formula (Iah): or a solvate. In some embodiments, the compound has the formula (Iae-1), (Iae-2), (Iaf- 1), (Iaf-2), (Iag-1), (Iag-2), (Iah-1), or (Ia h-2) [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has formula (Iae-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Iae-2): It is a salt or solvate thereof. In some embodiments, the compound has formula (Iaf-1): It is a salt or solvate thereof. In some embodiments, the compound has formula (Iaf-2): It is a salt or solvate thereof.

[0059] In some embodiments, the compound has formula (Iag-1): It is a salt or solvate thereof. In some embodiments, the compound has formula (Iag-2): It is a salt or solvate thereof. In some embodiments, the compound has formula (Iah-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Iah-2): It is a salt or solvate thereof. In some embodiments, the compound has the formula (Iai) or (Iaj) [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has the formula (Iai): or a solvate. In some embodiments, the compound has the formula (Iaj): or a solvate. In some embodiments, the compound has the formula (Iak): or a solvate. In some embodiments, the compound has the formula (Ial): or a solvate. In some embodiments, the compound has the formula (Iam): or a solvate. In some embodiments, the compound has the formula (Ian): or a solvate. In some embodiments, the compound has the formula (Iai-1), (Iai-2), (Iaj- 1), (Iaj-2), (Iak-1), (Iak-2), (Ial-1), (Ial- 2), (Iam-1), (Iam-2), (Ian-1), or (Ian-2) [ka] [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has formula (Iai-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Iai-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Iaj-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Iaj-2): It is a salt or solvate thereof. In some embodiments, the compound has the formula (Iak-1): It is a salt or solvate thereof. In some embodiments, the compound has the formula (Iak-2): It is a salt or solvate thereof. In some embodiments, the compound has formula (Ial-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Ial-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Iam-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Iam-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Ian-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Ian-2): It is a salt or solvate thereof. In some embodiments, the compound has the formula (Iba): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has the formula (Iba): or a solvate. In some embodiments, the compound has the formula (Iba-1) or (Iba-2): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has formula (Iba-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Iba-2): It is a salt or solvate thereof. In some embodiments, the compound has formula (Ibb), (Ibc), (Ibd), or (Ibb). Ibe) [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has the formula (Ibb): or a solvate. In some embodiments, the compound has the formula (Ibc): or a solvate. In some embodiments, the compound has the formula (Ibd): or a solvate. In some embodiments, the compound has the formula (Ibe): or a solvate. In some embodiments, the compound has the formula (Ibb-1), (Ibb-2), (Ibc- 1), (Ibc-2), (Ibd-1), (Ibd-2), (Ibe-1) or (Ibe -2) [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has formula (Ibb-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Ibb-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Ibc-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Ibc-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Ibd-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Ibd-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Ibe-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Ibe-2): It is a salt or solvate thereof. In some embodiments, the compound has formula (Ibf), (Ibg), (Ibh), or (Ibf). Ibi) [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0060] In some embodiments, the compound has the formula (Ibf): or a solvate. In some embodiments, the compound has the formula (Ibg): or a solvate. In some embodiments, the compound has the formula (Ibh): or a solvate. In some embodiments, the compound has the formula (Ibi): or a solvate. In some embodiments, the compound has the formula (Ibf-1), (Ibf-2), (Ibg- 1), (Ibg-2), (Ibh-1), (Ibh-2), (Ibi-1), (Ibi- 2), [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has formula (Ibf-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Ibf-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Ibg-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Ibg-2): It is a salt or solvate thereof. In some embodiments, the compound has the formula (Ibh-1): It is a salt or solvate thereof. In some embodiments, the compound has the formula (Ibh-2): It is a salt or solvate thereof. In some embodiments, the compound has formula (Ibi-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Ibi-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has the formula (Ibj): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has the formula (Ibj): or a solvate. In some embodiments, the compound has the formula (Ibj-1) or (Ibj-2): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has formula (Ibj-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Ibj-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has the formula (Ibk): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has the formula (Ibk): or a solvate. In some embodiments, the compound has the formula (Ibk-1) or (Ibk-2): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has formula (Ibk-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Ibk-2): It is a salt or solvate thereof. In some embodiments, the compound has the formula (Ibl): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has the formula (Ibl): or a solvate. In some embodiments, the compound has the formula (Ibl-1) or (Ibl-2): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has the formula (Ibl-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has the formula (Ibl-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has the formula (Ica): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has the formula (Ica-1) or (Ica-2) [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has the formula (Ica-1): It is a salt or solvate thereof. In some embodiments, the compound has the formula (Ica-2): It is a salt or solvate thereof. In some embodiments, the compound has formula (Icb), (Icc), (Icd), or ( Ice): [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0061] In some embodiments, the compound has the formula (Icb): or a solvate. In some embodiments, the compound has the formula (Icc): or a solvate. In some embodiments, the compound has the formula (Icd): or a solvate. In some embodiments, the compound has the formula (Ice): or a solvate. In some embodiments, the compound has the formula (Icb-1), (Icb-2), (Icc- 1), (Icc-2), (Icd-1), (Icd-2), (Ice-1) or (Ice -2) [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has formula (Icb-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Icb-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Icc-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Icc-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Icd-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Icd-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has the formula (Ice-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has the formula (Ice-2): It is a salt or solvate thereof. In some embodiments, the compound has formula (Icf), (Icg), (Ich), or ( Ici) [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has the formula (Icf): or a solvate. In some embodiments, the compound has the formula (Icg): or a solvate. In some embodiments, the compound has the formula (Ich): or a solvate. In some embodiments, the compound has the formula (Ici): or a solvate. In some embodiments, the compound has the formula (Icf-1), (Icf-2), (Icg- 1), (Icg-2), (Ich-1), (Ich-2), (Ici-1) or (Ici -2) [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has formula (Icf-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Icf-2): It is a salt or solvate thereof. In some embodiments, the compound has the formula (Icg-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has the formula (Icg-2): It is a salt or solvate thereof. In some embodiments, the compound has the formula (Ich-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has the formula (Ich-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Ici-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Ici-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has the formula (Icj): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has the formula (Icj): or a solvate. In some embodiments, the compound has the formula (Icj-1) or (Icj-2): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has formula (Icj-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (Icj-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has the formula (Ick): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has the formula (Ick): or a solvate. In some embodiments, the compound has the formula (Ick-1) or (Ick-2) [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has the formula (Ick-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has the formula (Ick-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has the formula (Icl): [ka] or a pharmaceutically acceptable salt or solvate thereof.

[0062] In some embodiments, the compound has the formula (Icl): or a solvate. In some embodiments, the compound has the formula (Icl-1) or (Icl-2) [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has formula (Icl-1) or a pharmaceutically acceptable salt thereof. It is a salt or solvate thereof. In some embodiments, the compound has formula (Icl-2): It is a salt or solvate thereof. In some embodiments, the compound has formula (II-1) or (II-2): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has formula (II-1) or a pharmaceutically acceptable salt thereof: It is a salt or a solvate. In some embodiments, the compound has formula (II-2) or a pharmaceutically acceptable salt thereof: It is a salt or a solvate. In some embodiments, the compound has formula (IIa): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has the formula (IIa): or a solvate. In some embodiments, the compound has formula (IIa-1) or (IIa-2): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has formula (IIa-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (IIa-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (IIb): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has the formula (IIb): or a solvate. In some embodiments, the compound has formula (IIb-1) or (IIb-2): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has formula (IIb-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (IIb-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (II'-1) or (II'-2): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has formula (II'-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (II'-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (II'a): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has formula (II'-a) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (II'a-1) or (II'a-2): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has formula (II'a-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (II'a-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (II'b): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has formula (II'b) or a pharmaceutically acceptable salt thereof: It is a salt or a solvate. In some embodiments, the compound has formula (II'b-1) or (II'b-2): [ka] or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound has formula (II'b-1) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. In some embodiments, the compound has formula (II'b-2) or a pharmaceutically acceptable salt thereof: It is a salt or solvate thereof. For any one compound of the formula disclosed herein, R, R 1a , R 1b , R1 c , R 1d , R 1e , R 1f , R 1g , R 1z , R2, R3, X, n, p, q, and r are , where applicable, selected from the groups described herein, and R, R 1a , R 1b , R1 c , R 1d , R 1e , R 1f , R 1g , R 1z , R2, R3, X, n, p, q, and r Any group described herein for either R, R, 1a , R 1b , R1c , R 1d , R 1e , R 1f , R 1g , R 1z , R2, R3, X, n, p, q, and and the remainder of r may be combined with one or more of any groups described herein. do.

[0063] In some embodiments, the compounds are those listed in Table 1 and their pharmaceutically acceptable salts. salts. In some embodiments, the compound is selected from the compounds set forth in Table 1. In some embodiments, the compounds include compounds Nos. 1-58 and their pharmaceutically acceptable salts. salts. In some embodiments, the compound is selected from Compound Nos. 1-58. In some embodiments, the compounds include Compound Nos. 59-115 and their pharmaceutically acceptable derivatives. The salt is selected from the group consisting of: In some embodiments, the compound is selected from Compound Nos. 59-115. In some embodiments, the compounds include compounds Nos. 116-188 and their pharmaceutically acceptable salts. The salt is selected from the group consisting of: In some embodiments, the compound is selected from Compound Nos. 116-188. In some embodiments, the compound is selected from the group consisting of Compound Nos. 189-296 and their pharmaceutically acceptable salts. The salt is selected from the group consisting of: In some embodiments, the compound is selected from Compound Nos. 189-296. In some embodiments, the compound is selected from the group consisting of Compound Nos. 297-369 and their pharmaceutically acceptable salts. The salt is selected from the group consisting of: In some embodiments, the compound is selected from Compound Nos. 297-369. In some embodiments, the compounds include compounds Nos. 370-495 and their pharmaceutically acceptable salts. The salt is selected from the group consisting of: In some embodiments, the compound is selected from Compound Nos. 370-495. In some embodiments, the compound is Compound Nos. 420-430 and its pharmaceutically acceptable salts. The salt is selected from the group consisting of: In some embodiments, the compound is selected from Compound Nos. 420-430. In some embodiments, the compound is Compound No. 420 or a pharmaceutically acceptable salt thereof. is. In some embodiments, the compound is Compound No. 420. In some embodiments, the compound is Compound No. 421 or a pharmaceutically acceptable salt thereof. is. In some embodiments, the compound is Compound No. 421. In some embodiments, the compound is Compound No. 422 or a pharmaceutically acceptable salt thereof. is. In some embodiments, the compound is Compound No. 422. In some embodiments, the compound is Compound No. 423 or a pharmaceutically acceptable salt thereof. is. In some embodiments, the compound is Compound No. 423. In some embodiments, the compound is Compound No. 424 or a pharmaceutically acceptable salt thereof. is. In some embodiments, the compound is Compound No. 424. In some embodiments, the compound is Compound No. 425 or a pharmaceutically acceptable salt thereof. is. In some embodiments, the compound is Compound No. 425. In some embodiments, the compound is Compound No. 426 or a pharmaceutically acceptable salt thereof. is. In some embodiments, the compound is Compound No. 426. In some embodiments, the compound is Compound No. 427 or a pharmaceutically acceptable salt thereof. is. In some embodiments, the compound is Compound No. 427. In some embodiments, the compound is Compound No. 428 or a pharmaceutically acceptable salt thereof. is. In some embodiments, the compound is Compound No. 428. In some embodiments, the compound is Compound No. 429 or a pharmaceutically acceptable salt thereof. is. In some embodiments, the compound is Compound No. 429. In some embodiments, the compound is Compound No. 430 or a pharmaceutically acceptable salt thereof. is. In some embodiments, the compound is Compound No. 430. In some embodiments, the compound is selected from the group consisting of Compound Nos. 496-579 and their pharmaceutically acceptable salts. The salt is selected from the group consisting of: In some embodiments, the compound is selected from Compound Nos. 496-579. In some embodiments, the compound is selected from the group consisting of Compound Nos. 580-699 and their pharmaceutically acceptable salts. The salt is selected from the group consisting of: In some embodiments, the compound is selected from Compound Nos. 580-699. In some embodiments, the compounds include compounds Nos. 700-879 and their pharmaceutically acceptable salts. The salt is selected from the group consisting of: In some embodiments, the compound is selected from Compound Nos. 700-879. In some embodiments, the compounds include Compound Nos. 880-967 and their pharmaceutically acceptable salts. The salt is selected from the group consisting of: In some embodiments, the compound is selected from Compound Nos. 880-967. In some embodiments, the compounds include Compound Nos. 968-1009 and their pharmaceutically acceptable salts. The salt is selected from among the salts that are acceptable for the treatment of rhodium. In some embodiments, the compound is selected from compound numbers 968-1009. In some embodiments, the compounds are compounds Nos. 1010-1141 and their pharmaceutically acceptable salts. It is selected from acceptable salts. In some embodiments, the compound is selected from compound numbers 1010-1141. In some embodiments, the compound is Compound No. 1142 and its pharmaceutically acceptable derivatives. It's salt. In some embodiments, the compound is Compound No. 1142. In some embodiments, the compounds are compounds Nos. 1143-1162 and their pharmaceutically acceptable salts. It is selected from acceptable salts. In some embodiments, the compound is selected from compound numbers 1143-1162. In some embodiments, the compounds are compounds Nos. 1163-1209 and their pharmaceutically acceptable salts. It is selected from acceptable salts. In some embodiments, the compound is selected from compound numbers 1163-1209. In some embodiments, the compounds are Compound Nos. 1210-1215 and their pharmaceutically acceptable salts. It is selected from acceptable salts. In some embodiments, the compound is selected from compound numbers 1210-1215. In some embodiments, the compound is selected from compound numbers 1222-1280. In some embodiments, the compound is selected from compound numbers 1282-1323. In some embodiments, the compound is Compound No. 1, 2, 4, 20, 25, 35, 36 , 37, 38, 39, 42, 46, 51, 57, 60, 63, 73, 82, 86, 116 , 138, 140, 145, 157, 183, 185, 214, 372, 382, ​​383 , 385, 390, 393, 397, 399, 400, 401, 405, 410, 411 , 412, 414, 415, 460, 500, 502, 560, 1227, 1228, 1 229, 1230, 1231, 1232, 1233, 1239, 1240, 1242, 1 245, 1246, 1247, 1248, 1249, 1250, 1252, 1264, 1 285, 1292, 1294, 1296, 1298, 1304, 1306, 1307, 1 309, 1310, and 1311. In some embodiments, the compound is Compound Nos. 2, 20, 145, 410, 500, and 1306.

[0064] [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] Table 1-11 Table 1-12 Table 1-13 Table 1-14 Table 1-15 Table 1-16 Table 1-17 Table 1-18 Table 1-19 Table 1-20 Table 1-21 Table 1-22 Table 1-23 Table 1-24 Table 1-25 Table 1-26 Table 1-27 Table 1-28 Table 1-29 Table 1-30 Table 1-31 Table 1-32 Table 1-33 Table 1-34 Table 1-35 Table 1-36 Table 1-37 Table 1-38 Table 1-39 Table 1-40 Table 1-41 Table 1-42 Table 1-43 Table 1-44 Table 1-45 Table 1-46 Table 1-47 Table 1-48 Table 1-49 Table 1-50 Table 1-51 Table 1-52 Table 1-53 Table 1-54 Table 1-55 Table 1-56 Table 1-57 Table 1-58 Table 1-59 Table 1-60 Table 1-61 Table 1-62 Table 1-63 Table 1-64 Table 1-65 Table 1-66

Table 1-67

Claims

1. A compound of formula (I) or (II'), 【Chemical 1】 or a pharmaceutically acceptable salt or solvate thereof, R １ is H, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl , -C(=O)-(C １ ~C ２０ alkyl), -C(=O)-(C ２ ~C ２０ Alkenyl ), -C(=O)-(C ２ ~C ２０ alkynyl), —C(═O)R １ｂ , -C(=O)R １ｃ 、-C(=O)R １ｚ 、-C(=O)-(CH=CH) ｎ -R １ａ 、-C(=O)C H ２ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -R １ａ 、-C(=O)CH ２ -[CH( OR １ｃ )-CH ２ ] ｐ -[CH ２ ] ｑ -R １ａ 、-C(=O)CH ２ -[C(=O)C H ２ ] ｐ -[CH(OR １ｃ )-CH ２ ] ｒ -[CH ２ ] ｑ -R １ａ 、-C(=O)-C H(C(=O)R １ｂ )-[C(=O)CH ２ ] ｐ -[CH(OR １ｃ )-CH ２ ] ｒ - [CH ２ ] ｑ -R １ａ 、-C(=O)CH ２ -[CH(OR １ｃ )-CH ２ ] ｒ -[C( =O)CH ２ ] ｐ -[CH ２ ] ｑ -R １ａ 、-C(=O)OR １ｃ 、-C(=O)N(R １ｃ ) ２ 、-C(=O)-CH=CH-C(=O)OR １ｃ 、-C(=O)-[CH ２ ] ｑ -C(=O)OR １ｃ 、-C(=O)-CH ２ CH ２ -C(=O)OR １ｃ 、-C(= O)CH ２ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -C(=O)OR １ｃ 、-C(=O )-[CH ２ ] ｑ -C(=O)R １ａ 、-C(=O)-[CH ２ ] ｑ -C(=O)R １ｚ 、-[C(=O)CH ２ ] ｑ -C(=O)R １ｚ 、-C(=O)-CH ２ CH ２ -C(= O)R １ｚ 、-C(=O)-CH=CH-[C(=O)] ｐ R １ｚ 、-C(=O)CH ２ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -C(=O)R １ｚ 、-SR １ｄ 、 【Chemistry 2】 wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl or C ２ ~C ２０ Archi Nil is one or more R １ａ optionally substituted with C １ ~C ２０ Alkyl, C ２ ~C ２０ a alkenyl, or C ２ ~C ２０ One or more methylene moieties of alkynyl may be one or more optionally substituted with a carbonyl moiety, Each R １ａ are independently H, oxo, halogen, C １ ~C ２０ Alkyl, C ２ ~C ２０ a ルケニル、-OR １ｃ 、-C(=O)OR １ｃ 、-C(=O)N(R １ｃ ) ２ 、-N(R １ｃ ) ２ 、-N(R １ｃ )C(=O)R １ｂ 、-N(R １ｃ )C(=O)R １ｚ 、-N( R １ｃ )C(=O)OR １ｃ 、-OC(=O)R １ｂ 、-OC(=O)R １ｚ 、-OC( =O)OR １ｃ 、-OSi(R １ｇ ) ３ 、-SC(=O)R １ｂ 、-SC(=O)R １ｚ 、-SC(=O)OR １ｃ 、-SC(=O)N(R １ｃ ) ２ 、-C(=O)R １ｂ 、-C (=O)R １ｚ , -SR １ｄ , or R １ｚ wherein C １ ~C ２０ Alkyl, C ２ ~ C ２０ Alkenyl, or C ２ ~C ２０ Alkynyl is one or more R １ｅ optionally replaced by R, Each R １ｂ are independently H, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２ ０ Alkynyl, -(CH ２ ) ｑ -C(=O)OR １ｃ , -(CH ２ ) ｑ -C(=O)R １ ｃ 、-CH ２ -C(=O)-(CH ２ ) ｑ -C(=O)OR １ｃ 、-CH ２ -[C(=O )CH ２ ] ｐ -[CH ２ ] ｑ -C(=O)OR １ｃ 、-CH=CH-C(=O)OR １ｃ 、－Ｃ（ R １ｅ )=C(R １ｅ )-C(=O)OR １ｃ、－Ｃ（ =O)OR １ｃ 、-C( =O)N(R １ｃ ) ２ , or R １ｚ wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, or C ２ ~C ２０ Alkynyl is one or more R １ｅ optionally replaced by Each R １ｃ are independently H, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~ C ２０ Alkynyl, C ３ ~C １２ Cycloalkyl, C ３ ~C １２ heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ Heteroaryl, -(C １ ~C ２０ alkyl)-( C ３ ~C １２ cycloalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Heterogeneity chloroalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １２ aryl), or -(C １ ~C ２０ alkyl)-(C ３ ~C １２ heteroaryl, wherein C １ ~C ２０ Al Kill, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, C ３ ~C １２ cycloalkyl , C ３ ~C １２ Heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ Hetero ant Rule, -(C １ ~C ２０ alkyl)-(C ３ ~ C １２ cycloalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １２ heterocycloalkyl), -(C １ ~C ２０ alkyl) -(C ３ ~C １２ aryl), or -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Hetero aryl) may be one or more R １ｅ or two R １ｃ But those together with one or more intervening atoms to which ３ ~C １２ Cycloalkyl or C ３ ~ C １２ forming a heterocycloalkyl, wherein C ３ ~C １２ Cycloalkyl or C ３ ~C １２ Heterocycloalkyl is one or more R １ｅ optionally replaced by Each R １ｄ are independently H, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２ ０ Alkynyl, C ３ ~C １０ Cycloalkyl, C ３ ~C １２ Cycloalkyl, C ３ ~C １ ２ Heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ Heteroaryl, -(C １ -C ２０ alkyl)-(C ３ ~C １２ cycloalkyl), -(C １ ~C ２０ alkyl) -(C ３ ~C １２ heterocycloalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １ ２ aryl), or -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Heteroaryl In the formula, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, C ３ ~C １２ Cycloalkyl, C ３ ~C １２ Heterocycloalkyl, C ３ ~C １２ Ally Lu, C ３ ~C １２ Heteroaryl, -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Cyclo alkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １２ heterocycloalkyl), - (C １ ~C ２０ alkyl)-(C ３ ~C １２ aryl), or -(C １ ~C ２０ Alkyl )-(C ３ ~C １２ heteroaryl) is one or more R １ｅ optionally replaced by Each R １ｅ are independently H, halogen, C １ ~C ２０ Alkyl, C ２ ~C ２０ alkenyl, C ２ ~C ２０ Alkynyl, -OR １ｇ , -C(=O)OR １ｇ , -C(=O)N(R １ｇ ) ２ 、-N(R １ｆ ) ２、－Ｎ（ R １ｇ ) ２ 、-N(R １ｇ )C(=O)R １ｆ 、-N( R １ｇ )C(=NH)R １ｆ 、-N(R １ｇ )C(=O)R １ｚ 、-N(R １ｇ )C(= O)OR １ｇ 、-OC(=O)R １ｆ 、-OC(=O)R １ｚ 、-OC(=O)OR １ｇ 、-OSi(R １ｇ ) ３ 、-SR １ｇ 、-N ＋ (R １ｇ ) ３ 、-SC(=O)R １ｆ 、- SC(=O)R １ｚ 、-SC(=O)OR １ｇ 、-SC(=O)N(R １ｇ ) ２ 、-C( =O)R １ｆ , -C(=O)R １ｚ , C ３ ~C １２ Cycloalkyl, C ３ ~C １２ Hetero Cycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ heteroaryl, or R １ｚ Yes In the formula, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, C ３ ~C １２ Cycloalkyl, C ３ ~C １２ Heterocycloalkyl, C ３ ~C １２ Ally Lu or C ３ ~C １２ Heteroaryl is one or more R １ｆ or R １ｚ Optionally replace with And Each R １ｆ are independently H, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２ ０ Alkynyl, —OSi(R １ｇ ) ３ , -OR １ｇ , -CH ２ C(=O)OR １ｇ , -C H=CH-C(=O)OR １ｇ、－Ｃ（ =O)OR １ｇ 、-C(=O)N(R １ｇ ) ２ 、 -N(R １ｇ ) ２ , or R １ｚ wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ Al kenyl, or C ２ ~C ２０ Alkynyl is one or more R １ｚ optionally replaced by Each R １ｇ are independently H, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~ C ２０ Alkynyl, C ３ ~C １２ Cycloalkyl, C ３ ~C １２ heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ Heteroaryl, -(C １ ~C ２０ alkyl)-( C ３ ~C １２ cycloalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Heterogeneity chloroalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １２ aryl), or -(C １ ~C ２０ alkyl)-(C ３ ~C １２ heteroaryl, wherein C １ ~C ２０ Al Kill, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, C ３ ~C １２ cycloalkyl , C ３ ~C １２ Heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ Hetero ant Rule, -(C １ ~C ２０ alkyl)-(C ３ ~C １２ cycloalkyl), -(C １ ~C ２ ０ alkyl)-(C ３ ~C １２ heterocycloalkyl), -(C １ ~C ２０ alkyl)- (C ３ ~C １２ aryl), or -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Heteroa reel) is one or more R １ｚ optionally replaced by Each R １ｚ is independent 【Chemistry 3】 and each n is independently an integer ranging from 0 to 20; each p is independently an integer ranging from 0 to 20; each q is independently an integer ranging from 0 to 20; each r is independently an integer ranging from 0 to 20; R ２ and R ３ are independently H, —C(═O)R １ｂ , -C(=O)OR １ｃ , -C(=O) N(R １ｃ ) ２ 、-C(=O)R １ｚ 、-C(=O)-CH=CH-C(=O)OR １ｃ 、－Ｃ（ =O)-CH ２ -CH ２ -C(=O)OR １ｃ 、 【Chemistry 4】 -C(=O)-CH=CH-C(=O)-R １ｚ 、-C(=O)-CH ２ -CH ２ -C( =O)-R １ｚ ,-Si(R １ｇ ) ３ 、 【Chemistry 5】 and Each X is independently -OR １ｃ , -SR １ｃ , -N(R １ｃ ) ２ , 【Chemistry 6】 or R １ｚ and or two Xs, together with one or more intervening atoms to which they are attached, form C ５ ~C １ ２ Heterocycloalkyl or C ５ ~C １２ forming a heteroaryl, wherein C ５ ~C １２ Heterocycloalkyl or C ５ ~C １２ Heteroaryl may optionally be one or more R １ａ is replaced by T is one or more R １ｅ or C １ ~C ２０ is alkyl , a compound, or a pharmaceutically acceptable salt or solvate thereof.

2. A compound of formula (I) or (II'), 【Chemistry 7】 or a pharmaceutically acceptable salt or solvate thereof, wherein: R １ is H, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl 、-C(=O)R １ｂ 、-C(=O)R １ｃ 、-C(=O)R １ｚ 、-C(=O)-(C H=CH) ｎ -R １ａ 、-C(=O)CH ２ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ - R １ａ 、-C(=O)CH ２ -[CH(OR １ｃ )-CH ２ ] ｐ -[CH ２ ] ｑ -R １ａ 、-C(=O)CH ２ -[C(=O)CH ２ ] ｐ -[CH(OR １ｃ )-CH ２ ] ｒ -[ CH ２ ] ｑ -R １ａ 、-C(=O)-CH(C(=O)R １ｂ )-[C(=O)CH ２ ] ｐ -[CH(OR １ｃ )-CH ２ ] ｒ -[CH ２ ] ｑ -R １ａ 、-C(=O)CH ２ -[ CH(OR １ｃ )-CH ２ ] ｒ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -R １ａ 、-C (=O)OR １ｃ 、-C(=O)N(R １ｃ ) ２ 、-C(=O)-CH=CH-C(=O )OR １ｃ 、-C(=O)-[CH ２ ] ｑ -C(=O)OR １ｃ 、-C(=O)-CH ２ CH ２ -C(=O)OR １ｃ 、-C(=O)CH ２ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -C(=O)OR １ｃ 、-C(=O)-[CH ２ ] ｑ -C(=O)R １ａ 、-C(= O)-[CH ２ ] ｑ -C(=O)R １ｚ 、-[C(=O)CH ２ ] ｑ -C(=O)R １ｚ 、-C(=O)-CH ２ CH ２ -C(=O)R １ｚ 、-C(=O)-CH=CH-[C( =O)] ｐ R １ｚ 、-C(=O)CH ２ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -C( =O)R １ｚ 、-SR １ｄ 、 【Chemistry 8】 wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl or C ２ ~C ２０ Archi Nyl may optionally be one or more R １ａ is substituted with C １ ~C ２０ One of the alkyl or multiple methylene moieties are C ２ ~C ２０ Alkenyl, or C ２ ~C ２０ Alkynyl is optionally substituted by one or more carbonyl moieties; Each R １ａ are independently H, halogen, C １ ~C ２０ Alkyl, C ２ ~C ２０ alkenyl, -OR １ｃ 、-C(=O)OR １ｃ 、-C(=O)N(R １ｃ ) ２ 、-N(R １ｃ ) ２ 、 -N(R １ｃ )C(=O)R １ｂ 、-N(R １ｃ )C(=O)R １ｚ 、-N(R １ｃ )C (=O)OR １ｃ 、-OC(=O)R １ｂ 、-OC(=O)R １ｚ 、-OC(=O)OR １ｃ 、-SC(=O)R １ｂ 、-SC(=O)R １ｚ 、-SC(=O)OR １ｃ 、-SC (=O)N(R １ｃ ), -C(=O)R ２ , -C(=O)R １ｂ , -C(=O)R １ｚ , -SR １ｄ 、or R １ｚ wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, or C ２ ~C ２ ０ The alkynyl may optionally be one or more R １ｅ is replaced by Each R １ｂ are independently H, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２ ０ Alkynyl, -(CH ２ ) ｑ -C(=O)OR １ｃ , -(CH ２ ) ｑ -C(=O)R １ ｃ 、-CH ２ -C(=O)-(CH ２ ) ｑ -C(=O)OR １ｃ 、-CH ２ -[C(=O )CH ２ ] ｐ -[CH ２ ] ｑ -C(=O)OR １ｃ 、-CH=CH-C(=O)OR １ｃ 、－Ｃ（ R １ｅ )=C(R １ｅ )-C(=O)OR １ｃ、－Ｃ（ =O)OR １ｃ 、-C( =O)N(R １ｃ ) ２ , or R １ｚ , in the formula C １ ~C ２０ Alkyl, C ２ ~C ２０ Arkeny Lu or C ２ ~C ２０ The alkynyl may optionally be one or more R １ｅ is replaced by Each R １ｃ are independently H, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~ C ２０ Alkynyl, C ３ ~C １２ Cycloalkyl, C ３ ~C １２ heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ Heteroaryl, -(C １ ~C ２０ alkyl)-( C ３ ~C １２ cycloalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Heterogeneity chloroalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １２ aryl), or -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Heteroaryl wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, C ３ ~C １２ Cycloalkyl, C ３ ~ C １２ Heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ Heteroaryl, - (C １ ~C ２０ alkyl)-(C ３ ~C １２ cycloalkyl), -(C １ ~C ２０ Archi ru)-(C ３ ~C １２ heterocycloalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~ C １２ aryl), or -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Heteroaryl) is optionally one or more R １ｅ or two R １ｃ But they are connected C, together with one or more intervening atoms ３ ~C １２ Cycloalkyl or C ３ ~C １２ forming a heterocycloalkyl, wherein C ３ ~C １２ Cycloalkyl or C ３ ~C １２ F The tetracycloalkyl may optionally be one or more R １ｅ is replaced by Each R １ｄ are independently H, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２ ０ Alkynyl, C3-C10 cycloalkyl, C ３ ~C １２ Cycloalkyl, C ３ ~C １ ２ Heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ Heteroaryl, -(C １ ~C ２０ alkyl)-(C ３ ~C １２ cycloalkyl), -(C １ ~C ２０ alkyl) -(C ３ ~C １２ heterocycloalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １ ２ aryl), or -(C １ ~C ２０ alkyl)-(C ３ ~C １２ heteroaryl), the formula Medium, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, C ３ ~ C １２ Cycloalkyl, C ３ ~C １２ Heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ Heteroaryl, -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Cycloalkane ru), -(C １ ~C ２０ alkyl)-(C ３ ~C １２ heterocycloalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １２ aryl), or -(C １ ~C ２０ alkyl)-( C ３ ~C １２ heteroaryl) optionally includes one or more R １ｅ is replaced by Each R １ｅ are independently H, halogen, C １ ~C ２０ Alkyl, C ２ ~C ２０ alkenyl, C ２ ~C ２０ Alkynyl, -OR １ｇ , -C(=O)OR １ｇ , -C(=O)N(R １ｇ ) ２ 、-N(R １ｇ ) ２ 、-N(R １ｇ )C(=O)R １ｆ 、-N(R １ｇ )C(=NH )R １ｆ 、-N(R １ｇ )C(=O)R １ｚ 、-N(R １ｇ )C(=O)OR １ｇ 、-O C(=O)R １ｆ 、-OC(=O)R １ｚ 、-OC(=O)OR １ｇ 、-SR １ｇ 、-N ＋（ R １ｇ ) ３ 、-SC(=O)R １ｆ 、-SC(=O)R １ｚ 、-SC(=O)OR １ ｇ 、-SC(=O)N(R １ｇ ) ２ 、-C(=O)R １ｆ 、-C(=O)R １ｚ 、C ３ ~ C １２ Cycloalkyl, C ３ ~C １２ Heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ heteroaryl, or R １ｚ , in the formula, C １ ~C ２０ Alkyl, C ２ ~C ２０ a Alkenyl, C ２ ~C ２０ Alkynyl, C ３ ~C １２ Cycloalkyl, C ３ ~C １２ Hetero Cycloalkyl, C ３ ~C １２ Aryl, or C ３ ~C １２ Optionally one heteroaryl or multiple R １ｆ or R １ｚ is replaced by Each R １ｆ are independently H, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, -OR １ｇ , -CH ２ C(=O)OR １ｇ , -CH=CH-C(=O) OR １ｇ、－Ｃ（ =O) OR １ｇ ,-C(=O)N(R １ｇ ) ２ ,-N(R １ｇ ) ２ 、also is R １ｚ wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, or C ２ ~C ２０ The alkynyl may optionally be one or more -OR １ｇ or R １ｚ is replaced by Each R １ｇ are independently H, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~ C ２０ Alkynyl, C ３ ~C １２ Cycloalkyl, C ３ ~C １２ heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ Heteroaryl, -(C １ ~C ２０ alkyl)-( C ３ ~C １２ cycloalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Heterogeneity chloroalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １２ aryl), or -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Heteroaryl wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, C ３ ~C １２ Cycloalkyl, C ３ ~ C １２ Heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ Heteroaryl, - (C １ ~C ２０ alkyl)-(C ３ ~C １２ cycloalkyl), -(C １ ~C ２０ Archi ru)-(C ３ ~C １２ heterocycloalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~ C １２ aryl), or -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Heteroaryl) is optionally one or more R １ｚ is replaced by Each R １ｚ is independent 【Chemistry 9】 and each n is independently an integer ranging from 0 to 20; each p is independently an integer ranging from 0 to 20; each q is independently an integer ranging from 0 to 20; each r is independently an integer ranging from 0 to 20; R ２ and R ３ are independently H, —C(═O)R １ｂ , -C(=O)OR １ｃ , -C(=O) N(R １ｃ ) ２ 、-C(=O)R １ｚ 、-C(=O)-CH=CH-C(=O)OR １ｃ 、－Ｃ（ =O)-CH ２ -CH ２ -C(=O)OR １ｃ 、 【Chemistry 10】 -C(=O)-CH=CH-C(=O)-R １ｚ 、-C(=O)-CH ２ -CH ２ -C( =O)-R １ｚ 、 【Chemistry 11】 and Each X is independently -OR １ｃ , -SR １ｃ , -N(R １ｃ ) ２ , 【Chemistry 12】 or R １ｚ and or two Xs, together with one or more intervening atoms to which they are attached, form C ５ ~C １ ２ Heterocycloalkyl or C ５ ~C １２ forming a heteroaryl, wherein C ５ ~C １２ Heterocycloalkyl or C ５ ~C １２ Heteroaryl may optionally be one or more R １ａ is replaced by, and T is one or more R １ｅ a bond optionally substituted with １ ~C ２０ is alkyl , a compound, or a pharmaceutically acceptable salt or solvate thereof.

3. Compounds of formula (I) or (II) 【Chemistry 13】 or a pharmaceutically acceptable salt or solvate thereof, wherein: R １ is H, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl 、-C(=O)R １ｂ 、-C(=O)R １ｚ 、-C(=O)-(CH=CH) ｎ -R １ａ 、-C(=O)CH ２ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -R １ａ 、-C(=O) CH ２ -[CH(OR １ｃ )-CH ２ ] ｐ -[CH ２ ] ｑ -R １ａ 、-C(=O)CH ２ -[C(=O)CH ２ ] ｐ -[CH(OR １ｃ )-CH ２ ] ｒ -[CH ２ ] ｑ -R １ａ 、 -C(=O)CH ２ -[CH(OR １ｃ )-CH ２ ] ｒ -[C(=O)CH ２ ] ｐ -[C H ２ ] ｑ -R １ａ 、-C(=O)OR １ｃ 、-C(=O)N(R １ｃ ) ２ 、-C(=O) -CH=CH-C(=O)OR １ｃ 、-C(=O)-[CH ２ ] ｑ -C(=O)OR １ｃ 、-C(=O)-CH ２ CH ２ -C(=O)OR １ｃ 、-C(=O)CH ２ -[C(=O )CH ２ ] ｐ -[CH ２ ] ｑ -C(=O)OR １ｃ 、-C(=O)-[CH ２ ] ｑ -C( =O)R １ｚ 、-C(=O)-CH ２ CH ２ -C(=O)R １ｚ 、-C(=O)CH ２ - [C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -C(=O)R １ｚ 、-SR １ｄ 、 【Chemistry 14】 wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl or C ２ ~C ２０ Archi Nyl may optionally be one or more R １ａ is substituted with C １ ~C ２０ Alkyl, C ２ ~ C ２０ Alkenyl, or C ２ ~C ２０ The methylene moieties of an alkynyl may be one or optionally substituted by multiple carbonyl moieties; Each R １ａ are independently H, halogen, C １ ~C ２０ Alkyl, C ２ ~C ２０ alkenyl, -OR １ｃ 、-C(=O)OR １ｃ 、-C(=O)N(R １ｃ ) ２ 、-N(R １ｃ ) ２ 、 -N(R １ｃ )C(=O)R １ｂ 、-N(R １ｃ )C(=O)R １ｚ 、-N(R １ｃ )C (=O)OR １ｃ 、-OC(=O)R １ｂ 、-OC(=O)R １ｚ 、-OC(=O)OR １ｃ 、-SC(=O)R １ｂ 、-SC(=O)R １ｚ 、-SC(=O)OR １ｃ 、-SC (=O)N(R １ｃ ), -C(=O)R ２ 、-C(=O)R １ｂ 、-C(=O)R １ｚ 、-SR １ｄ 、or R １ｚ wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, or C ２ ~C ２ ０ Alkynyl is one or more R １ｅ optionally replaced by Each R １ｂ are independently H, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２ ０ Alkynyl, -(CH ２ ) ｑ -C(=O)OR １ｃ , -CH ２ -C(=O)-(CH ２ ) ｑ -C(=O)OR １ｃ 、-CH ２ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -C(= O)OR １ｃ 、-CH=CH-C(=O)OR １ｃ、－Ｃ（ =O)OR １ｃ 、-C(=O ) N (R １ｃ ) ２ , or R １ｚ , in the formula C １ ~C ２０ Alkyl, C ２ ~C ２０ alkenyl, or C ２ ~C ２０ The alkynyl may optionally be one or more R １ｅ is replaced by Each R １ｃ are independently H, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~ C ２０ Alkynyl, C ３ ~C １２ Cycloalkyl, C ３ ~C １２ heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ Heteroaryl, -(C １ ~C ２０ alkyl)-( C ３ ~C １２ cycloalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Heterogeneity chloroalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １２ aryl), or -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Heteroaryl wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, C ３ ~C １２ Cycloalkyl, C ３ ~ C １２ Heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ Heteroaryl, - (C １ ~C ２０ alkyl)-(C ３ ~C １２ cycloalkyl), -(C １ ~C ２０ Archi ru)-(C ３ ~C １２ heterocycloalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~ C １２ aryl), or -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Heteroaryl) is optionally one or more R １ｅ or two R １ｃ But they are connected C, together with one or more intervening atoms ３ ~C １２ Cycloalkyl or C ３ ~C １２ forming a heterocycloalkyl, wherein C ３ ~C １２ Cycloalkyl or C ３ ~C １２ F The tetracycloalkyl may optionally be one or more R １ｅ is replaced by Each R １ｄ are independently H, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２ ０ Alkynyl, C3-C10 cycloalkyl, C ３ ~C １２ Cycloalkyl, C ３ ~C １ ２ Heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ Heteroaryl, -(C １ ~C ２０ alkyl)-(C ３ ~C １２ cycloalkyl), -(C １ ~C ２０ alkyl) -(C ３ ~C １２ heterocycloalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １ ２ aryl), or -(C １ ~C ２０ alkyl)-(C ３ ~C １２ heteroaryl), the formula Medium, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, C ３ ~ C １２ Cycloalkyl, C ３ ~C １２ Heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ Heteroaryl, -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Cycloalkane ru), -(C １ ~C ２０ alkyl)-(C ３ ~C １２ heterocycloalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １２ aryl), or -(C １ ~C ２０ alkyl)-( C ３ ~C １２ heteroaryl) optionally includes one or more R １ｅ is replaced by Each R １ｅ are independently H, halogen, C １ ~C ２０ Alkyl, C ２ ~C ２０ alkenyl, C ２ ~C ２０ Alkynyl, -OR １ｇ , -C(=O)OR １ｇ , -C(=O)N(R １ｇ ) ２ 、-N(R １ｇ ) ２ 、-N(R １ｇ )C(=O)R １ｆ 、-N(R １ｇ )C(=O) R １ｚ 、-N(R １ｇ )C(=O)OR １ｇ 、-OC(=O)R １ｆ 、-OC(=O)R １ｚ 、-OC(=O)OR １ｇ 、-SR １ｇ 、-N ＋ (R １ｇ ) ３ 、-SC(=O)R １ ｆ 、-SC(=O)R １ｚ 、-SC(=O)OR １ｇ 、-SC(=O)N(R １ｇ ) ２ 、 -C(=O)R １ｆ , -C(=O)R １ｚ , or R １ｚ , in the formula, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, or C ２ ~C ２０ The alkynyl may optionally be one or more R １ｚ in is replaced, Each R １ｆ are independently H, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２ ０ Alkynyl, —CH ２ C(=O)OR １ｇ , -CH=CH-C(=O)OR １ｇ、－Ｃ （ =O) OR １ｇ , -C(=O)N(R １ｇ ) ２ , or R １ｚ , in the formula, C １ ~C ２０ Al Kill, C ２ ~C ２０ Alkenyl, or C ２ ~C ２０ Alkynyl optionally includes one or more R １ｚ is replaced by Each R １ｇ are independently H, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~ C ２０ Alkynyl, C ３ ~C １２ Cycloalkyl, C ３ ~C １２ heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ Heteroaryl, -(C １ ~C ２０ alkyl)-( C ３ ~C １２ cycloalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Heterogeneity chloroalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １２ aryl), or -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Heteroaryl wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, C ３ ~C １２ Cycloalkyl, C ３ ~ C １２ Heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ Heteroaryl, - (C １ ~C ２０ alkyl)-(C ３ ~C １２ cycloalkyl), -(C １ ~C ２０ Archi ru)-(C ３ ~C １２ heterocycloalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~ C １２ aryl), or -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Heteroaryl) optionally one or more R １ｚ is replaced by Each R １ｚ is independent 【Chemistry 15】 and each n is independently an integer ranging from 0 to 20; each p is independently an integer ranging from 0 to 20; each q is independently an integer ranging from 0 to 20; each r is independently an integer ranging from 0 to 20; R ２ and R ３ are independently H, —C(═O)R １ｂ , -C(=O)OR １ｃ , -C(=O) N(R １ｃ ) ２ 、-C(=O)R １ｚ 、-C(=O)-CH=CH-C(=O)OR １ｃ 、－Ｃ（ =O)-CH ２ -CH ２ -C(=O)OR １ｃ 、 【Chemistry 16】 -C(=O)-CH=CH-C(=O)-R １ｚ 、-C(=O)-CH ２ -CH ２ -C( =O)-R １ｚ 、 【Chemistry 17】 and Each X is independently -OR １ｃ , -SR １ｃ , -N(R １ｃ ) ２ , 【Chemistry 18】 or R １ｚ or a pharmaceutically acceptable salt or solvate thereof.

4. R １ The compound of any one of claims 1 to 3, wherein is H.

5. R １ But C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, -C(=O)R １ｂ 、-C(=O)R １ｚ 、-C(=O)-(CH=CH) ｎ -R １ａ 、 -C(=O)CH ２ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -R １ａ 、-C(=O)C H ２ -[CH(OR １ｃ )-CH ２ ] ｐ -[CH ２ ] ｑ -R １ａ 、-C(=O)CH ２ - [C(=O)CH ２ ] ｐ -[CH(OR １ｃ )-CH ２ ] ｒ -[CH ２ ] ｑ -R １ａ 、- C(=O)CH ２ -[CH(OR １ｃ )-CH ２ ] ｒ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -R １ａ 、-C(=O)OR １ｃ 、-C(=O)N(R １ｃ ) ２ 、-C(=O)- CH=CH-C(=O)OR １ｃ 、-C(=O)-[CH ２ ] ｑ -C(=O)OR １ｃ 、 -C(=O)-CH ２ CH ２ -C(=O)OR １ｃ 、-C(=O)CH ２ -[C(=O) CH ２ ] ｐ -[CH ２ ] ｑ -C(=O)OR １ｃ 、-C(=O)-[CH ２ ] ｑ -C(= O)R １ｚ 、-C(=O)-CH ２ CH ２ -C(=O)R １ｚ 、-C(=O)-CH=C H-[C(=O)] ｐ R １ｚ 、-C(=O)CH ２ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -C(=O)R １ｚ 、-SR １ｄ 、 【Chemistry 19】 wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl or C ２ ~C ２０ Archi Nyl is one or more R １ａ wherein C １ ~C ２０ Alkyl, C ２ ~ C ２０ Alkenyl, or C ２ ~C ２０ The methylene moieties of an alkynyl may be one 5. The compound according to claim 1, optionally substituted with one or more carbonyl moieties. The compounds listed above.

6. R １ But C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, -C(=O)R １ｂ 、-C(=O)R １ｃ 、-C(=O)R １ｚ 、-C(=O)-(CH =CH) ｎ -R １ａ 、-C(=O)CH ２ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -R １ａ 、-C(=O)CH ２ -[CH(OR １ｃ )-CH ２ ] ｐ -[CH ２ ] ｑ -R １ａ 、 -C(=O)CH ２ -[C(=O)CH ２ ] ｐ -[CH(OR １ｃ )-CH ２ ] ｒ -[C H ２ ] ｑ -R １ａ 、-C(=O)-CH(C(=O)R １ｂ )-[C(=O)CH ２ ] ｐ -[CH(OR １ｃ )-CH ２ ] ｒ -[CH ２ ] ｑ -R １ａ 、-C(=O)CH ２ -[C H(OR １ｃ )-CH ２ ] ｒ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -R １ａ 、-C( =O)OR １ｃ 、-C(=O)N(R １ｃ ) ２ 、-C(=O)-CH=CH-C(=O) OR １ｃ 、-C(=O)-[CH ２ ] ｑ -C(=O)OR １ｃ 、-C(=O)-CH ２ C H ２ -C(=O)OR １ｃ 、-C(=O)CH ２ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -C(=O)OR １ｃ 、-C(=O)-[CH ２ ] ｑ -C(=O)R １ａ 、-C(=O )-[CH ２ ] ｑ -C(=O)R １ｚ 、-[C(=O)CH ２ ] ｑ -C(=O)R １ｚ 、 -C(=O)-CH ２ CH ２ -C(=O)R １ｚ 、-C(=O)-CH=CH-[C(= O)] ｐ R １ｚ 、-C(=O)CH ２ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -C(= O)R １ｚ 、-SR １ｄ 、 【Chemistry 20】 wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl or C ２ ~C ２０ Archi Nyl is one or more R １ａ optionally substituted with C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, or C ２ ~C ２０ The methylene moiety or moieties of an alkynyl may be one or more 6. The compound of any one of claims 1 to 5, optionally substituted with a number of carbonyl moieties.

7. R １ But C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, -C(=O)R １ｂ 、-C(=O)R １ｚ 、-C(=O)-(CH=CH) ｎ -R １ａ 、 -C(=O)CH ２ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -R １ａ 、-C(=O)C H ２ -[CH(OR １ｃ )-CH ２ ] ｐ -[CH ２ ] ｑ -R １ａ 、-C(=O)CH ２ - [C(=O)CH ２ ] ｐ -[CH(OR １ｃ )-CH ２ ] ｒ -[CH ２ ] ｑ -R １ａ 、- C(=O)CH ２ -[CH(OR １ｃ )-CH ２ ] ｒ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -R １ａ 、-C(=O)OR １ｃ 、-C(=O)N(R １ｃ ) ２ 、-C(=O)- CH=CH-C(=O)OR １ｃ 、-C(=O)-[CH ２ ] ｑ -C(=O)OR １ｃ 、 -C(=O)-CH ２ CH ２ -C(=O)OR １ｃ 、-C(=O)CH ２ -[C(=O) CH ２ ] ｐ -[CH ２ ] ｑ -C(=O)OR １ｃ 、-C(=O)-[CH ２ ] ｑ -C(= O)R １ｚ 、-C(=O)-CH ２ CH ２ -C(=O)R １ｚ 、-C(=O)CH ２ -[ C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -C(=O)R １ｚ 、-SR １ｄ 、 【Chemical 21】 wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl or C ２ ~C ２０ Archi Nyl is one or more R １ａ wherein C １ ~C ２０ Alkyl, C ２ ~ C ２０ Alkenyl, or C ２ ~C ２０ The methylene moieties of an alkynyl may be one 7. The compound according to claim 1, optionally substituted by one or more carbonyl moieties. thing.

8. R １ が、-C(=O)R １ｂ 、-C(=O)R １ｚ 、-C(=O)-(CH=CH) ｎ -R １ａ 、-C(=O)CH ２ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -R １ａ 、-C (=O)CH ２ -[CH(OR １ｃ )-CH ２ ] ｐ -[CH ２ ] ｑ -R １ａ 、-C(=O )CH ２ -[C(=O)CH ２ ] ｐ -[CH(OR １ｃ )-CH ２ ] ｒ -[CH ２ ] ｑ - R １ａ 、-C(=O)CH ２ -[CH(OR １ｃ )-CH ２ ] ｒ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -R １ａ 、-C(=O)OR １ｃ 、-C(=O)N(R １ｃ ) ２ 、-C (=O)-CH=CH-C(=O)OR １ｃ 、-C(=O)-[CH ２ ] ｑ -C(=O) OR １ｃ 、-C(=O)-CH ２ CH ２ -C(=O)OR １ｃ 、-C(=O)CH ２ -[ C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -C(=O)OR １ｃ 、-C(=O)-[CH ２ ] ｑ -C(=O)R １ｚ 、-C(=O)-CH ２ CH ２ -C(=O)R １ｚ 、-C(=O) CH ２ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -C(=O)R １ｚ 、-SR １ｄ 、 【Chemical 22】 The compound according to any one of claims 1 to 7,

9. R １ is -C(=O)R １ｂ The compound according to any one of claims 1 to 8, wherein

10. R １ is -C(=O)R １ｃ The compound according to any one of claims 1 to 9,

11. R １ が-C(=O)-CH(C(=O)R １ｂ )-[C(=O)CH ２ ] ｐ -[CH( OR １ｃ )-CH ２ ] ｒ - [CH ２ ] ｑ -R １ａ Any one of claims 1 to 10, The compound described in

12. R １ -C(=O)-[CH ２ ] ｑ -C(=O)R １ａ Any of claims 1 to 11, The compound according to any one of claims 1 to 4.

13. R １ -[C(=O)CH ２ ] ｑ -C(=O)R １ｚ Any one of claims 1 to 12, 3. The compound according to claim 1.

14. R １ -C(=O)-(CH ２ ) ｑ -C(=O)OR １ｃ Any of claims 1 to 13, The compound according to any one of claims 1 to 4.

15. R １ -C(=O)-CH ２ CH ２ -C(=O)OR １ｃ Any of claims 1 to 14, The compound according to any one of claims 1 to 4.

16. R １ -C(=O)-CH ２ -C(=O)-(CH ２ ) ｑ -C(=O)OR １ｃ is The compound according to any one of claims 1 to 15.

17. R １ -C(=O)-CH ２ —C(═O)—CH ２ CH ２ -C(=O)OR １ｃ is The compound according to any one of claims 1 to 16.

18. R １ is -C(=O)-CH=CH-C(=O)OR １ｃ Any of claims 1 to 17, The compound according to any one of claims 1 to 4.

19. R １ is -C(=O)-CH=CH-[C(=O)] ｐ R １ｚ 19. The compound according to claim 1 to 18, The compound according to any one of claims 1 to 4.

20. R １ is -C(=O)R １ｚ The compound according to any one of claims 1 to 19,

21. R １ but 【Chemical 23】 The compound according to any one of claims 1 to 20,

22. R １ but 【Chemistry 24】 The compound according to any one of claims 1 to 21,

23. R １ -C(=O)-(CH=CH) ｎ -R １ａ Any one of claims 1 to 22, Item 1. The compound according to item 1.

24. R １ -C(=O)-(CH=CH) ｎ -C(=O)OR １ｃ Claims 1 to 23 The compound according to any one of claims 1 to 4.

25. R １ -C(=O)-(CH=CH) ｎ -C(=O)OR １ｚ Claims 1 to 24 The compound according to any one of claims 1 to 4.

26. R １ is -C(=O)-CH=CH-C(=O)R １ｚ Any one of claims 1 to 25, 3. The compound according to claim 1.

27. R １ -C(=O)CH ２ -[C(=O)CH ２ ] ｐ - [CH ２ ] ｑ -R １ａ That is, A compound according to any one of claims 1 to 26.

28. R １ -C(=O)CH ２ -[C(=O)CH ２ ] ｐ -R １ａ Claims 1 to 27 The compound according to any one of claims 1 to 4.

29. R １ -C(=O)CH ２ -[C(=O)CH ２ ] ｐ -C(=O)OR １ｃ Please The compound according to any one of claims 1 to 28.

30. R １ but 【Chemistry 25】 The compound according to any one of claims 1 to 29,

31. R １ but 【Chemical 26】 The compound of any one of claims 1 to 30, which is not

32. R １ but 【Chemical 27】 The compound according to any one of claims 1 to 31,

33. R １ but 【Chemical 28】 The compound according to any one of claims 1 to 32,

34. R １ but 【Chemical 29】 The compound according to any one of claims 1 to 33,

35. R １ but 【Chemistry 30】 The compound according to any one of claims 1 to 34, wherein

36. R １ but 【Chemical 31】 The compound according to any one of claims 1 to 35,

37. R １ but 【Chemical 32】 The compound according to any one of claims 1 to 36,

38. R １ but 【Chemical 33】 The compound according to any one of claims 1 to 37,

39. R １ -C(=O)CH ２ - [CH ２ ] ｑ -R １ａ Any one of claims 1 to 38, The compound according to claim 1.

40. R １ -C(=O)CH ２ - [CH ２ ] ｑ -C(=O)OR １ｃ Claims 1 to 3 9. The compound according to any one of claims 9.

41. R １ but 【Chemical 34】 The compound according to any one of claims 1 to 40,

42. R １ but 【Chemistry 35】 The compound according to any one of claims 1 to 41,

43. R １ but 【Chemical 36】 The compound according to any one of claims 1 to 42,

44. R １ but 【Chemical 37】 The compound according to any one of claims 1 to 43, wherein

45. R １ but 【Chemical 38】 The compound according to any one of claims 1 to 44, wherein

46. R １ -C(=O)CH ２ -[C(=O)CH ２ ] ｐ - [CH ２ ] ｑ -R １ｚ That is, 46. ​​The compound according to any one of claims 1 to 45.

47. R １ -C(=O)CH ２ -[C(=O)CH ２ ] ｐ -R １ｚ Claims 1 to 46 In some embodiments, R １ is -C(=O)CH ２ - [CH ２ ] ｑ -R １ｚ is.

48. R １ が-C(=O)CH ２ -[CH(OR １ｃ )-CH ２ ] ｐ -[CH ２ ] ｑ -R １ａ The compound according to any one of claims 1 to 47,

49. R １ が-C(=O)CH ２ -[CH(OR １ｃ )-CH ２ ] ｐ -[CH ２ ] ｑ -C(= O)R １ｃ The compound according to any one of claims 1 to 48,

50. R １ が-C(=O)CH ２ -[CH(OR １ｃ )-CH ２ ] ｐ -[CH ２ ] ｑ -C(= O)R １ｚ 50. The compound according to any one of claims 1 to 49, wherein

51. R １ が-C(=O)CH ２ -[C(=O)CH ２ ] ｐ -[CH(OR １ｃ )-CH ２ ] ｒ - [CH ２ ] ｑ -R １ａ 51. The compound according to any one of claims 1 to 50,

52. R １ が-C(=O)CH ２ -[CH(OR １ｃ )-CH ２ ] ｒ -[C(=O)CH ２ ] ｐ - [CH ２ ] ｑ -R １ａ 52. The compound according to any one of claims 1 to 51, wherein

53. R １ が-C(=O)CH ２ -[C(=O)CH ２ ] ｐ -[CH(OR １ｃ )-CH ２ ] ｒ - [CH ２ ] ｑ -C(=O)OR １ｃ 53. The compound according to claim 1, wherein compound.

54. R １ が-C(=O)CH ２ -[CH(OR １ｃ )-CH ２ ] ｒ -[C(=O)CH ２ ] ｐ - [CH ２ ] ｑ -C(=O)OR １ａ 54. The compound according to claim 1, wherein compound.

55. R １ -C(=O)OR １ｃ 55. The compound according to any one of claims 1 to 54, wherein

56. R １ -C(=O)N(R １ｃ ) ２ The compound according to any one of claims 1 to 55, Compound.

57. R １ is -C(=O)-CH=CH-C(=O)OR １ｃ Any of claims 1 to 56, The compound according to any one of claims 1 to 4.

58. R １ -C(=O)-[CH ２ ] ｑ -C(=O)OR １ｃ Any of claims 1 to 57, The compound according to any one of claims 1 to 4.

59. R １ Ga-SR １ｄ 59. The compound of any one of claims 1 to 58, wherein

60. R １ but 【Chemical Formula 39】 (for example, 【Chemistry 40】 60. The compound according to any one of claims 1 to 59, wherein

61. R １ but 【Chemistry 41】 (for example, 【Chemistry 42】 61. The compound according to any one of claims 1 to 60, wherein

62. R １ but 【Chemistry 43】 (for example, 【Chemical 44】 62. The compound according to any one of claims 1 to 61, wherein

63. R １ but 【Chemistry 45】 (for example, 【Chemistry 46】 63. The compound according to any one of claims 1 to 62, wherein

64. At least one R １ａ The compound of any one of claims 1 to 63, wherein is H.

65. At least one R １ａ But halogen, C １ ~C ２０ Alkyl, C ２ ~C ２０ Arkeny ル、-OR １ｃ 、-C(=O)OR １ｃ 、-C(=O)N(R １ｃ ) ２ 、-N(R １ｃ ) ２ 、-N(R １ｃ )C(=O)R １ｂ 、-N(R １ｃ )C(=O)R １ｚ 、-N(R １ｃ )C(=O)OR １ｃ 、-OC(=O)R １ｂ 、-OC(=O)R １ｚ 、-OC(=O) OR １ｃ 、-SC(=O)R １ｂ 、-SC(=O)R １ｚ 、-SC(=O)OR １ｃ 、- SC(=O)N(R １ｃ ) ２ 、-C(=O)R １ｂ 、-C(=O)R １ｚ 、-SR １ｄ 、 or R １ｚ wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, or C ２ ~ C ２０ Alkynyl is one or more R １ｅ Any of claims 1 to 64, optionally substituted with The compound according to any one of claims 1 to 4.

66. At least one R １ａ But halogen, C １ ~C ２０ Alkyl, or C ２ ~C ２０ Al is phenyl, wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, or C ２ ~C ２ ０ Alkynyl is one or more R １ｅ 66. Any of claims 1 to 65, optionally substituted with The compound according to claim 1.

67. At least one R １ａ Ga-OR １ｃ 67. The compound according to claim 1, wherein compound.

68. At least one R １ａ -C(=O)OR １ｃ Any one of claims 1 to 67, Item 1. The compound according to item 1.

69. At least one R １ａ -C(=O)N(R １ｃ ) ２ Any of claims 1 to 68, The compound according to any one of claims 1 to 4.

70. At least one R １ａ -N (R １ｃ ) ２ 70. The method according to claim 1, wherein The compound described.

71. At least one R １ａ -N (R １ｃ ) C(=O)R １ｂ 71. The compound according to claim 1 to 70, The compound according to any one of claims 1 to 4.

72. At least one R １ａ -N (R １ｃ ) C(=O)R １ｚ 72. The compound according to claim 1 to 71, The compound according to any one of claims 1 to 4.

73. At least one R １ａ -NHC(=O)R １ｂ Any one of claims 1 to 72, The compound according to claim 1.

74. At least one R １ａ -N (R １ｃ ) C(=O) OR １ｃ Claims 1 to 73 The compound according to any one of claims 1 to 4.

75. At least one R １ａ -OC(=O)R １ｂ Any one of claims 1 to 74, Item 1. The compound according to item 1.

76. At least one R １ａ -OC(=O)R １ｚ Any one of claims 1 to 75, Item 1. The compound according to item 1.

77. At least one R １ａ -OC(=O)OR １ｃ Any one of claims 1 to 76, The compound according to claim 1.

78. At least one R １ａ -SC(=O)R １ｂ Any one of claims 1 to 77, Item 1. The compound according to item 1.

79. At least one R １ａ -SC(=O)R １ｚ Any one of claims 1 to 78, Item 1. The compound according to item 1.

80. At least one R １ａ -SC(=O)OR １ｃ Any one of claims 1 to 79, The compound according to claim 1.

81. At least one R １ａ -SC(=O)N(R １ｃ ) ２ Any of claims 1 to 80, The compound according to any one of claims 1 to 4.

82. At least one R １ａ is -C(=O)R １ｂ Any one of claims 1 to 81, The compound described in

83. At least one R １ａ -C(=O)CH ２ C(=O)OR １ｃ Claims 1 to 5 82. The compound according to any one of claims 82.

84. At least one R １ａ Ga-SR １ｄ According to any one of claims 1 to 83, compound.

85. At least one R １ａ is R １ｚ The compound according to any one of claims 1 to 84, thing.

86. At least one R １ｂ The compound of any one of claims 1 to 85, wherein is H.

87. At least one R １ｂ is one or more R １ｅ C optionally substituted with １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, or C ２ ~C ２０ alkynyl, claims 1 to 8 7. The compound according to any one of claims 6.

88. At least one R １ｂ But C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~ C ２０ Alkynyl, -(CH ２ ) ｑ -C(=O)OR １ｃ , -(CH ２ ) ｑ -C(=O) R １ｃ 、-CH ２ -C(=O)-(CH ２ ) ｑ -C(=O)OR １ｃ 、-CH ２ -[C( =O)CH ２ ] ｐ -[CH ２ ] ｑ -C(=O)OR １ｃ 、-CH=CH-C(=O)OR １ｃ、－Ｃ（ R １ｅ )=C(R １ｅ )-C(=O)OR １ｃ、－Ｃ（ =O)OR １ｃ 、- C(=O)N(R １ｃ ) ２ , or R １ｚ wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl or C ２ ~C ２０ Alkynyl is one or more R １ｅ optionally replaced by 88. The compound according to any one of claims 1 to 87.

89. At least one R １ｂ But -(CH ２ ) ｑ -C(=O)OR １ｃ , -CH ２ -C (= O)-(CH ２ ) ｑ -C(=O)OR １ｃ 、-CH ２ -[C(=O)CH ２ ] ｐ -[CH ２ ] ｑ -C(=O)OR １ｃ 、-CH=CH-C(=O)OR １ｃ、－Ｃ（ =O)OR １ ｃ , -C(=O)N(R １ｃ ) ２、 or R １ｚ Any one of claims 1 to 88, The compound described.

90. At least one R １ｃ The compound of any one of claims 1 to 89, wherein is H.

91. At least one R １ｃ But independently, C １ ~C ２０ Alkyl, C ２ ~C ２０ Arkeny Lu, C ２ ~C ２０ Alkynyl, C ３ ~C １２ Cycloalkyl, C ３ ~C １２ Heterocyclo Alkyl, C ３ ~C １２ Aryl, C ３ ~C １２ Heteroaryl, -(C １ ~C ２０ Al Kill)-(C ３ ~C １２ cycloalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １ ２ heterocycloalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １２ aryl), or -(C １ ~C ２０ alkyl)-(C ３ ~C １２ heteroaryl), wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, C ３ ~C １２ S Chloroalkyl, C ３ ~C １２ Heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １ ２ Heteroaryl, -(C １ ~C ２０ alkyl)-(C ３ ~C １２ cycloalkyl), - (C １ ~C ２０ alkyl)-(C ３ ~C １２ heterocycloalkyl), -(C １ ~C ２０ alkyl)-(C ３ ~C １２ aryl), or -(C １ ~C ２０ alkyl)-(C ３ ~C １２ heteroaryl) is one or more R １ｅ or two R １ｃ together with the intervening atom or atoms to which they are attached, C ３ ~C １２ Cycloa Rukill or C ３ ~C １２ forming a heterocycloalkyl, wherein C ３ ~C １２ Cycloal Kill or C ３ ~C １２ Heterocycloalkyl is one or more R １ｅ optionally replaced by The compound according to any one of claims 1 to 90.

92. At least one R １ｃ is one or more R １ｅ C optionally substituted with １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, C ３ ~C １２ Cycloal Kill, C ３ ~C １２ Heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ Hetero Aryl, -(C １ ~C ２０ alkyl)-(C ３ ~C １２ cycloalkyl), -(C １ ~ C ２０ alkyl)-(C ３ ~C １２ heterocycloalkyl), -(C １ ~C ２０ Alkyl )-(C ３ ~C １２ aryl), or -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Haitai 92. The compound of any one of claims 1 to 91, wherein the compound is a hydroxyl group.

93. At least two R １ｃ together with the intervening atom or atoms to which they are attached, C ３ ~C １２ The compound according to any one of claims 1 to 92, which forms a heterocycloalkyl. Compound.

94. At least one R １ｄ The compound of any one of claims 1 to 93, wherein is H.

95. At least one R １ｃ is one or more R １ｅ C optionally substituted with １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, C ３ ~C １２ Cycloal Kill, C ３ ~C １２ Heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ Hetero Aryl, -(C １ ~C ２０ alkyl)-(C ３ ~C １２ cycloalkyl), -(C １ ~ C ２０ alkyl)-(C ３ ~C １２ heterocycloalkyl), -(C １ ~C ２０ Alkyl )-(C ３ ~C １２ aryl), or -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Haitai 95. The compound of any one of claims 1 to 94, wherein the compound is a aryl.

96. At least one R １ｅ The compound of any one of claims 1 to 95, wherein is H.

97. At least one R １ｅ are independently halogen, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, -OR １ｇ , -C(=O)OR １ｇ , -C(=O )N(R １ｇ ) ２ 、-N(R １ｇ ) ２ 、-N(R １ｇ )C(=O)R １ｆ 、-N(R １ｇ )C(=NH)R １ｆ 、-N(R １ｇ )C(=O)R １ｚ 、-N(R １ｇ )C(=O)O R １ｇ 、-OC(=O)R １ｆ 、-OC(=O)R １ｚ 、-OC(=O)OR １ｇ 、-S R １ｇ 、-N ＋（ R １ｇ ) ３ 、-SC(=O)R １ｆ 、-SC(=O)R １ｚ 、-SC( =O)OR １ｇ 、-SC(=O)N(R １ｇ ) ２ 、-C(=O)R １ｆ 、-C(=O)R １ｚ , C ３ ~C １２ Cycloalkyl, C ３ ~C １２ Heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ heteroaryl, or R １ｚ wherein C １ ~C ２０ Archi Lu, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, C ３ ~C １２ cycloalkyl, C ３ ~C １２ Heterocycloalkyl, C ３ ~C １２ Aryl, or C ３ ~C １２ Heteroa The reels may have one or more R １ｆ or R １ｚ Any of claims 1 to 96, optionally substituted with The compound according to any one of claims 1 to 4.

98. At least one R １ｅ But halogen, C １ ~C ２０ Alkyl, C ２ ~C ２０ Arkeny Lu, C ２ ~C ２０ Alkynyl, -OR １ｇ , -C(=O)OR １ｇ , -C(=O)N(R １ｇ ) ２ 、-N(R １ｇ ) ２ 、-N(R １ｇ )C(=O)R １ｆ 、-N(R １ｇ )C(= O)R １ｚ 、-N(R １ｇ )C(=O)OR １ｇ 、-OC(=O)R １ｆ 、-OC(=O )R １ｚ 、-OC(=O)OR １ｇ 、-SR １ｇ 、-N ＋ (R １ｇ ) ３ 、-SC(=O) R １ｆ 、-SC(=O)R １ｚ 、-SC(=O)OR １ｇ 、-SC(=O)N(R １ｇ ) ２ , -C(=O)R １ｆ , -C(=O)R １ｚ , or R １ｚ wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, or C ２ ~C ２０ Alkynyl is one or more R １ ｚ 98. The compound of any one of claims 1 to 97, optionally substituted with

99. At least one R １ｅ became independent and C ３ ~C １２ Cycloalkyl, C ３ ~C １２ Haitai Cycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ heteroaryl, wherein C ３ ~C １２ Cycloalkyl, C ３ ~C １２ Heterocycloalkyl, C ３ ~C １２ Ally Lu or C ３ ~C １２ Heteroaryl is one or more R １ｆ or R １ｚ Optionally replace with 99. The compound of any one of claims 1 to 98,

100. At least one R １ｆ 100. The compound of any one of claims 1 to 99, wherein is H.

101. At least one R １ｆ independently, C １ ~C ２０ Alkyl, C ２ ~C ２０ alkenyl, C ２ ~C ２０ Alkynyl, -OR １ｇ , -CH ２ C(=O)OR １ｇ , -CH=CH-C (=O)OR １ｇ 、-C(=O)OR １ｇ 、-C(=O)N(R １ｇ ) ２ 、-N(R １ｇ ) ２ , or R １ｚ wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ alkenyl, or C ２ ~C ２０ Alkynyl is one or more -OR １ｇ or R １ｚ optionally replaced by A compound according to any one of claims 1 to 100.

102. At least one R １ｆ is C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~ C ２０ Alkynyl, —CH ２ C(=O)OR １ｇ , -CH=CH-C(=O)OR １ｇ , -C(=O)OR １ｇ , -C(=O)N(R １ｇ ) ２ , or R １ｚ wherein C １ ~ C ２０ Alkyl, C ２ ~C ２０ Alkenyl, or C ２ ~C ２０ Alkynyl can be one or more R in numbers １ｚ 102. The compound of any one of claims 1 to 101, optionally substituted with

103. At least one R １ｆ Ga-OR １ｇ According to any one of claims 1 to 102, Compound.

104. At least one R １ｆ -N (R １ｇ ) ２ Any one of claims 1 to 103, The compound described in

105. At least one R １ｇ The compound of any one of claims 1 to 104, wherein is H. 。

106. At least one R １ｇ is one or more R １ｚ C optionally substituted with １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, C ３ ~C １２ Cycloal Kill, C ３ ~C １２ Heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ Hetero Aryl, -(C １ ~C ２０ alkyl)-(C ３ ~C １２ cycloalkyl), -(C １ ~ C ２０ alkyl)-(C ３ ~C １２ heterocycloalkyl), -(C １ ~C ２０ Alkyl )-(C ３ ~C １２ aryl), or -(C １ ~C ２０ alkyl)-(C ３ ~C １２ Haitai 106. The compound of any one of claims 1 to 105, wherein the compound is a aryl.

107. At least one R １ｚ but 【Chemistry 47】 The compound according to any one of claims 1 to 106,

108. At least one R １ｚ but 【Chemistry 48】 The compound according to any one of claims 1 to 107,

109. At least one R １ｚ but 【Chemistry 49】 The compound according to any one of claims 1 to 108,

110. At least one R １ｚ but 【Chemistry 50】 The compound according to any one of claims 1 to 109,

111. At least one R １ｚ but 【Chemistry 51】 The compound according to any one of claims 1 to 110,

112. At least one R １ｚ but 【Chemistry 52】 The compound according to any one of claims 1 to 111,

113. one or more R １ｚ All of 【Chemistry 53】 The compound according to any one of claims 1 to 112,

114. one or more R １ｚ All of 【Chemical 54】 The compound according to any one of claims 1 to 113,

115. one or more R １ｚ All of 【Chemistry 55】 The compound according to any one of claims 1 to 114,

116. one or more R １ｚ All of 【Chemical 56】 The compound according to any one of claims 1 to 115,

117. Two or more R １ｚ At least one of 【Chemical 57】 and two or more R １ｚ At least one of 【Chemistry 58】 The compound according to any one of claims 1 to 116,

118. Two or more R １ｚ At least one of 【Chemical Formula 59】 and two or more R １ｚ At least one of 【Chemistry 60】 The compound according to any one of claims 1 to 117,

119. Two or more R １ｚ At least one of 【Hua 61】 and two or more R １ｚ At least one of 【Hua 62】 The compound according to any one of claims 1 to 118,

120. n is 0 to 20, 0 to 15, 0 to 10, 0 to 6, 0 to 4, or 0 to 2, 119. The compound according to any one of claims 119.

121. n is 1 to 20, 2 to 20, 3 to 20, 4 to 20, 5 to 20, 6 to 20, 7 to 20, 8 to ２０、９～２０、１０～２０、１１～２０、１２～２０、１３～２０、１４～２０、１５ 16 to 20, 17 to 20, 18 to 20, or 19 to 20, claims 1 to 12 10. The compound according to any one of claims 1 to 8.

122. wherein p is 0 to 20, 0 to 15, 0 to 10, 0 to 6, 0 to 4, or 0 to 2.

121. The compound according to any one of claims 121.

123. p is 1-20, 2-20, 3-20, 4-20, 5-20, 6-20, 7-20, 8- ２０、９～２０、１０～２０、１１～２０、１２～２０、１３～２０、１４～２０、１５ 16 to 20, 17 to 20, 18 to 20, or 19 to 20, claims 1 to 12 2. The compound according to any one of claims 1 to 11.

124. q is 0 to 20, 0 to 15, 0 to 10, 0 to 6, 0 to 4, or 0 to 2, 123. The compound according to any one of claims 123.

125. q is 1 to 20, 2 to 20, 3 to 20, 4 to 20, 5 to 20, 6 to 20, 7 to 20, 8 to ２０、９～２０、１０～２０、１１～２０、１２～２０、１３～２０、１４～２０、１５ 16 to 20, 17 to 20, 18 to 20, or 19 to 20, claims 1 to 12 4. The compound according to any one of claims 1 to 3.

126. r is 0 to 20, 0 to 15, 0 to 10, 0 to 6, 0 to 4, or 0 to 2, 125. The compound according to any one of claims 125.

127. r is 1 to 20, 2 to 20, 3 to 20, 4 to 20, 5 to 20, 6 to 20, 7 to 20, 8 to ２０、９～２０、１０～２０、１１～２０、１２～２０、１３～２０、１４～２０、１５ 16 to 20, 17 to 20, 18 to 20, or 19 to 20, claims 1 to 12 7. The compound according to any one of claims 6.

128. R ２ The compound of any one of claims 1 to 127, wherein is H.

129. R ２ が-C(=O)R １ｂ 、-C(=O)OR １ｃ 、-C(=O)N(R １ｃ ) ２ 、- C(=O)R １ｚ 、-C(=O)-CH=CH-C(=O)OR １ｃ 、-C(=O)-C H ２ -CH ２ -C(=O)OR １ｃ 、 【Chemistry 63】 -C(=O)-CH=CH-C(=O)-R １ｚ 、-C(=O)-CH ２ -CH ２ -C( =O)-R １ｚ 、 【Hua 64】 The compound according to any one of claims 1 to 128,

130. R ２ is -C(=O)R １ｂ The compound according to any one of claims 1 to 129,

131. R ２ Ga-(CH ２ ) ｑ -C(=O)OR １ｃ Any one of claims 1 to 130, The compound described in

132. R ２ Ga-CH ２ CH ２ -C(=O)OR １ｃ Any one of claims 1 to 131, The compound described in

133. R ２ Ga-CH ２ -C(=O)-(CH ２ ) ｑ -C(=O)OR １ｃ Claims 1 to 5 132. The compound according to any one of claims 132.

134. R ２ Ga-CH ２ —C(═O)—CH ２ CH ２ -C(=O)OR １ｃ Claims 1 to 5 133. The compound according to any one of claims 133.

135. R ２ is -C(=O)-CH=CH-C(=O)OR １ｃ Any of claims 1 to 134, The compound according to any one of claims 1 to 4.

136. R ２ is -C(=O)R １ｚ The compound according to any one of claims 1 to 135,

137. R ２ -C(=O)OR １ｃ The compound according to any one of claims 1 to 136, 。

138. R ２ -C(=O)N(R １ｃ ) ２ According to any one of claims 1 to 137, compound.

139. R ２ is -C(=O)-CH=CH-C(=O)OR １ｃ Any of claims 1 to 138, The compound according to any one of claims 1 to 4.

140. R ２ -C(=O)-CH ２ -CH ２ -C(=O)OR １ｃ Claims 1 to 139 The compound according to any one of claims 1 to 4.

141. R ２ but 【Chemistry 65】 (for example, 【Hua 66】 141. The compound of any one of claims 1 to 140, wherein

142. R ２ but 【Chemical 67】 (for example, 【Chemistry 68】 142. The compound according to any one of claims 1 to 141, wherein

143. R ２ but 【Chemical Formula 69】 (for example, 【Chemistry 70】 143. The compound according to any one of claims 1 to 142, wherein

144. R ２ but 【Chemical 71】 (for example, 【Chemical 72】 144. The compound according to any one of claims 1 to 143, wherein

145. R ２ is -C(=O)-CH=CH-C(=O)-R １ｚ Any of claims 1 to 144, The compound according to any one of claims 1 to 4.

146. R ２ -C(=O)-CH ２ -CH ２ -C(=O)-R １ｚ Claims 1 to 145 The compound according to any one of claims 1 to 4.

147. R ２ but 【Chemical Formula 73】 The compound of any one of claims 1 to 146,

148. R ２ but 【Chemical 74】 The compound of any one of claims 1 to 147,

149. R ３ The compound of any one of claims 1 to 148, wherein is H.

150. R ３ が-C(=O)R １ｂ 、-C(=O)OR １ｃ 、-C(=O)N(R １ｃ ) ２ 、- C(=O)R １ｚ 、-C(=O)-CH=CH-C(=O)OR １ｃ、－Ｃ（ =O)-C H ２ -CH ２ -C(=O)OR １ｃ 、 【Chemistry 75】 -C(=O)-CH=CH-C(=O)-R １ｚ 、-C(=O)-CH ２ -CH ２ -C( =O)-R １ｚ 、 【Chemical Formula 76】 The compound of any one of claims 1 to 149,

151. R ３ is -C(=O)R １ｂ The compound of any one of claims 1 to 150,

152. R ３ Ga-(CH ２ ) ｑ -C(=O)OR １ｃ Any one of claims 1 to 151, The compound described in

153. R ３ Ga-CH ２ CH ２ -C(=O)OR １ｃ Any one of claims 1 to 152, The compound described in

154. R ３ Ga-CH ２ -C(=O)-(CH ２ ) ｑ -C(=O)OR １ｃ Claims 1 to 5 153. The compound according to any one of claims 153.

155. R ３ Ga-CH ２ —C(═O)—CH ２ CH ２ -C(=O)OR １ｃ Claims 1 to 5 154. The compound according to any one of claims 154.

156. R ３ is -C(=O)-CH=CH-C(=O)OR １ｃ Any of claims 1 to 155, The compound according to any one of claims 1 to 4.

157. R ３ is -C(=O)R １ｚ 157. The compound of any one of claims 1 to 156,

158. R ３ -C(=O)OR １ｃ The compound according to any one of claims 1 to 157, 。

159. R ３ -C(=O)N(R １ｃ ) ２ According to any one of claims 1 to 158, compound.

160. R ３ is -C(=O)-CH=CH-C(=O)OR １ｃ Any of claims 1 to 159, The compound according to any one of claims 1 to 4.

161. R ３ -C(=O)-CH ２ -CH ２ -C(=O)OR １ｃ Claims 1 to 160 The compound according to any one of claims 1 to 4.

162. R ３ but 【Chemical 77】 (for example, 【Chemical Formula 78】 162. The compound according to any one of claims 1 to 161, wherein

163. R ３ but 【Chemical 79】 (for example, 【Chemistry 80】 163. The compound according to any one of claims 1 to 162, wherein

164. R ３ but 【Chemistry 81】 (for example, 【Chemistry 82】 164. The compound according to any one of claims 1 to 163, wherein

165. R ３ but 【Chemistry 83】 (for example, 【Chemistry 84】 165. The compound of claim 1, wherein

166. R ３ is -C(=O)-CH=CH-C(=O)-R １ｚ Any of claims 1 to 165, The compound according to any one of claims 1 to 4.

167. R ３ -C(=O)-CH ２ -CH ２ -C(=O)-R １ｚ Claims 1 to 166 The compound according to any one of claims 1 to 4.

168. R ３ but 【Chemistry 85】 The compound of any one of claims 1 to 167,

169. R ３ but 【Chemistry 86】 The compound of any one of claims 1 to 168,

170. At least one X is -OR １ｃ The compound according to any one of claims 1 to 169, Compound.

171. At least one X is -SR １ｃ The compound according to any one of claims 1 to 170, Compound.

172. At least one X is -N(R １ｃ ) ２ The method according to any one of claims 1 to 171, The compounds listed above.

173. At least one X 【Hua 87】 The compound according to any one of claims 1 to 172,

174. At least one X 【Hua 88】 The compound according to any one of claims 1 to 173,

175. At least one X 【Chemistry 89】 The compound according to any one of claims 1 to 174,

176. At least one X 【Chemistry 90】 The compound of any one of claims 1 to 175,

177. At least one X 【Chemistry 91】 The compound of any one of claims 1 to 176,

178. At least one X 【Chemistry 92】 The compound of any one of claims 1 to 177,

179. At least one X 【Chemistry 93】 The compound of any one of claims 1 to 178,

180. At least one X 【Chemistry 94】 The compound of any one of claims 1 to 179,

181. At least one X 【Chemistry 95】 The compound according to any one of claims 1 to 180,

182. At least one X 【Chemistry 96】 The compound according to any one of claims 1 to 181,

183. At least one X 【Chemistry 97】 The compound according to any one of claims 1 to 182,

184. At least one X 【Chemistry 98】 The compound according to any one of claims 1 to 183,

185. At least one X 【Hua99】 The compound according to any one of claims 1 to 184,

186. At least one X 【Chemistry 100】 The compound according to any one of claims 1 to 185,

187. At least one X is R １ｚ The compound according to any one of claims 1 to 186, 。

188. At least one X 【Chemistry 101】 The compound of any one of claims 1 to 187,

189. At least one X 【Chemistry 102】 The compound of any one of claims 1 to 188,

190. Two X's, together with one or more intervening atoms to which they are attached, form C ５ ~C １２ Heterogeneity Chloroalkyl or C ５ ~C １２ forming a heteroaryl, wherein C ５ ~C １２ Heterothymic alkyl or C ５ ~C １２ Heteroaryl is one or more R １ａ optionally replaced by The compound according to any one of claims 1 to 189.

191. Two X's, together with one or more intervening atoms to which they are attached, form C ５ ~C １２ Haitai Cycloalkyl or C ５ ~C １２ Any of claims 1 to 190 forming a heteroaryl The compound according to any one of claims 1 to 4.

192. 192. The compound of any one of claims 1 to 191, wherein at least one T is a bond.

193. At least one T is C １ ~C ２０ Any one of claims 1 to 192, wherein the alkyl is The compound described in

194. At least one T is selected from one or more R １ｅ C optionally substituted with １ ~C ２０ Archi The compound according to any one of claims 1 to 193,

195. At least one T is selected from one or more R １ｅ C optionally substituted with １ ~C ２０ Archi wherein at least one R １ｅ is H, halogen, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, -OR １ｇ , -C(=O)OR １ｇ , -C(=O)N(R １ｇ ) ２ 、-N(R １ｇ ) ２ 、-N(R １ｇ )C(=O)R １ｆ 、- N(R １ｇ )C(=NH)R １ｆ 、-N(R １ｇ )C(=O)R １ｚ 、-N(R １ｇ )C (=O)OR １ｇ 、-OC(=O)R １ｆ 、-OC(=O)R １ｚ 、-OC(=O)OR １ｇ 、-SR １ｇ 、-N ＋ (R １ｇ ) ３ 、-SC(=O)R １ｆ 、-SC(=O)R １ｚ 、-SC(=O)OR １ｇ 、-SC(=O)N(R １ｇ ) ２ 、-C(=O)R １ｆ 、-C (=O)R １ｚ , C ３ ~C １２ Cycloalkyl, C ３ ~C １２ Heterocycloalkyl, C ３ ~C １２ Aryl, C ３ ~C １２ heteroaryl, or R １ｚ wherein C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, C ２ ~C ２０ Alkynyl, C ３ ~C １２ Cyclo Alkyl, C ３ ~C １２ Heterocycloalkyl, C ３ ~C １２ Aryl, or C ３ ~C １ ２ Heteroaryl is one or more R １ｆ or R １ｚ Optionally substituted with 194. The compound according to any one of claims 194.

196. At least one T is at least one R １ｅ one or more R １ｅ C optionally substituted with １ ~C ２０ The compound according to any one of claims 1 to 195, wherein the alkyl group is alkyl. The compounds listed above.

197. At least one T is at least one R １ｅ is —C(═O)OH R in numbers １ｅ C optionally substituted with １ ~C ２０ Any of claims 1 to 196, wherein the alkyl is 3. The compound according to claim 1.

198. R １ But H, C １ ~C ２０ Alkyl, C ２ ~C ２０ Alkenyl, —C(═O)—(C １ ~C ２０ alkyl), -C(=O)-(C ２ ~C ２０ alkenyl), —C(═O)R １ｃ 、-C(=O)R １ｚ 、-C(=O)CH ２ -[CH(OR １ｃ )-CH ２ ] ｐ -[CH ２ ] ｑ -R １ａ 、-C(=O)CH ２ -[C(=O)CH ２ ] ｐ -[CH(OR １ｃ )- CH ２ ] ｒ -[CH ２ ] ｑ -R １ａ 、-C(=O)-CH=CH-C(=O)OR １ｃ 、 -C(=O)-[CH ２ ] ｑ -C(=O)OR １ｃ 、-C(=O)-[CH ２ ] ｑ -C( =O)R １ａ 、 【Chemistry 103】 200. The compound of any one of claims 1 to 197, selected from:

199. R １ But C １ ~C ２０ Alkyl, —C(═O)—(C １ ~C ２０ alkyl), -C(= O)-(C ２ ~C ２０ alkenyl), and —C(═O)—[CH ２ ] ｑ -C(=O)R １ ａ 200. The compound of any one of claims 1 to 198, selected from:

200. R １ is H, -CH ３ , 【Chemistry 104】 200. The compound of any one of claims 1 to 199, selected from:

201. R １ but 【Chemistry 105】 The compound of any one of claims 1 to 200, selected from:

202. R ２ がH、-C(=O)R １ｂ 、-C(=O)R １ｚ 、-C(=O)-CH ２ -CH ２ -C(=O)OR １ｃ , and 【Chemistry 106】 202. The compound of any one of claims 1 to 201, selected from:

203. R ２ is H and -C(=O)R １ｂ Any one of claims 1 to 202 selected from The compound described.

204. R ２ But H, 【Chemistry 107】 204. The compound of any one of claims 1 to 203, selected from:

205. R ２ H and 【Chemistry 108】 205. The compound of any one of claims 1 to 204, selected from:

206. R ３ is H, -C(=O)R １ｂ and —C(═O)—CH ２ -CH ２ -C(=O)OR １ｃ 206. The compound of any one of claims 1 to 205, selected from:

207. R ３ But H, 【Chemistry 109】 208. The compound of any one of claims 1 to 207, selected from:

208. Formula (I-1) or (I-2) 【Chemistry 110】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

209. Formula (Iaa), (Iab), (Iac), or (Iad) 【Chemistry 111】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

210. Formulas (Iaa-1), (Iaa-2), (Iab-1), (Iab-2), (Iac-1 ), (Iac-2), (Iad-1), or (Iad-2) 【Chemistry 112】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

211. Formula (Iae), (Iaf), (Iag), or (Iah) 【Chemistry 113】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

212. Formula (Iae-1), (Iae-2), (Iaf-1), (Iaf-2), (Iag-1 ), (Iag-2), (Iah-1), or (Iah-2) 【Chemistry 114】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

213. Formula (Iai) or (Iaj) 【Chemistry 115】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

214. Formulas (Iai-1), (Iai-2), (Iaj-1), (Iaj-2), (Iak-1 ), (Iak-2), (Ial-1), (Ial-2), (Iam-1), (Iam-2 ), (Ian-1), or (Ian-2): 【Chemistry 116-1】 【Chemistry 116-2】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

215. Formula (Iba) 【Chemistry 117】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

216. Formula (Iba-1) or (Iba-2) 【Chemistry 118】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

217. Formula (Ibb), (Ibc), (Ibd), or (Ibe) 【Chemistry 119】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

218. Formula (Ibb-1), (Ibb-2), (Ibc-1), (Ibc-2), (Ibd-1 ), (Ibd-2), (Ibe-1), or (Ibe-2) 【Chemistry 120】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

219. Formula (Ibf), (Ibg), (Ibh), or (Ibi) 【Chemistry 121】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

220. Formula (Ibf-1), (Ibf-2), (Ibg-1), (Ibg-2), (Ibh-1 ), (Ibh-2), (Ibi-1), (Ibi-2), : 【Chemistry 122】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

221. Formula (Ibj) 【Chemical 123】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

222. Formula (Ibj-1) or (Ibj-2) 【Chemical 124】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

223. Formula (Ibk) 【Chemistry 125】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

224. Formula (Ibk-1) or (Ibk-2) 【Chemical 126】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

225. Formula (Ibl) 【127】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

226. Formula (Ibl-1) or (Ibl-2) 【128】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

227. Formula (Ica) 【Chemical 129】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

228. Formula (Ica-1) or (Ica-2) 【Chemistry 130】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

229. Formula (Icb), (Icc), (Icd), or (Ice) 【Chemistry 131】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

230. Formula (Icb-1), (Icb-2), (Icc-1), (Icc-2), (Icd-1 ), (Icd-2), (Ice-1), or (Ice-2) 【Chemistry 132】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

231. Formula (Icf), (Icg), (Ich), or (Ici) 【Chemistry 133】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

232. Formula (Icf-1), (Icf-2), (Icg-1), (Icg-2), (Ich-1 ), (Ich-2), (Ici-1), (Ici-2): 【Chemistry 134】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

233. Formula (Icj) 【Chemistry 135】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

234. Formula (Icj-1) or (Icj-2) 【Chemistry 136】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

235. Formula (Ick) 【Chemistry 137】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

236. Formula (Ick-1) or (Ick-2) 【Chemistry 138】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

237. Formula (Icl) 【Chemistry 139】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

238. Formula (Icl-1) or (Icl-2) 【Chemistry 140】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

239. Formula (II-1) or (II-2) 【Chemistry 141】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

240. Formula (IIa) 【142】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

241. Formula (IIa-1) or (IIa-2) 【143】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

242. Formula (IIb) 【Chemical 144】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

243. Formula (IIb-1) or (IIb-2) 【Chemistry 145】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

244. Formula (II'-1) or (II'-2) 【Chemistry 146】 【147】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

245. Formula (II'a) 【148】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

246. Formula (II'a-1) or (II'a-2) 【149】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

247. Formula (II'b) 【Chemistry 150】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

248. Formula (II'b-1) or (II'b-2) 【Chemistry 151】 or a pharmaceutically acceptable salt or solvate thereof. The compound according to claim 1.

249. Claims 1 to 248 are selected from the compounds listed in Table 1 and pharmaceutically acceptable salts thereof. The compound according to any one of claims 1 to 4.

250. Claims 1 to 249 are selected from Compound Nos. 1 to 58 and pharmaceutically acceptable salts thereof. The compound according to any one of claims 1 to 4.

251. The compound according to any one of claims 1 to 250, selected from compound numbers 1 to 58 。

252. Compounds 1 to 2 selected from Compound Nos. 59 to 115 and pharmaceutically acceptable salts thereof.

51. A compound according to any one of claims 1 to 51.

253. The compound according to any one of claims 1 to 252, selected from compound numbers 59 to 115. Compound.

254. Compounds 1 to 188 and pharmaceutically acceptable salts thereof are selected from the group consisting of compounds 1 to 188.

253. The compound according to any one of claims 253.

255. The compound according to any one of claims 1 to 254, selected from compound numbers 116 to 188 compound.

256. Compounds 1 to 296 and pharmaceutically acceptable salts thereof are selected from the group consisting of compounds 1 to 296.

255. The compound according to any one of claims 255.

257. The compound according to any one of claims 1 to 256, selected from compound numbers 189 to 296 compound.

258. Compounds Nos. 297 to 369 and pharmaceutically acceptable salts thereof, 257. The compound according to any one of claims 257.

259. The compound according to any one of claims 1 to 259, selected from compound numbers 297 to 369 compound.

260. Compounds 1 to 495 and pharmaceutically acceptable salts thereof are selected from the group consisting of compounds 1 to 495 and pharmaceutically acceptable salts thereof.

259. The compound according to any one of claims 259.

261. The compound according to any one of claims 1 to 260, selected from compound numbers 370 to 495 compound.

262. Compounds Nos. 496 to 579 and pharmaceutically acceptable salts thereof.

261. The compound according to any one of claims 261.

263. The compound according to any one of claims 1 to 262, selected from compound numbers 496 to 579 compound.

264. Compounds Nos. 580 to 699 and pharmaceutically acceptable salts thereof, 263. The compound according to any one of claims 263.

265. The compound according to any one of claims 1 to 264, selected from compound numbers 580 to 699 compound.

266. Compounds Nos. 700 to 879 and pharmaceutically acceptable salts thereof, 265. The compound according to any one of claims 265.

267. The compound according to any one of claims 1 to 266, selected from compound numbers 700 to 879 compound.

268. Compounds 1 to 967 and pharmaceutically acceptable salts thereof are selected from the group consisting of:

267. The compound according to any one of claims 267.

269. The compound according to any one of claims 1 to 268, selected from compound numbers 880 to 967 compound.

270. Compound Nos. 968 to 1009 and pharmaceutically acceptable salts thereof.

269. The compound according to any one of claims 1 to 269.

271. The compound according to any one of claims 1 to 270, selected from compound numbers 968 to 1009 Compound.

272. Compounds selected from Compound Nos. 1010 to 1141 and pharmaceutically acceptable salts thereof. 1-271. The compound according to any one of claims 1-271.

273. The compound according to any one of claims 1 to 272, selected from compound numbers 1010 to 1141. The compounds listed above.

274. Claims 1 to 273 selected from Compound No. 1142 and pharmaceutically acceptable salts thereof The compound according to any one of claims 1 to 4.

275. The compound according to any one of claims 1 to 274, selected from compound number 1142 。

276. Compounds Nos. 1143 to 1162 and pharmaceutically acceptable salts thereof. 1-275. The compound according to any one of claims 1-275.

277. The compound according to any one of claims 1 to 276, selected from compound numbers 1143 to 1162. The compounds listed above.

278. Compounds selected from Compound Nos. 1163 to 1209 and pharmaceutically acceptable salts thereof. 1-277. The compound according to any one of claims 1-277.

279. The compound according to any one of claims 1 to 278, selected from compound numbers 1163 to 1209. The compounds listed above.

280. Compounds selected from Compound Nos. 1210 to 1215 and pharmaceutically acceptable salts thereof. 1-279. The compound according to any one of claims 1-279.

281. The compound according to any one of claims 1 to 280, selected from compound numbers 1210 to 1215. The compounds listed above.

282. The compound according to any one of claims 1 to 281, selected from compound numbers 1222 to 1280. The compounds listed above.

283. The compound according to any one of claims 1 to 282, selected from compound numbers 1282 to 1323. The compounds listed above.

284. Compounds are compound numbers 1, 2, 4, 20, 25, 35, 36, 37, 38, 39, and 42. ４６、５１、５７、６０、６３、７３、８２、８６、１１６、１３８、１４０、１４５、 １５７、１８３、１８５、２１４、３７２、３８２、３８３、３８５、３９０、３９３、 ３９７、３９９、４００、４０１、４０５、４１０、４１１、４１２、４１４、４１５、 ４６０、５００、５０２、５６０、１２２７、１２２８、１２２９、１２３０、１２３１ 、１２３２、１２３３、１２３９、１２４０、１２４２、１２４５、１２４６、１２４７ 、１２４８、１２４９、１２５０、１２５２、１２６４、１２８５、１２９２、１２９４ , 1296, 1298, 1304, 1306, 1307, 1309, 1310, and 13 284. The compound of any one of claims 1 to 283, selected from:

285. The compound is selected from compound numbers 2, 20, 145, 410, 500, and 1306. The compound according to any one of claims 1 to 284.

286. 286. A compound which is an isotopic derivative of the compound of any one of claims 1 to 285.

287. Obtained by a process for preparing a compound according to any one of claims 1 to 286. A compound that is an intermediate in the synthesis of a compound.

288. The compound according to any one of claims 1 to 287 or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions.

289. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 288 to a subject. A method for activating or enhancing acetyl-CoA synthesis in a subject, comprising:

290. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 289 to a subject. A method for increasing acetyl-CoA levels in a subject, comprising:

291. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 290 to a subject. A method of treating a subject having a disease, comprising:

292. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 291 to a subject. A method for preventing a disease in a subject.

293. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 292 to a subject. A method for reducing CoA degradation in a subject, comprising:

294. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 293 to a subject. A method for increasing the half-life of CoA in a subject, comprising:

295. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 294 to a subject. A method for extending availability of a CoA in a subject.

296. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 295 to a subject.

2. A method for delivering an acyl moiety to the mitochondrial matrix of a subject's mitochondria, comprising: 。

297. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 296 to a subject.

10. A method for reducing the concentration of reactive oxygen species (ROS) in a subject, comprising:

298. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 297 to a subject.

10. A method for reducing the concentration of acyl-CoA in a subject, comprising:

299. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 298 to a subject.

20. A method for increasing fatty acid metabolism in a subject, comprising:

300. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 299.

20. A method for increasing amino acid metabolism in a subject, comprising:

301. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 300.

20. A method for increasing mitochondrial respiration in a subject, comprising:

302. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 301 to a subject.

20. A method for increasing ATP concentration in a subject, comprising:

303. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 302 to a subject.

10. A method of treating a subject with cancer, comprising:

304. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 303 to a subject.

20. A method for preventing cancer in a subject, comprising:

305. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 304. A method for reducing the size of a tumor, including

306. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 305 to a subject.

20. A method of inducing tumor cell apoptosis in a subject, comprising:

307. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 306.

20. A method of inducing cell cycle arrest in a subject, comprising:

308. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 307. A method for inducing differentiation of cells in a subject, comprising:

309. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 308. A method for inducing cellular senescence in a subject, comprising:

310. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 309. A method for enhancing an immune response to cancer in a subject, comprising:

311. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 310.

20. A method for inhibiting angiogenesis in a subject, comprising:

312. A therapeutically effective amount of an anti-cancer agent and a therapeutically effective amount of a compound according to any one of claims 1 to 311. A method for enhancing the apoptotic effect of an anti-cancer agent, comprising administering to a subject a combination of:

313. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 312 to a subject. A method for increasing post-translational modification of a protein in a subject, comprising:

314. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 313.

20. A method for increasing protein acetylation in a subject, comprising:

315. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 314.

20. A method for increasing histone acetylation in a subject, comprising:

316. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 315.

20. A method for increasing acetylation of tubulin in a subject, comprising:

317. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 316.

10. A method of treating a subject having a neurodegenerative disease, comprising:

318. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 317 to a subject. A method for preventing a neurodegenerative disease in a subject, comprising:

319. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 318.

10. A method of treating a subject having an ataxia disorder, comprising:

320. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 319 to a subject.

10. A method for preventing ataxia in a subject, comprising:

321. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 320.

10. A method of treating non-alcoholic steatohepatitis in a subject, comprising:

322. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 321.

10. A method for preventing non-alcoholic steatohepatitis in a subject, comprising administering to a subject a therapeutically effective amount of a compound selected from the group consisting of acetaminophen, benzodiazepine, benzodiazepine, benzodiazepine, benzocaine, benzoyl peroxidase ...

323. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 322.

10. A method of treating non-alcoholic fatty liver disease in a subject, comprising:

324. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 323.

10. A method for preventing non-alcoholic fatty liver disease in a subject, comprising administering to a subject a

325. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 324.

10. A method for preventing an inappropriate shift towards fatty acid biosynthesis in a subject, comprising:

326. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 325.

10. A method of treating an inflammatory disease in a subject, comprising:

327. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 326.

20. A method for preventing an inflammatory disease in a subject, comprising:

328. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 327.

20. A method of reducing inflammation in a subject, comprising:

329. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 328.

20. A method of reducing fibrosis in a subject, comprising:

330. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 329. A method for stimulating regulatory T cell activity in a subject, comprising:

331. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 330.

10. A method of treating Crohn's disease in a subject, comprising:

332. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 331.

10. A method for preventing Crohn's disease in a subject, comprising:

333. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 332 to a subject.

10. A method of treating colitis in a subject, comprising:

334. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 333 to a subject.

20. A method for preventing colitis in a subject, comprising:

335. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 334 to a subject.

10. A method of treating chronic enteritis in a subject, comprising:

336. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 335.

10. A method for preventing chronic enteritis in a subject, comprising:

337. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 336.

10. A method of treating HIV in a subject, comprising:

338. A therapeutically effective amount of a compound according to any one of claims 1 to 337 and a therapeutically effective amount of an immunomodulatory agent. A method of treating HIV comprising administering to a subject a combination of the compounds of the clause.

339. A therapeutically effective amount of a compound according to any one of claims 1 to 338 and a therapeutically effective amount of an anti-HI A method of treating HIV comprising administering to a subject a combination of V agents.

340. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 339.

10. A method of reactivating latent HIV in a subject, comprising:

341. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 340. reactivating latent HIV without inducing global T cell activation in a subject, How to do it.

342. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 341.

10. A method of treating acute coronary syndrome in a subject, comprising:

343. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 342.

10. A method of reducing cardiac cell damage in a subject with acute coronary syndrome, comprising:

344. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 343. Reduces damage caused by ischemia, inflammation, fibrosis, remodeling, or a combination thereof, including method.

345. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 344.

20. A method for preventing reinfarction in a subject, comprising:

346. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 345.

10. A method for preventing ischemic stroke in a subject, comprising:

347. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 346.

20. A method for increasing cardiac cell survival in a subject, comprising:

348. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 347.

10. A method of treating major depressive disorder in a subject, comprising:

349. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 348 to a subject.

10. A method for preventing major depressive disorder in a subject, comprising:

350. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 349 to a subject. A method for reversing acetylation patterns due to major depressive disorder, comprising:

351. A therapeutically effective amount of an antidepressant compound and a therapeutically effective amount of any one of claims 1 to 350 and administering to the subject a combination of the compounds of formula (I) and (II). How to increase the effect.

352. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 351. A method for improving mitochondrial health in a subject, comprising:

353. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 352.

20. A method of reducing neuroinflammation in a subject, comprising:

354. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 353.

2. A method for improving neurological function, including:

355. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 354.

20. A method for improving neuronal survival, comprising:

356. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 355 to a subject. A method for inhibiting microglia-mediated neuroinflammation.

357. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 356 to a subject.

10. A method of treating a subject with Huntington's disease, comprising administering to a subject a therapeutically effective amount of a compound selected from the group consisting of acetaminophen, benzodiazepine ...

358. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 357.

20. A method for preventing Huntington's disease in a subject, comprising:

359. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 358.

10. A method for re-establishing CoA homeostasis in a subject, comprising:

360. and administering to the subject at least one therapeutically effective amount of a compound that increases acetyl-CoA concentration in the subject.

360. A compound according to any one of claims 1 to 359 for use in increasing the strength of vision.

361. and administering to the subject at least one therapeutically effective amount of a compound that increases acetyl-CoA concentration in the subject. A compound according to any one of claims 1 to 360 for the manufacture of a drug for increasing the blood pressure Use of.

362. for administering to a subject in at least one therapeutically effective amount for treating a disease in a subject; 362. The compound of claim 1 for use in treating a stomach ulcer.

363. 2. A drug for treating a disease in a subject, for administration to the subject in at least one therapeutically effective amount.

363. Use of a compound according to any one of claims 1 to 362 for the manufacture of an article.

364. and administering to a subject at least one therapeutically effective amount of a compound for preventing a disease in a subject.

364. A compound according to any one of claims 1 to 363 for use in

365. 2. A method for preventing a disease in a subject, comprising administering to the subject at least one therapeutically effective amount of the drug.

365. Use of a compound according to any one of claims 1 to 364 for the manufacture of an article.

366. for administering to a subject at least one therapeutically effective amount of 366. A compound according to any one of claims 1 to 365 for use in

367. 2. A method for treating cancer in a subject, comprising administering to the subject at least one therapeutically effective amount of a 10. Use of a compound according to any one of claims 1 to 366 for the manufacture of:

368. For administration to a subject in at least one therapeutically effective amount, for preventing cancer in a subject.

368. A compound according to any one of claims 1 to 367 for use in

369. 2. A drug for preventing cancer in a subject, for administration to the subject in at least one therapeutically effective amount.

10. Use of a compound according to any one of claims 1 to 368 for the manufacture of:

370. 1. Treating an inflammatory disease in a subject, for administration to the subject in at least one therapeutically effective amount.

370. A compound according to any one of claims 1 to 369 for use in treating a stomach ulcer.

371. 1. Treating an inflammatory disease in a subject, for administration to the subject in at least one therapeutically effective amount.

20. Use of a compound according to any one of claims 1 to 370 for the manufacture of a medicament for treating atopic dermatitis.

372. Preventing an inflammatory disease in a subject, for administration to the subject in at least one therapeutically effective amount.

372. A compound according to any one of claims 1 to 371 for use in treating a patient suffering from atopic dermatitis.

373. Preventing an inflammatory disease in a subject, for administration to the subject in at least one therapeutically effective amount.

20. Use of a compound according to any one of claims 1 to 372 for the manufacture of a medicament for treating atopic dermatitis.

374. and administering to the subject at least one therapeutically effective amount of a compound for treating a neurodegenerative disease in a subject.

374. A compound according to any one of claims 1 to 373 for use in treating

375. and administering to the subject at least one therapeutically effective amount of a compound for treating a neurodegenerative disease in a subject.

10. Use of a compound according to any one of claims 1 to 374 for the manufacture of a medicament for the treatment of

376. and administering to the subject at least one therapeutically effective amount of a compound or compound(s) for preventing or preventing a neurodegenerative disease in a subject. A compound according to any one of claims 1 to 375 for use in preventing

377. and administering to the subject at least one therapeutically effective amount of a compound or compound(s) for preventing or preventing a neurodegenerative disease in a subject.

10. Use of a compound according to any one of claims 1 to 376 for the manufacture of a medicament for preventing

378. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 377 to a subject.

10. A method of treating a subject with multiple sclerosis, comprising:

379. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 378 to a subject.

10. A method of treating a subject with epilepsy, comprising:

380. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 379.

10. A method of treating a subject having schizophrenia, comprising administering to a subject a therapeutically effective amount of schizophrenia.

381. Administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 380. A method for restoring acetylation of a protein from a hypoacetylated state, comprising:

382. The acetyl-CoA precursor is administered to a subject in at least one therapeutically effective amount. Any one of claims 1 to 381 for use in treating acute kidney injury in a subject The compound described in

383. The acetyl-CoA precursor is administered to a subject in at least one therapeutically effective amount. Any of claims 1 to 382 for the manufacture of a medicament for treating acute kidney injury in a subject. The compound according to any one of claims 1 to 4.

384. The acetyl-CoA precursor is administered to a subject in at least one therapeutically effective amount. A compound according to any one of claims 1 to 383 for use in preventing acute kidney injury in a subject. The compound described in

385. The acetyl-CoA precursor is administered to a subject in at least one therapeutically effective amount. Any of claims 1 to 384 for the manufacture of a medicament for preventing acute kidney injury in a subject. The compound according to any one of claims 1 to 4.

386. Administering a therapeutically effective amount of a compound according to any one of claims 1 to 385 to a subject.

10. A method of treating a subject having a mitochondrial disease, comprising:

387. A method for treating mitochondrial disease in a subject, for administration to the subject in at least one therapeutically effective amount.

10. A compound according to any one of claims 1 to 386 for the manufacture of a medicament for the treatment of a disease.

388. A method for treating mitochondrial disease in a subject, for administration to the subject in at least one therapeutically effective amount.

10. A compound according to any one of claims 1 to 387 for use in treating a disease.

Images